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The dimeric naphthylisoquinoline alkaloid michellamine B, with its moderate anti-HIV 
activity, has gained significant interest as a potential lead compound. Herein, both 
monomeric and dimeric analogues with novel isoquinoline units were synthesized to 
evaluate the importance of this isoquinoline unit for HIV RT inhibitory activity.  
The synthesis started from the preparation of key precursors of naphthylboronic 
acid/ester and halogenated dihydroisoquinolines. The naphthylboronic acid 37 was 
synthesized by a Diels-Alder method over 8 steps proceeding in 37% overall yield from 
commercially available 3,3-dimethylacrylic acid 59. The naphthylboronic ester 38, with 
an ethyl ester substituent in the naphthyl ring, was prepared by a Wittig method over 7 
steps with an overall yield of 43%. Halogenated 3,4-dihydroisoquinolines (39-41) 
featuring methoxy groups and double bonds between C1 and N were obtained from a 
four-step synthesis proceeding in 39-48% overall yields from commercially available 
benzaldehydes. Brominated 3,4-dihydroisoquinolin-1(2H)-ones 42 with a carbonyl 
group were successfully prepared over 4 steps with an overall yield of 18%. 
Three monomeric naphthylisoquinolines (96-98) with an ethyl ester substituent in the 
naphthyl ring were prepared from the naphthylboronic ester (38) and halogenated 
isoquinolines (39-42) via Pd-catalyzed Suzuki cross-coupling, while three monomeric 
naphthylisoquinolines (43, 99-100) with methyl substituent in the naphthyl ring were 
prepared from the naphthyl boronic acid (37) and halogenated isoquinolines (39-42). In 
order to activate the ArC3 position for the subsequent dimerization, three phenolic 
monomeric naphthylisoquinolines (44, 107 and 109) were obtained via debenzylation 
ix 
 
reactions using Pd/C/H2 reduction system. Two dimeric naphthylisoquinolines (112 and 
113), as michellamine B analogues, were successfully synthesized from the phenolic 
monomeric naphthylisoquinolines (44 and 107) via a Ag2O-induced oxidative 
dimerization strategy. 
The synthesized monomeric and dimeric naphthylisoquinolines were tested in vitro 
against the HIV-1 RT enzyme showing weak to mild inhibitory activities with IC50 
values up to 61.3 μM. Five monomeric naphthylisoquinolines (99, 43, 97, 109 and 44) 
exhibited moderate activity against Plasmodium falciparum (2.66-4.34 μg/mL), while 
all the monomeric naphthylisoquinolines showed high cytotoxicity (1.95-30.09 μg/mL). 
All the monomeric naphthylisoquinolines exhibited moderate to low activities against 
the three cell lines KB (oral cavity cancer), MCF-7 (breast cancer) and NCI-H187 
(small cell lung cancer). All the monomeric naphthylisoquinolines showed no activities 
against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and 
Pseudomonas aeruginosa, while three compounds (99, 43 and 109) exhibited low 
activity against Staphylococcus aureus with MIC values from 16 µg/mL to 32 µg/mL. 
Coelenterazine-like imidazo[1,2-a]pyridines, as inhibitors of bioluminescent luciferase 
for the study of its enzymatic kinetics, were synthesized via a highly convergent and 
adaptable synthesis route. This simple synthesis involves 11 steps in total with only six 
linear steps, proceeding in respectable 33-44% overall yields from commercially 
available 2-aminonicotinic acid. The antioxidant abilities of four new coelenterazine 
analogues (121, 123-125) were evaluated, showing moderate activities with IC50 values 
from 58.7 μM to 72.8 μM. Their optical properties, including UV absorption, 
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Chapter 1: Introduction 
1.1 Human immunodeficiency virus (HIV) 
1.1.1 The background of HIV 
Acquired immune deficiency syndrome (AIDS) is a disease caused by HIV.1,2 HIV 
infects vital cells such as CD4
+ T cells which play essential roles in the human immune 
system.3 Once the CD4
+ T cell numbers drop to 500 cells/mm3,4 cell immunity is 
gradually lost and the body becomes more susceptible to life-threatening infections, 
including opportunistic infections and tumors which do not usually affect people who 
have fully functional immune systems. 
The first case of HIV infection was reported in early 1980s,5,6 and it then spread rapidly 
around the world. HIV is transmitted primarily via unprotected sex, contaminated blood 
transfusions, hypodermic needles, and mother to child transmission. It is estimated that 
there were 35 million people living with HIV at the end of 2013 and a reported 1.5 
million individuals dying of the disease including 190,000 children (younger than 15 
years old) over the year 2013.7 There is no cure or vaccine for AIDS; however, 
antiretroviral treatment can slow the course of the disease. AIDS has had a great impact 
both on society and economic, and it has become a common issue of the world. 
Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that 
was initially discovered and is associated with stronger virulence and infectivity,8 and is 
therefore the cause of the majority of HIV infections globally. In this thesis, any 
reference to HIV refers to HIV-1 unless otherwise stated. 
 




1.1.2 HIV lifecycle and RT enzyme 
Upon entry into the target cell in human body, the HIV retrovirus uses three key 
enzymes to complete its life cycle: reverse transcriptase (RT), integrase (IN) and 
protease (PR). Reverse transcription is catalyzed by the retroviral enzyme RT. RT 
reverse transcribes a single-stranded genomic RNA molecule into double-stranded DNA, 
which can subsequently be integrated into host cell DNA, depending on the retroviral 
enzyme IN as well as host cellular cofactors. After the successful addition of viral DNA 
to the host genome, the virus can replicate.9 RT has two enzymatic activities: a 
polymerase that can copy either RNA or DNA and an RNase H that degrades the RNA 
strand of RNA-DNA intermediates formed during viral DNA synthesis, thus RT present 
a crucial target for inhibition of HIV replication. 
1.1.3 Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and highly active antiretroviral therapy 
(HAART) 
The RT can be inhibited by two classes of drugs: NRTIs and NNRTIs. Table 1.1 
summarizes the characteristics of the two classes of HIV RT inhibitors, and highlights 










Table 1.1 Characteristics of HIV RT inhibitors: NRTIs and NNRTIs. 
Characteristic NRTIs11-13 NNRTIs14,15 
Chemical 
structure 
Analogues of the natural substrates,  
i.e. nucleosides 
Chemically diverse, non-nucleoside 
Active from Metabolic conversion to 
5′-triphosphates by host-cell 
enzymes 
No metabolic conversion 
Mechanism of 
action 
Incorporate into growing DNA 
chain, terminate chain synthesis 
Induce conformational changes in RT, 
reducing catalytic activities 
Type of 
inhibition 
Competitive with the natural 
substrates 
Non-competitive or uncompetitive 
Binding site  Catalytic site Hydrophobic pocket 
Spectrum Broad spectrum antiretrovirals HIV specific RT inhibitors 
Selectivity Low to moderate Very high 
 
The first RT inhibitors approved zidovudine13 (Figure 1.1) were the NRTIs which 
compete as triphosphates with normal nucleoside substrates for incorporation into the 
viral genome, thus behaving as chain terminators. NNRTIs with a wide range of 
chemically diverse structures, have gained a definitive and important place in clinical 
use based on their unique antiviral potency with generally low toxicity and favourable 
pharmacokinetic properties.16-18 Unlike nucleoside analogues, NNRTIs bind in specific 
pockets of the HIV RT, which will alter its reverse replication without interfering with 
the human cell cycle or mitochondrial DNA synthesis because of their different 
structures from the nucleoside analogues. NNRTIs were found have a more potential 
than the NRTIs, and have gained the greatest importance due to their specificity and low 
 






Figure 1.1 First RT inhibitor zidovudine. 
HIV undergoes dramatic genetic variation due to the rapid replication of the virus in 
human body, which further complicates the development of effective agents and 
vaccines.19 Since 1996, a combination of different inhibitors called HAART, has 
provided an effective way to treat AIDS patients by dramatic reduction in viral loads 
and restoration of the immune system.20 As NNRTIs represent the most potent anti-HIV 
drugs due to their unique antiviral potency, high specificity and low cytotoxicity, they 
have become indispensable components of HAART regimen. However, the rapid 
emergence of drug resistance and serious side effects from the long-term drug use has 
become a new issue. Therefore, it is essential to design and develop new anti-HIV drugs, 
especially new NNRTIs. 
1.1.3.1 Currently marketed NNRTIs  
The era of NNRTIs started with the independent discovery of two series of compounds: 
1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) (1) derivatives21,22 and 
4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) (2) 
derivatives (Figure 1.2).23,24 Both HEPT (1) and TIBO derivative (2) are highly active 
compounds against HIV by interacting with an allosteric site of RT.  
 





Figure 1.2 The structure of the early NNRTIs: HEPT and TIBO derivative R82150. 
Following the discovery of HEPT (1) and TIBO (2), three other compounds were 
identified as first-generation NNRTIs, including nevirapine (3), delavirdine (4), 
efavirenz (5) (Figure 1.3). nevirapine (3), a dipyridodiazepinone, which was first 
approved by the FDA for clinical use in 1996, is a highly specific inhibitor of HIV-1 
reverse transcriptase (RT) and exhibits an IC50 of 84 nM in enzyme assays and an IC50 
of 40 nM against HIV-1 replication in cell culture.25 The following year, delavirdine (4), 
a bis(heteroary1)piperazine (BHAP) analogue with 98% inhibition and an IC50 value of 
1.1 μM, entered the market.26 In 1998, the 1,4-dihydro-2H-3,1-benzoxazin-2-ones 
analogue efavirenz (5), which exhibited a 95% inhibitory concentration of 1.5 nM for 
the inhibition of HIV-1 replicative spread in cell culture, was approved by the FDA as a 
NNRTI for clinical use.27  
 





Figure 1.3 Currently marketed first-generation and second-generation NNRTIs and their 
biological activities against HIV in cell culture. * The IC95 was the concentration of test 
compound that inhibited virus expression by at least 95% relative to virus expression in 
untreated control samples. 
Second-generation NNRTIs include etravirine (6), and rilpivirine (7) (Figure 1.3), 
which are the analogues of diarylpyrimidine (DAPY)  compounds. Compared to the 
first-generation NNRTIs, these flexible antiretroviral drugs display a higher genetic 
barrier to resistance. Structural studies showed that DAPY analogues can bind the 
enzyme RT in multiple conformations and adapt to changes in the NNRTI-binding 
pocket, which helps it escape the effects of drug-resistance mutations.28 Etravirine (6) 
and rilpivirine (7) were introduced to the market in 2008 and 2011 respectively, and 
both drugs show superior activity profiles against wild-type and mutant HIV-1 strains 
compared to all currently approved NNRTIs.29 The high potency, minimal adverse 
effects, easy synthesis and formulation make them the best NNRTIs in the market. 
All five marketed NNRTIs are generally safe and well tolerated, although central 
nervous system side effects are associated with the use of efavirenz (5),30 whereas 
 




nevirapine (3) causes hepatotoxicity and a severe rash.31 
1.1.3.2 Next generation NNRTIs 
The need for new therapeutic agents that are able to overcome resistance and safety 
problems prompted the development of new NNRTIs. At present, the next generation of 
NNRTIs are undergoing clinical development (Figure 1.4).  
3-Cyanophenoxypyrazole lersivirine (8)32 and aryl phosphinate-indole GSK 2248761 
(9)33 had been undergo phase IIb trials. However, on 10 February 2011, the FDA put a 
hold on development of GSK 2248761 (9) due to four reports of seizures as part of a 
clinical trial involving treatment-experienced patients, and on 5 February 2013, ViiV 
Healthcare announced that the company has decided to stop the development of 
lersivirine (8) as it was determined that the compound would not provide an 
improvement over existing medicines in the NNRTI class. 
There are two NNRTIs undergoing phase IIa trials, the triazole analogue RDEA806 
(10)34 and the dipyridodiazepinone BILR 355 BS (11).35 They have been demonstrated 
to be safe, well tolerated and potent in antiretroviral activity studies.  
 
 





Figure 1.4 Chemical structures of the next-generation NNRTIs and their biological activities 
against HIV in cell culture. 
The other four NNRTIs including the natural substrate (+)-calanolide A (12),36 and three 
biaryl ether moiety compounds MK-4965 (13),37 MK-1439 (14)38 and MK-6186 (15),39 
showed promising anti-HIV properties and are currently undergoing Phase I clinical 
trials. While none of these drugs have currently been approved by the FDA for use as 
anti-HIV treatments, the current stage of development and companies responsible for 
 




each drug are showed in Table 1.2.40 
Table 1.2 Current statuses of the clinical trials of next-generation NNRTIs. 
Research code Sponsor Status 
UK-453,061 ViiV Healthcare Phase IIb (withdrawn) 
GSK 2248761 ViiV Healthcare Phase IIb (withdrawn) 
RDEA806 Ardea Bioscience Phase IIa 
RILR 355 BS Boehringer Ingelheim Pharmaceuticals Phase IIa 
(+)-Calanolide A Sarawak MediChem Pharmaceuticals Phase I 
MK-4965 Merck Research Laboratories Phase I 
MK-1439 Merck Research Laboratories Phase I 
MK-6186 Merck Research Laboratories Phase I 
 
1.2 Michellamine analogues 
1.2.1 Background of the michellamines 
The continuous worldwide threat due to the AIDS epidemic has stimulated huge efforts 
in developing medical drugs or vaccines against this rapidly spreading disease, and the 
steps of screening natural substrates for new class drugs have always continued. In the 
course of a broad screening program on a large number of natural sources by the Boyd 
laboratory at the National Cancer Institute in US, the michellamines (Figure 1.5) were 
discovered from the leaves of the tropical plant Ancistrocladus korupensis in 
Cameroon.41 A more extensive testing showed that michellamines B (17) exhibited EC50 
values (inhibition of viral cell killing or noncytopathic infections) between 1 and 88 µM, 
and IC50 values of cytotoxicity from 42 to greater than 240 µM against a remarkable 
 




diversity of strains of both HIV-1 and HIV-2 in a wide spectrum of cell types.42 
Subsequent studies to uncover the mechanism of the action of michellamine B have 
indicated that it does not block the initial binding of HIV to target cells; rather it inhibits 
cellular fusion and syncytium formation, and is a non-competitive inhibitor of HIV 
RT.43 
The michellamines (16-18) are not only of biological and pharmaceutical significance in 
the search for novel anti-HIV agents, but also represented three new members in a novel 
class of naturally occurring dimeric naphthylisoquinoline alkaloids. They are each 
composed of four aromatic systems: two naphthyl and two tetrahydroisoquinoline 
systems (Figure 1.4). These unique structures contain rare C5-C8′ and C5′′′-C8′′ biaryl 
linkages as well as six phenolic OH and two secondary amino groups which result in the 




































EC50 = 10 M
Michellamine B (17)









































Figure 1.5. Chemical structures of michellamine A-C and their biological activities against HIV 
(RF Strain) in cell culture. 
Moreover, four new monomeric alkaloids korupensamines A-D (19-22) (Figure 1.6) 
were isolated from the A. korupensis at a later date. These biosynthetic precursors of 
michellamine showed no anti-HIV activity, but were found to have antimalarial activity 
 




against Plasmodium falciparum and Plasmodium berghei. The IC50 values for 
Korupensamine A (19) were 0.31 and 0.56 µg/mL against P. falciparum and P. berghei, 
respectively, and 0.18 and 0.41 µg/mL for korupensamine B (20). Conversely the 
michellamines (16-18) showed only weak activity against both of the malarial parasite 









































Figure 1.6 Chemical structures of korupensamines A-D. 
1.2.2 Previous synthetic strategy for preparing michellamine B  
Due to the promising anti-HIV properties of the michellamines and the demonstrated 
need of large quantities for further pharmaceutical studies, several research groups 
developed syntheses of michellamines A-C (16-18).45-51 The strategies towards the 
synthesis of the michellamine skeleton mainly followed two pathways (Scheme 1.1). 
Both routes required the initial synthesis of the naphthyl unit and isoquinoline unit. In 
route A, a naphthylisoquinoline was formed first via a cross coupling before the 
dimerization reaction. Pd-catalyzed Suzuki reactions and Stille reactions were applied to 
achieve the cross coupling, and in some case, the “lactone methodology” as a different 
strategy to build the naphthylisoquinoline alkaloid, was also used.52,53 While in route B, 
a binaphthyl core was first prepared, followed by a di-coupling with isoquinoline unit. 
In some reports, instead of starting from a naphthyl unit, biphenol was used to prepare 
the binaphthyl core.54,55 
 





Scheme 1.1 Two pathways for synthesis of michellamine. A: forming naphthylisoquinoline 
before dimerization; B: forming binaphthyl core before coupling isoquinoline. 
Besides these two main pathways, in a recent report of stereo-selective synthesis of 
michellamine B (17), axial chirality was installed by asymmetric Suzuki-Miyaura 
coupling reactions before the isoquinoline was constructed in the monomeric biaryl 
compound.56  
1.2.3 Analogues of michellamine B 
Michellamine B (17), as a novel class of natural products that feature promising 
bioactivities against HIV, has captured the attention of scientists. Although elegant 
pathways have been developed for the stereoselective total synthesis of michellamine B 
(17), there is an urgent demand for the design and synthesis of even more active and 
less toxic analogues with more simple structures. 
1.2.3.1 Michellamine B analogues based on the modification of the isoquinoline and 
binaphthyl units 
In order to assess the importance of the methoxy and isoquinoline substituents to 
anti-HIV activity and simplify the synthetic sequence, simplified analogues of 
michellamine B lacking the two methoxy and methyl groups on central binaphthyl core 
 




(23) or lacking a second tetrahydroisoquinoline group (24) were synthesized (Figure 
1.7).57 The RT inhibition activities of 23 and 24 were obtained with IC50 values of 62 
μM and 1000 μM, respectively, while the IC50 value of michellamine B was 33 μM. 
However, these two simplified analogues exhibited more activity (IC50 values of 36 μM 
and 30 μM, respectively) in inhibiting phosphorylation of histones by rat brain protein 
kinase C (IC50 = 130 μM) (Table 1.3). 
 
Figure 1.7 Simplified analogues of michellamine B. 




Protein kinase C 
IC50 (μM) 
michellamine B (17) 33 130 
23 62 36 
24 1000 30 
 
The importance of the isoquinoline unit in michellamine B to anti-HIV activity was 
evaluated by a series of structural analogues, in which the tetrahydroisoquinoline rings 
 




were exchanged with a variety of simple aromatic rings and the R unit was tested as 
either H, Me or OMe (Figure 1.8).58 All the analogues (25-27) showed no activities for 
anti-HIV, which indicated that the tetrahydroisoquinoline ring is an essential part for 
desired biological activity. Moreover, 25ie, 26iie and 27iiie bearing the 
dihydroxyphenyl substitution exhibited elicited toxicity in the CEM-SS cytoprotection 
assay,59 which suggested that the 2,4-dihydroxy substitution may play a significant role 







25i: R = H; 25ii: R = CH3; 25iii: R = OMe
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Figure 1.8 Michellamine B analogues in which isoquinoline units were replaced by different 
aromatic rings. 
Similar work from our group also indicate that the isoquinoline unit is essential to the 
anti-HIV activity (Figure 1.9).60 In this work, the central binaphthyl core of the 
michellamine B analogues was selectively attached with ethyl ester group instead of the 
original methyl group in some scaffolds, and aromatic ring units like phenyl or naphthyl 
were used to replace the isoquinoline unit. From the assays of activity against HIV-RT, 
all the analogues only showed weak inhibitory activities with a maximum 28% RT 
inhibition (26ia). The poor inhibition may be considered evidence for the importance of 
isoquinoline unit for anti-HIV properties. 
 






Figure 1.9 Michellamine B analogues in which isoquinoline units were replaced by different 
aromatic rings. 
Another report from our group has shown that binaphthyl derivative gossypol (27) 
(Figure 1.10) is a weak reverse transcriptase inhibitor and this pharmacophore based 
study was also supported by HIV RT testing.61 
 
Figure 1.10 Chemical structure of gossypol. 
1.2.3.2 Biaryl analogues inspired by michellamine B 
Since michellamine B (17) is a large lead compound with a molecular weight of 757 
g/mol, analogues with a smaller core unit replacing the binaphthyl core unit were 
designed and synthesized. During the last few years, our group was interested in the 
synthesis of biaryl scaffolds based on michellamine B (17) as a novel class of NNRTIs. 
 




The design of new michellamine B analogues was primarily based on decreasing the 
size of the molecules while maintaining the hydrophobic nature of the binaphthyl core. 
This can be done through the replacement of this core by smaller biaryl or biheterocyle 
scaffolds, including biindole (28), biphenyl (29), bipyrimidine (30), biaryl compound 
containing pyridine and uracil (31), biaryl compound containing pyridine and 
pyrimidine (32-33) (Figure 1.11). However, all the compounds only show weak to 
medium inhibitory activities against HIV RT, with a maximum 68.1% RT inhibition. 
 
Figure 1.11 Biaryl substitutions of the binaphthyl core of the michellamine B. 
1.2.3.3 Michellamine B analogues from or based on natural substrates  
Apart from the simplifying the structures of the michellamine B, efforts have been made 
to search for structural analogues of this promising anti-HIV lead with better 
 




pharmacological properties, either by isolation of further representatives from the plants 
or by synthetic procedures based on the obtained natural substrates.  
Jozimine A (35), as a first non-natural dimer of natural substrate dioncophylline A (34) 
which isolated from Triphyophyllum peltatum, was synthesized and evaluated for 
biological activity (Figure 1.12).62 Although, regrettably, it did not show a particular 
antiviral activity comparable to that of michellamine B (17), it surprisingly displayed a 
high antimalarial activity against P. falciparum, with an IC50 value of 0.075 μg/mL. On 
the other hand, michellamines are inactive towards P. falciparum and the monomeric 
alkaloid dioncophylline A (34) only showed a moderate activity with IC50 value of 1.44 
μg/ml (Table 1.4). These results provide impetus to design, synthesize, and test further 
related and non-related unnatural dimers of naturally occurring or artificial monomeric 
naphthylisoquinoline alkaloids.  
 
Figure 1.12 Chemical structure of dioncophylline A, jozimine A and C. 
A number of dimeric naphthylisoquinoline alkaloidsa were synthesized or isolated in 
the past few years, including pindikamine A,63 jozimine C (36),64 jozipeltine A,65 
ancistrogriffithine A,66 shuangancistrotectorines A-E,67 jozimine A2
68 and 
                                                              
a The structures of these dimeric naphthylisoquinoline alkaloids are showed in Appendix 1. 
 




mbandakamines A and B.69 Similar to jozimine A (35), these structural analogues of 
michellamine B all exhibit good anti-malarial activities. Only jozimine C (36) which 
has a close structural relationship to the michellamines showed comparable anti-HIV 
activity (EC50 = 27 μg/mL) to that of michellamine B (17) (EC50 = 14 μg/mL) 
(Table 1.4). 
Table 1.4 Bioactivities against HIV RT and P. falciparum.* 
Compounds IC50 (μg/mL) 
 HIV RT P. falciparum 
michellamine B64 14 NA 
jozimine A62 NA 0.075  
pindikamine A63 NA 1.23  
jozimine C64 27 0.445  
jozipeltine A65 NA 0.875~2.53  
ancistrogriffithine  A66 NA 0.035  
shuangancistrotectorines A-E67 NA 0.052~1.05  
jozimine A2
68 NA 0.0014 μM 
mbandakamines A and B69 NA 0.043~0.148 μM 
*The data are collected from different reported papers and the biological test conditions used 
may be different.  
1.3 Aims 
Since the discovery of the michellamine B as a potential anti-HIV drug, a great range of 
its analogues were designed and synthesized for the evaluation of bioactivities. From 
 




the previous reports,58,60,70 the isoquinoline unit has proven to play an essential part for 
bioactivity against HIV RT. Although, numerous works have been performed based on 
michellamine B, there is no systematic study of the isoquinoline analogues for anti-HIV 
properties.  
Therefore, the aims of this project are: 
1) To synthesis naphthyl boronic acid (37) or ester (38) as the core of the michellamine 
B analogues for subsequent Suzuki cross-coupling (discussed in Chapter 2).  
 
2) To design and synthesize novel halogenated isoquinolines (39-42) as the subunits of 
the michellamines B analogues for the subsequent Suzuki cross-coupling with naphthyl 
boronic acid (discussed in Chapter 2).  
 
3) To establish a robust Pd-catalyzed Suzuki cross coupling between the naphthyl 
boronic acid/ester (37, 38) and halogenated isoquinolines (39-42) leading to the 
monomeric naphthylisoquinolines. For example, 43 can be obtained from the Suzuki 
cross-coupling between 37 and 40. (discussed in Chapter 3). 
 





4) To synthesize the target dimeric michellamine B analogues via Ag2O-mediated 
oxidative dimerization of unprotected monomeric naphthylisoquinolines. For example, 
michellamine B analogue 45 can be obtained from the dimerization reaction of 
















5) To test the obtained michellamine B analogues and all the monomeric intermediates 
for their inhibition activity against HIV RT and to obtain information of 
structure-activity relationship (SAR). To test all the monomeric naphthylisoquinolines 





Chapter 2: Synthesis of Precursors 
2.1 The synthetic strategy  
Michellamine B, with its moderate anti-HIV activity, has gained significant interest, and 
various methods for constructing this unique dimeric naphthylisoquinoline alkaloid 
have been achieved.42,46,48,50 One of the most popular strategies is building this dimeric 
compound from active anti-malarial monomeric naphthylisoquinolines. In this strategy, 
naphthylisoquinoline is first synthesized from naphthylboronic acid/ester and 
brominated isoquinoline via a palladium-catalyzed Suzuki cross-coupling.48,50,56,71  
In this project, a similar strategy will be adopted to complete the synthesis of the 
michellamine B analogues. In order to prepare the monomeric naphthylisoquinoline, a 
naphthylboronic acid/ester and halogenated isoquinoline unit will be first prepared as 
precursors for the subsequent Suzuki cross-coupling. For example, the synthesis of 45 
can be achieved from monomeric naphthylisoquinoline 43 which requires two 
precursors 37 and 40 for the synthesis (Scheme 2.1). 
 
Scheme 2.1 The synthetic strategy towards the michellamine B analogue 45. 
 




2.2 Synthesis of naphthylboronic acid/ester 
2.2.1 The designed synthetic routes of naphthylboronic acid/ester 
The naphthylboronic acid/ester, as a major intermediate in the synthesis of 
michellamine B analogues, will be used for the subsequent Suzuki cross-coupling with 
isoquinoline units. There are currently two methodologies for the synthesis of this key 
intermediate.56,71 In this project, both methodologies were applied to obtain the target 
naphthylboronic acid/ester (37, 38). 
The first strategy starts from commercially available 3-hydroxybenzaldehyde 46, 
followed by a bromination reaction to give intermediate 47. A Wittig reaction will be 
applied to afford 48, then the naphthyl ring 49 can be obtained from the cyclization 
reaction. Finally a Miyaura borylation reaction will give the naphthylboronic ester 38 
(Scheme 2.2).71 This method was first established for the synthesis of the 
korupensamines, and the subsequent biomimetic synthesis of the michellamines.71  
 
Scheme 2.2 The synthetic strategy for naphthylboronic ester 38. 
The ethyl ester group at the 2-position in the naphthyl ring of 38 served as possible 
 




variable, which is structurally different compared to the methyl group in the naphthyl 
moiety of michellamine B. It allows for possible transformations, such as to the 
carboxylic acid or the methyl alcohol, allowing for the impact of this variable in HIV 
inhibition to be assessed. The bromo substituent at the C8 position served as a good 
handle for the subsequent borylation reaction or direct Suzuki cross-coupling with 
boronic acids/esters.  
The second strategy is a recently developed methodology to build the naphthyl ring.56 
Starting from the commercially available 3,3-dimethylacrylic acid 50, an esterification 
and addition reaction will give diene 51. Then, a Diels-Alder reaction with 
1,4-benzoquinone will be employed to afford the dione 52. After 5 steps (reduction, 
protection, deprotection, triflation and Miyaura borylation), the naphthylboronic acid 37 
can be obtained for the subsequent Suzuki cross-coupling reaction (Scheme 2.3).  
 
Scheme 2.3 The synthetic strategy of naphthylboronic acid 37. 
2.2.2 Naphthylboronic ester synthesized by the Wittig method 
2.2.2.1 Synthesis of brominated naphthyl 49 
The precursor ylide 54 was first prepared from triethyl phosphonoacetate and tert-butyl 
bromoacetate in quantitative yield using the Arbuzov reaction and was purified via 
bulb-to-bulb distillation. The hydroxyl group in the commercially available 
benzaldehyde 46 was protected using 2-bromopropane, followed by a bromination 
reaction on the phenyl ring to afford 47, both in 87% yield. A 
 




Horner-Wadsworth-Emmons reaction was then applied using the prepared ylide 54 to 
afford the intermediate 48 in 71% yield. A one-pot, three-step (hydrolysis, cyclisation 
and hydrolysis) ring closure gave naphthyl 56 with free phenol group in a 98% yield. 
Methylation of 56 gave the brominated naphthyl 49 in 92% (Scheme 2.4). 
 
Scheme 2.4 Reagents and conditions: (i) tert-butyl bromoacetate, NaH, THF, 0 oC, 15 h, 96%; 
(ii) 2-bromopropane, K2CO3, DMF, 18 h, 87%; (iii) Br2, NaOAc, DMF, rt, 18 h, 87%; (iv) NaH, 
THF, 0 oC, 18 h, 71%; (v) 1) TFA, rt, 15 h; 2) acetic anhydride, 5 h; 3) NaOEt, rt, 4 h; 98%; (vi) 
K2CO3, acetone, 15 h, 92%. 
Analysis of the EI mass spectrum of 49 showed a peak at m/z 366 assigned as molecular 
ion. The protons of the C4 methoxy group were assigned to the singlet at δ 4.00 ppm in 
the 1H NMR spectrum, while the ethyl ester protons were assigned to the coupled triplet 
and quartet at δ 1.45 ppm and δ 4.45 ppm respectively. The isopropyl methyl groups 
were equivalent, assigned to the doublet at δ 1.40 ppm. The naphthyl ArH1 and ArH3 
were assigned to the doublets at δ 8.56 ppm and δ 7.46 ppm respectively with a 
coupling constant of 1.2 Hz, while the ArH6 and ArH7 were assigned to the doublets at 
δ 6.87 ppm and δ 7.70 ppm respectively with a coupling constant of J = 7.8 Hz. 
 




This six-step synthesis proceeded in 47% overall yield and all the compounds 
synthesized were spectroscopically identical to those reported.70 
2.2.2.2 Attempted reduction of the ethyl ester group in 49 
In order to be consistent with the structure of michellamine B, the ethyl ester group in 
49 required conversion into the methyl group via reduction (57), bromination (58) 
followed by another reduction reaction (59) (Scheme 2.5). However, attempts at the 
initial reduction of the bromine handle at C8 position using LiAlH4 at 0 
oC resulted in 
the naphthyl 60 in 76% yield, despite a high yield being reported for the same 
reaction.71 As the ester group in the naphthyl ring could impact anti-HIV activity of 
michellamine B analogues, and hence be important for the SAR studies in this project, it 
remained in our scaffolds. An alternative methodology will be used to achieve the 
desired naphthylboronic acid with the methyl substituent 37 (discussed in next section 
2.2.3). 
 
Scheme 2.5 Attempted reduction of ethyl ester group in 49. 
 
 




2.2.2.3 Borylation of the brominated naphthyl 49 
The preparation of boronic esters via a palladium catalyzed cross-coupling reaction of 
bis(pinacolato)diboron and aryl halides were described for the first time in 1995.72 
Before that, arylboronic acids were traditionally synthesized using Grignard or lithium 
reagents.73,74 For this project, borylation was attempted using activated aryl halides and 
the critical base, potassium acetate. 
The boronic ester 38 was prepared using the Miyaura borylation conditions 
(Scheme 2.6). A solution of brominated naphthyl 49, bis(pinacolato)diboron (61), 
potassium acetate and PdCl2(dppf) in THF was heated at reflux for 18 h to give the 
naphthylboronic ester 38 in 91% yield. Analysis of the 1H NMR spectrum of 38 
indicated a new strong singlet peak located at δ 1.26 ppm assigned to the tetramethyl 
groups (2×C(CH3)2) in the boronic ester. From the 
13C NMR spectrum of 38, the peaks 
at δ 83.6 and δ 83.7 ppm were assigned to the two quaternary carbons and the 
tetramethyl groups were assigned to the peaks at δ 25.1 and δ 25.0 ppm. The peak in the 
MS (EI) spectrum at m/z 414 was assigned as the molecular ion of the boronated 
naphthyl 38. The boronated naphthyl 38 was spectroscopically identical to that reported 
in the literature.60 
 
Scheme 2.6 Borylation of the brominated naphthyl 53. 
 




Scheme 2.7 illustrates the proposed catalytic cycle75 of the Miyaura borylation to 
produce the boronated naphthyl 38. It proceeds via oxidative addition of the aryl halide 
to the palladium complex. Then, the halogen of the arylpalladium(II) halide is replaced 
by an acetate ion, followed by a transmetalation between bis(pinacolato)diboron and 
this acetate arylpalladium(II) intermediate species. Finally, reductive elimination 







































Scheme 2.7 Suggested catalytic cycle for the Miyaura borylation. 
2.2.3 Naphthylboronic acid prepared by the Diels-Alder method 
Due to the failure of the reduction reaction from ethyl ester group to the methyl in the 
naphthyl unit 49, an alternative methodology was employed. This recently reported 
strategy developed boronic acid 37 from the commercially available carbocyclic acid 50 
in a concise synthesis with high yields.56 Key steps include a Diels-Alder reaction, a 
selective protection of phenol, and a Miyaura borylation. 
 




Starting from commercially available 3,3-dimethylacrylic acid 50, esterification with 
excess methanol catalyzed by concentrated H2SO4 provided the ester 62 as a colourless 
oil in 83% yield after purification by a reduced pressure distillation (Scheme 2.8).  
Commercial LDA reagent and TMSCl was first used to react with 62 to prepare the 
desired diene 51, however, a low yield (37%) was obtained. This was attributed to the 
deactivation of the LDA reagent. Therefore, the LDA was freshly prepared before 
reaction from diisopropylamine and n-BuLi,76 and the desired diene 51 was obtained as 
a light yellow liquid in a quantitative yield (98%) and used for next step without further 
purification. 
 
Scheme 2.8 Reagents and conditions: (i) MeOH, conc. H2SO4, reflux, 16 h, 83%; 
(ii) 1) diisopropylamine, n-BuLi, THF, −78 oC to rt, 2 h; 2) TMSCl, −78 oC to rt, 3 h, 98%; 
(iii) benzoquinone, CH2Cl2, AcOH, rt, 24 h, 84%; (iv) 1) Na2S2O4, CH2Cl2, H2O, rt, 1 h; 
2) PivCl, Et3N, CH2Cl2, 0 
oC, 2.5 h, 87%; (v) BnBr, NaH, DMF, 0 oC to rt, 1 h, 93%; 
(vi) 1) conc. KOH, MeOH, H2O, 50 
oC, 3 h; 2) Tf2O, Et3N, −78 
oC, 0.5 h, 89% (vii) Pd(dppf)Cl2, 
dppf, bis(pinacolato)diboron, dioxane, 100 oC, 7 h, 92 %; (viii) NaIO4, conc. HCl, THF, H2O, rt, 
12 h, 82%.  
A Diels-Alder reaction between diene 51 and 1,4-benzoquinone afforded dione 52 in 84% 
yield as yellow crystals after recrystallization from methanol. Na2S2O4 was used to 
 




reduce the dione 52 to a diphenol intermediate, followed by a selective substitution of 
the phenolic substituent. The phenol not protected by H-bonding is more reactive and 
was substituted by the pivaloyl chloride, affording 63 as a white solid in 87% yield over 
two steps. Benzyl bromide was used to protect the other phenol group giving 64 in 93% 
yield. The pivaloyl group in 64 was then removed using KOH and then the deprotected 
intermediate was reacted with triflic anhydride to afford the triflate compound 65 in 89% 
yield.  
The boronic ester 66 was prepared in 92% yield via a Miyaura borylation reaction using 
Pd(dppf)Cl2 and bis(pinacolato)diboron (61). In order to improve the yield of the 
subsequent Suzuki coupling, a more active boronic acid 37 was prepared from 66 in 82% 
yield using NaIO4 in an acidic aqueous condition (Scheme 2.8). 
The structure of boronic acid 37 was initially identified from the peak at m/z 322 in the 
MS (EI) spectrum assigned as the molecular ion. A comparison of the 1H NMR spectra 
of boronic ester 66 with the boronic acid 37 showed that the highfield singlet peak at δ 
1.40 ppm assigned to tetramethyl groups in the spectrum of 66 could not be observed in 
the spectrum of 37, indicating the boronic ester had been removed. The signals of ArH3 
and ArH6 in the spectrum of 37 were shifted downfield to δ 6.95 ppm and δ 6.80 ppm 
compared to δ 6.84 ppm and δ 6.70 ppm in 66, the peaks assigned to the methyl group 
in the spectrum of 37 were shifted highfield to δ 2.46 ppm compared to δ 2.49 ppm in 
66, while the peak assigned to the methoxy stayed the same at δ 3.92 ppm in both 66 
and 37. Notably, the carbon directly attached to the boron atom in both 66 and 37 didn’t 
show any signal in the 13C NMR spectra, even after a 12 h scan in high concentration. 
The naphthylboronic acid 37 was spectroscopically identical to that reported in the 
literature.56 
 




2.3 Synthesis of 3,4-dihydroisoquinolines 
2.3.1 Design of dihydroisoquinoline units 
There have been limited studies on the importance of the tetrahydroisoquinoline unit of 
michellamine B for anti-HIV activity. There is only one report mentioning that the 
tetrahydroisoquinoline unit plays an essential role in its activity.58 In this report, the 
tetrahydroisoquinoline unit in michellamine B was replaced by different aromatic 
substituents, and most of the tested derivatives showed little or no activity against 
HIV.58 Similar work from our group concurred with this result.60,70  
However, in these studies none of the substituents have structural similarity to the 
tetrahydroisoquinoline unit. Therefore, investigation towards tetrahydroisoquinoline 
analogues, such as dihydroisoquinoline and dihydroisoquinolin-1(2H)-one, in 
michellamine B derivatives is of great significance, and will also provide information 
for SAR study. 
The design of these dihydroisoquinoline units (39-42, Figure 2.1) was based on: 
1) An introduction of double bound between C1 and N to afford the 
3,4-dihydroisoquinoline system, which removes one chiral element in the 
tetrahydroisoquinoline and shortens the synthetic procedure. 
2) A removal or replacement of OH groups on C6 and C8 by OMe groups due to the 
reported toxicity associated with phenolic groups.58  
3) The introduction of a carbonyl group on C1 to increase the hydrophilicity of the 
molecule. 
4) An introduction of halogen handles (Br or I) at C5 for subsequent Suzuki coupling 
 




reaction to afford the monomeric naphthylisoquinoline alkaloid. 
 
Figure 2.1 Structure of michellamine B and the designed 3,4-dihydroisoquinoline derivatives. 
2.3.2 Synthetic strategy 
There are many synthetic strategies developed for the synthesis of 1,2,3,4-tetra- and 
3,4-dihydroisoquinoline derivatives and most of them contains a key step – a cyclisation 
reaction of phenylethylamine derivatives which can be achieved under the 
Bischler-Napieralski conditions. It is reported that electron donating aryl substituents 
such as hydroxyl and methoxy groups are required to allow such ring closures to 
occur.77-79  
The synthesis of the designed 3,4-dihydroisoquinoline derivative 72 was proposed in 
Scheme 2.9. The first step involves the condensation between the appropriate aldehyde 
and nitromethane which would afford the nitrostyrene 68. Reduction of nitrostyrene 
would produce the phenylethylamine derivative 69, which can then be converted to the 
key acetamide intermediate 70 by acetylation. Bromination at C2 would afford the 
intermediate 71 which can be cyclized at C5 position under Bischler-Napieralski 
conditions to produce the desired dihydroisoquinoline derivatives 72. 
 





Scheme 2.9 Proposed synthesis of brominated 3,4-dihydroisoquinoline 72. 
In order to introduce the carbonyl group in the isoquinoline unit to increase the 
hydrophilicity of the molecule, 3,4-dihydroisoquinolin-1(2H)-one is designed and the 
synthesis of this scaffold involves a key electrophile intermediate 
isocyanatoalkylbenzene (Scheme 2.10). This isocyanate intermediate also allows the 
ring closure to occur in intermediate 75, as a normal Bischler-Napieralski reaction 
requires electron donating aryl substituents such as hydroxyl and methoxy groups for 
such ring closures; groups lacking in 75. 
In this proposed synthetic strategy for 3,4-dihydroisoquinolin-1(2H)-one, a nitroaldol 
condensation reaction with commercially available 2-bromobenzyaldehyde will first 
give nitrostyrene intermediate 74, followed by a reduction reaction to afford 
phenylethylamine derivative 75. An isocyanate formation reaction of 75 will then give 
the key intermediate isocyanatoalkylbenzene 76. A Friedel-Crafts type cyclisation 
reaction will finally furnish the 3,4-dihydroisoquinolin-1(2H)-one 42 (Scheme 2.10). 
 





Scheme 2.10 Proposed synthesis of 3,4-dihydroisoquinolin-1(2H)-one. 
2.3.3 Synthesis of 3,4-dihydroisoquinolines 39-42 
2.3.3.1 Synthesis of 3,4-dihydroisoquinolines 39-41 
Starting from commercially available benzaldehyde 77 and 78, a nitroaldol reaction 
using nitromethane catalysed by ammonium acetate produced the desired nitrostyrenes 
79 (91%) and 80 (96%) in high yields after purification by recrystallization from 
methanol.  
The nitrostyrenes were then reduced by LiAlH4 to afford the corresponding 
phenylethylamine intermediates which were directly acetylated using acetyl chloride to 
afford N-phenethylacetamide 81 (56%) and 82 (63%). N-acetyl-N-phenethylacetamides 
were also obtained as side products from these reactions. The purification of the 
phenylethylamine intermediates were also attempted and lower yields of acetamide 81 
(38%) and 82 (45%) were eventually obtained. These may be attributed to the loss of 
phenylethylamines during the column chromatography. 
The bromination reaction using Br2 gave the brominated amides 83 (87%) and 84 (89%). 
Finally, a Bischler-Napieralski cyclisation with POCl3 furnished the brominated 
3,4-dihydroisoquinolines 39 and 40 as brown solids in 88% and 90% yields, 
 




respectively (Scheme 2.11).  
 
Scheme 2.11 Reagents and conditions: (i) CH3NO2, CH3COONH4, AcOH, reflux, 5 h; 
(ii) a. LiAlH4, THF, 0 
oC to reflux, 5 h; b. CH3COCl, Et3N, THF, 0 
oC, 15 min; (iii) Br2, CH2Cl2, 
0 oC to rt, 2 h; (iv) P2O5, POCl3, CH3CN, reflux, 6 h. 
Analysis of the mass spectrum (EI) of 39 showed isotopic peaks for the 
monobrominated derivative at m/z 253 and m/z 255 assigned to the molecular ion peak. 
Analysis of the 1H NMR spectrum for 39 revealed two ortho-split doublets at δ 7.87 
ppm and δ 7.00 ppm, each with a relative integration of one, were assigned to the 
aromatic protons H6 and H7 respectively, with the corresponding carbons assigned to 
the peaks at δ 141.5 ppm (C6) and δ 113.2 ppm (C7) in the 13C NMR spectrum. 
Analysis of the mass spectrum (EI) of 40 showed isotopic peaks for the 
monobrominated derivative at m/z 283 and m/z 285 assigned to the molecular ion peak. 
The 1H NMR spectrum for 40 showed only one singlet proton in the aromatic region at 
δ 6.81 ppm assigned to the aromatic proton H7 with the corresponding carbon assigned 
to a resonance at δ 96.9 ppm (C7) in the 13C NMR spectrum. The NMR and MS spectra 
of both 39 and 40 were consistent with the reported data.80 
 




The mechanism for the cyclization of phenylethylamides under Bischler-Napieralski 
conditions has been studied by Fodor and Nagubandi.81 The reaction involves an initial 
dehydration step of the amide, mediated by the condensing agent, followed by 
cyclization (Scheme 2.12). The dehydration step starts by the nucleophilic attack of the 
carbonyl group on the phosphorus atom of POCl3, forming species 85. Deprotonation of 
85 leads to the formation of the imidoyl phosphate species 86 in which the loss of the 
phosphate as a good leaving group affords the imidoyl salt 87. At elevated temperatures, 
the benzene ring affects the new ring closure through the nucleophilic attack at 
acetyleynic carbon forming the intermediate 88 which deprotonates rapidly under the 
influence of aromaticity to afford the 3,4-dihydroisoquinoline derivative 72. 
 
Scheme 2.12 Mechanism of the Bischler-Napieralski cyclization. 
Later experiments (see Chapter 3.1.2) illustrated that a more active handle on the 
isoquinoline with methoxy on C6 was required. Therefore, iodo 3,4-dihydroisoquinoline 
41 was prepared. From the acetamide 89, iodination using I2 and Ag2SO4 furnished the 
iodo acetamide intermediate 90 as a white solid in 87% yield. Iodo 
3,4-dihydroisoquinoline 41 was then obtained as a yellow solid in 86% yield via a 
 




Bischler-Napieralski cyclisation of 90 with POCl3 (Scheme 2.13).  
Scheme 2.13 Synthesis of iodo-3,4-dihydroisoquinoline 41. 
Analysis of the mass spectrum (EI) of 41 showed a peak at m/z 331 assigned to the 
molecular ion. The 1H NMR spectrum of 41 showed only one singlet proton in the 
aromatic region at δ 6.76 ppm assigned to the aromatic proton H7, with the 
corresponding carbon assigned to a resonance at δ 96.0 ppm (C7) in the 13C NMR 
spectrum. Two triplets at δ 3.71 ppm and δ 3.19 ppm were assigned to the H3 and H4 
protons respectively. The most downfield peak located at δ 176.1 ppm was assigned to 
C1 in the 13C NMR spectrum. Two close peaks located at δ 167.7 ppm and δ 166.7 ppm 
were assigned to the C8 and C6 attached with methoxy group. 
2.3.3.2 Synthesis of 3,4-dihydroisoquinolin-1(2H)-one 42 
The synthesis of 3,4-dihydroisoquinolin-1(2H)-one82 started from commercially 
available 2-bromobenzaldehyde 73. Nitroaldol condensation of 73 was first carried out 
using nitroethane and resulted in the synthesis of nitrostyrene 74 in 96% yield. The 
compound 74 was then reduced to the primary amine 75 using LiAlH4 in 87% yield. 
The isocyanate 76 was obtained in 71% from the reaction between primary amine 75 
and triphosgene. The final cyclisation reaction of 76 with AlCl3 and tetrachloroethylene 
gave the desired 3,4-dihydroisoquinolin-1(2H)-one 42 in 31% yield (Scheme 2.14). 
 





Scheme 2.14 Reagents and conditions: (i) CH3CH2NO2, CH3COONH4, AcOH, reflux, 2 h, 96%; 
(ii) LiAlH4, H2SO4, THF, 0 
oC to rt, 18 h, 87%; (iii) triphosgene, toluene, reflux, 3 h, 71%; (iv) 
AlCl3, tetrachloroethylene, 80 
oC, 3 h, 31%. 
Analysis of the EI mass spectrum of 42 showed isotopic peaks for the monobrominated 
derivative at m/z 241 and m/z 239 assigned to the molecular ion. The 1H NMR spectrum 
of 42 showed two doublets at δ 8.00 ppm and δ 7.72 ppm assigned to the aromatic 
proton H8 and H6 respectively, with the corresponding carbons assigned to the peaks at 
δ 127.3 ppm (C8) and δ 135.9 ppm (C6) in the 13C NMR spectrum. A triplet (J = 8.0 Hz) 
at δ 7.28 ppm was assigned to the aromatic proton H7, with the corresponding carbon 
assigned to the peak at δ 128.4 ppm in the 13C NMR spectrum. The peak at δ 164.6 ppm 
in the 13C NMR spectrum was assigned to the carbonyl carbon C1. The 
3,4-dihydroisoquinolin-1(2H)-one 42 was spectroscopically identical to that reported in 
the literature.82 
The ring closure in this reaction is based on the 1:1 complex formation of aluminum 
chloride and the corresponding isocyanate. Upon the formation of the intermediate 91 
an intramolecular nucleophilic attack at the electrophilic carbon leads to ring closure 
(species 92). Rearomatisation and protonation of the oxygen atom give rise to 
intermediate 93 and subsequent keto-enol tautomerism affords the 
3,4-dihydroisoquinolin-1(2H)-one 42 (Scheme 2.15). 
 





Scheme 2.15 Proposed mechanism of the cyclization reaction of isocyanate (69) to afford 
3,4-dihydroisoquinolin-1(2H)-one (42). 
2.4 Conclusions  
The naphthylboronic acid/ester (37-38) and halogenated isoquinolines (39-42) were 
synthesized as precursors for the subsequent Suzuki cross-coupling to afford the 
monomeric naphthylisoquinoline alkaloids. 
The naphthylboronic acid 37 was synthesized by a Diels-Alder method over 8 steps 
proceeding in 37% overall yield from commercially available 3,3-dimethylacrylic acid 
50. The naphthylboronic ester 38, with an ethyl ester substituent in the naphthyl ring, 
was prepared by a Wittig method over 7 steps with an overall yield of 43%. 
 




Halogenated 3,4-dihydroisoquinolines (39-41) featuring methoxy groups and double 
bonds between C1 and N were obtained from a four-step synthesis proceeding in 39-48% 
overall yields from commercially available benzaldehydes. Brominated 
3,4-dihydroisoquinolin-1(2H)-one 42 with a carbonyl group was successfully prepared 
over 4 steps with an overall yield of 18%.  
  
 








Chapter 3: Synthesis of Michellamine B Analogues 
3.1 Preparation of monomeric naphthylisoquinoline alkaloids via Suzuki coupling 
3.1.1 Background of the Suzuki coupling 
There are many synthetic routes for the construction of aryl-alkyl bonds in modern 
synthetic chemistry and palladium-catalyzed reactions have a prominent place among 
these methods.83,84 These reactions are widespread in the synthesis of active/functional 
molecules in life sciences and material sciences. Palladium-catalyzed Suzuki–Miyaura 
cross-coupling, which was first reported in 1979,85 has contributed with a great impact 
on organic synthesis due to the easy preparation of the precursors, high yield and the 
low toxicity of by-products.86 This reaction is widely used to build the biaryl linkage in 
the synthesis of michellamine B analogues.46,51,56,71 The 2010 Nobel Prize in Chemistry 
was awarded jointly to Richard F. Heck, Ei-ichi Negishi and Akira Suzuki for their 
work on Pd-catalyzed cross-coupling synthesis.87-89  
In the Suzuki reaction, the coupling of arylboronic acids/esters with aryl halides has 
been widely explored and these reactions are generally catalyzed by palladium 
complexes with various ligands. The general scheme for the Suzuki reaction is shown 
below where a carbon-carbon single bond is formed by coupling an organoborane with 
a halide using a palladium catalyst and a base (Scheme 3.1). 
 
 





Scheme 3.1 Palladium-catalyzed Suzuki-Miyaura cross-coupling reaction. 
The reaction rate of Suzuki coupling is determined by the relative reactivity of the aryl 
halide decreasing depending on the halogen substituent in order of I > OTf > Br > Cl. 
Moreover, aryl halides with electron-withdrawing groups are more reactive compared to 
electron rich aryl halides.74,903.1.2 Synthetic strategy towards towards monomeric 
naphthylisoquinoline alkaloids 
The monomeric naphthylisoquinoline alkaloids, which showed good anti-malarial 
activity, are the precursors of the michellamine B analogues. They can be synthesized 
by a coupling reaction between the corresponding naphthyl unit and isoquinoline unit. 
Herein, naphthylboronic ester 38 and naphthylboronic acid 37 will be used to react with 
halogenated isoquinoline 39-42 separately via Pd-catalyzed Suzuki cross-coupling to 
synthesize the monomeric naphthylisoquinoline alkaloids 94 and 95. 
 
 




Scheme 3.2 Synthetic strategy towards towards monomeric naphthylisoquinoline via Suzuki 
cross-coupling. 
3.1.3 Suzuki coupling using naphthylboronic ester 38 towards monomeric 
naphthylisoquinoline alkaloids 
The initial attempt at this Suzuki cross-coupling was based on the method developed in 
the previous synthesis of biaryl scaffolds in our group.80 In this reaction, a catalyst 
system of Pd(dba)3, Buchwald’s ligands
91-93 and K3PO4 were used to give the 
naphthylisoquinoline alkaloid 96 (Entry 1, Table 3.1). However, the reaction in the 
presence of this powerful catalyst afforded the desired product 96 in only 11% yield. 
Other separated products from the reaction mixture included the de-brominated 
derivative, starting material, and homo-coupled product, as evidenced by mass 
spectroscopy (ESI) analysis. Compound 96 obtained relative good solubility in most 
polar solvents such as CH2Cl2 and methanol, and a triethylamine deactivated column 
chromatography (hexane/ethyl acetate: 50/50) was used to purify this compound. 
Analysis of the 1H NMR spectrum of 96 showed two ortho-split doublets (J = 8.5 Hz) at 
δ 7.28 ppm and δ 6.97 ppm assigned to the aromatic protons H6 and H7 in the 
isoquinoline unit, with the corresponding carbons assigned to the peaks at δ 133.7 ppm 
(C6) and δ 109.9 ppm (C7) in the 13C NMR spectrum. The two meta-split doublets (J = 
1.0 Hz) at δ 7.78 ppm and δ 7.39 ppm in 1H NMR spectrum were assigned to the 
aromatic protons ArH1 and ArH3 in the naphthyl ring with the corresponding carbons 
assigned to the peaks at δ 121.8 ppm (ArC1) and δ 105.1 ppm (ArC3) in the 13C NMR 
spectrum. 2D NMR spectroscopy (gCOSY, gHSQC and gHMBC) was used to assign 
the two methoxy groups Ar4-OCH3 (δ 4.02 ppm) and 8-OCH3 (δ 3.95 ppm), 
corresponding to the peaks at δ 56.5 ppm and δ 55.6 ppm in the 13C NMR spectrum, 
respectively. The peak at lowest downfield (δ 166.8 ppm) in 13C NMR spectrum was 
 




assigned to the carbonyl carbon in the ester group and the following peak (δ 164.9 ppm) 
was assigned to C1 in the isoquinoline unit. The peak at m/z 461 in the MS (EI) 










Table 3.1 Trial coupling reactions to give naphthylisoquinoline alkaloid 96.  
 









1 Pd(dba)3* K3PO4 dioxane/H2O 18 h 11% 
2 Pd(dppf)Cl2 K2CO3 dioxane/H2O 18 h 39% 
3 Pd(PPh3)4 K3PO4 dioxane/H2O 18 h 58% 
4 Pd(PPh3)4 K3PO4 DME/H2O 18 h 57% 
5 Pd(PPh3)4 Ba(OH)2 DME/H2O 18 h 40% 
6 Pd(PPh3)4 NaHCO3 DME/H2O 18 h trace 
7 Pd(PPh3)4 Na2CO3 DME/H2O 18 h 42% 
8 Pd(PPh3)4 Na2CO3 toluene/H2O 18 h 44% 
9 Pd(PPh3)4 K3PO4 toluene/H2O 18 h 57% 
       *Buchwald’s ligands were used in this reaction. 
The optimisation of this reaction involved the use of different palladium catalysts, bases 
and solvents, and is summarised in Table 3.1. The first attempt (Entry 1) using a 
catalytic system of Pd(dba)3 and Buchwald’s ligands afforded the coupled product 96 
only 11% yield. After replacing the catalyst with Pd(dppf)Cl2/K2CO3 (Entry 2), a 
moderate yield of 39% was obtained and a lower amount of the de-brominated product 
was detected by TLC and MS spectrum. Probing the reaction conditions using 
Pd(PPh3)4 as the palladium catalyst while keeping the base with K3PO4 and solvent 
dioxane significantly increased the yield of 96 (58%, Entry 3), even with a half load of 
the catalyst. All the Pd(PPh3)4 used in the coupling reactions are prepared from PdCl2 
and triphenylphosphine in our laboratory.  
The screening of different bases indicated that K3PO4 was more efficiently applied in 
palladium catalytic systems containing Pd(PPh3)4, although the choice of base is still 
empirical and no general rule for their selection has been established. Specifically, the 
 




strong base of Ba(OH)2 gave a decreased yield of 40% (Entry 5), the weak Na2CO3 
resulted in a comparable yields (42% in DME and 44% in toluene, Entry 7 and Entry 8), 
while the weakest base NaHCO3 obtained the worst results and only trace amount of 96 
was produced in this reaction (Entry 6). All the bases used were dissolved in distilled 
water with a concentration of 5 M. 
The use of different solvents indicated that the solvent had only small impact to the 
yield of the coupling reaction. The reaction involves the solvent dioxane (Entry 3) gave 
the best yield of 58%, while the reactions with the other two solvents (DME and toluene, 
Entry 4 and Entry 9) produced slightly less compound, both with the yield of 57%. 
The reaction time of this Suzuki cross-coupling hasn’t been systematically studied. The 
only information obtained from the experiments illustrated that the reaction with a 
longer time (24 h) resulted in the same yield (58%) under the catalytic system of 
Pd(PPh3)4/K3PO4/dioxane.   
The catalytic cycle74 of this Suzuki cross-coupling reaction starts with oxidative 
addition, followed by transmetalation and then reductive elimination (Scheme 3.3). The 
first step is the oxidative addition of the organohalide to the Pd(0) to form a Pd(II) 
complex. A molecule of the hydroxide or alkoxide base then replaces the halide on the 
palladium complex, while another adds to the organoborane to form a borate reagent 
making its R2 group more nucleophilic. In the transmetalation step, the R2 group from 
the borate replaces the halide anion on the palladium complex. Reductive elimination 
then gives the final coupled product, regenerates the palladium catalyst, and the 
catalytic cycle can begin again. 
 





Scheme 3.3 Palladium-catalyzed Suzuki-Miyaura cross-coupling catalytic cycle.74 
Based on the above trial reactions, a catalytic system of Pd(PPh3)4/K3PO4/dioxane was 
selected to conduct the Suzuki coupling reactions with an additional two isoquinoline 
units (Table 3.2). The reaction of boronic ester 38 with brominated isoquinoline 40 was 
then attempted under these conditions, giving the desired 97 in trace amount only 
(Table 3.2, Entry 1). The low yield obtained was attributed to the decreased reactivity 
of the aryl halide caused by the electron rich methoxy group attached in C6 
position.74,94,95 Instead of searching a more efficient catalytic system, a more reactive 
substituent in the isoquinoline unit such as iodo or OTf groups was evaluated to 
optimize the yield of 97. This concept was also supported by previous report.96 A novel 
isoquinoline scaffold 41 with a iodide handle was then prepared and used for the Suzuki 
coupling reaction. To be expected, 97 was obtained in a much better yield of 44% under 
the same reaction conditions (Entry 2) after purification by a triethylamine deactivated 
 




flash silica gel column chromatography (hexane/ethyl acetate: 50/50). The problem 
associated with steric hindrance at C5 position in the isoquinoline unit made this 
moderate yield satisfactory for the purpose of this project. 
Analysis of the 1H NMR spectrum of 97 showed a singlet at δ 6.52 ppm assigned to the 
aromatic proton in the isoquinoline unit with the corresponding carbon assigned to a 
resonance at δ 94.1 ppm in the 13C NMR spectrum. Two ortho-split doublets (J = 7.8 
Hz) at δ 7.20 ppm and δ 7.06 ppm were assigned to the aromatic protons ArH7 and 
ArH6 in the naphthyl ring with the corresponding carbons assigned to the peaks at δ 
129.6 ppm (ArC7) and δ 114.1 ppm (ArC6) in the 13C NMR spectrum. Two singlets 
located at δ 7.71 ppm and δ 7.37 ppm in the aromatic range of 1H NMR spectrum were 
assigned to the aromatic protons ArH1 and ArH3 in the naphthyl ring with the 
corresponding carbons assigned to the peaks at δ 121.7 ppm and δ 105.2 ppm in the 13C 
NMR spectrum. 2D NMR spectroscopy (gCOSY, gHSQC and gHMBC) was used to 
assign the three methoxy groups Ar4-OCH3 (δ 4.01 ppm), 8-OCH3 (δ 3.97 ppm) and 
6-OCH3 (δ 3.68 ppm), corresponding to the peaks at δ 56.6 ppm, δ 55.8 ppm and δ 55.6 
ppm in the 13C NMR spectrum, respectively. The peak in the MS (EI) spectrum at m/z 
491 was assigned as the molecular ion of the naphthylisoquinoline alkaloid 97. 
Table 3.2 Suzuki coupling reaction to synthesize naphthylisoquinoline alkaloid 97-98. 
 
 




Entry Ar X Isoquinoline Product Yield 
1 
 
Br 40 97 trace 
2 
 
I 41 97 44% 
3 
 
Br 42 98 54% 
 
The same catalytic system of Pd(PPh3)4/K3PO4/dioxane was applied to the coupling 
reaction between naphthylboronic ester 38 and brominated 
3,4-dihydroisoquinolin-1(2H)-ones 42 (Table 3.2, Entry 3). Naphthylisoquinoline 
alkaloid 98 was obtained as a brown solid in 54% yield and was purified by a 
triethylamine deactivated flash silica gel column chromatography (hexane/ethyl acetate: 
50/50).  
X-ray quality crystals of 98 were obtained by recrystallization from a mixture of CH2Cl2 
and hexane. The X-ray structureb of compound 98 (see Appendix 2.1 for X-ray 
crystallographic data) showed that the naphthyl ring and isoquinoline ring are not in the 
same plane but distributed as vertical to each other, which significantly reduces the 
steric hindrance of C5 position in the isoquinoline unit, allowing the Suzuki reaction to 
occur. The ethyl ester substituent in the naphthyl ring and the methyl group in the 
                                                              
b
  All the X-ray crystallographic structures in this thesis were solved by Dr. Anthony Willis from 
Australian National University. 
 




isoquinoline unit stop the axis between C10 and C11 from freely rotation, making 
compound 98 feature an axial chirality (Figure 3.1).  
 
Figure 3.1 The crystal structure of naphthylisoquinoline alkaloid 98. 
Diastereomerism of 98, caused by axial chirality, can be observed from the 1H NMR 
spectrum. Two singlets located at δ 7.78 ppm and δ 7.60 ppm, each with a relative 
integration of half proton, were assigned to the aromatic proton ArH1 in the naphthyl 
ring. Similarly, the peaks located at δ 7.28 ppm and δ 7.23 ppm, each with a relative 
integration of half proton, were assigned to the aromatic proton ArH7. 
Comparing the four Suzuki cross-coupling reactions between naphthylboronic ester 38 
and four different isoquinoline units (39-41), reaction involving 39 gave the best 
coupling yield (58%), while the brominated isoquinoline 40 with a methoxy group in 
C6 position were inactive in the coupling reaction. The X-ray quality crystal of 
naphthylisoquinoline alkaloid 98 can be obtained, which may be attributed to the 
introduction of carbonyl group in the isoquinoline unit favouring the formation of 
H-bonds. 
 




3.1.4 Suzuki coupling using naphthylboronic acid 37 towards monomeric 
naphthylisoquinoline alkaloids 
The Suzuki cross-coupling reactions between naphthylboronic acid 37 and halogenated 
isoquinolines 39-42 were performed using the catalyst system of 










Table 3.3 Suzuki coupling reaction to synthesize naphthylisoquinoline alkaloid 43, 99-100. 
 
Entry Ar X Isoquinoline Product Yield 
 





OMe Me  
Br 39 99 57% 
2 
 
Br 40 43 trace 
3 
 
I 41 43 51% 
4 
 
Br 42 100 75% 
 
Naphthylisoquinoline 99 was obtained as a light brown solid in 57% (Entry 1) after 
purification by a triethylamine deactivated flash silica gel column chromatography 
(hexane/ethyl acetate: 60/40). Analysis of the 1H NMR spectrum of 99 showed peaks 
located at the range of δ 7.66-7.33 ppm and δ 5.23 ppm which were assigned to the 
aromatic protons and the methylene protons respectively of the benzyl protecting group. 
Two ortho-split doublets (J = 8.5 Hz) at δ 7.27 ppm and δ 6.95 ppm were assigned to 
the aromatic protons H6 and H7 in the isoquinoline unit with the corresponding carbons 
assigned to the peaks at δ 133.6 ppm (C6) and δ 109.8 ppm (C7) in the 13C NMR 
spectrum. The other two ortho-split doublets (J = 7.9 Hz) at δ 7.14 ppm and δ 6.89 ppm 
were assigned to the aromatic protons ArH2 and ArH3 in the naphthyl ring with the 
corresponding carbons assigned to the peaks at δ 128.2 ppm (ArC2) and δ 107.2 ppm 
(ArC3) in the 13C NMR spectrum. 2D NMR spectroscopy (gCOSY, gHSQC and 
gHMBC) were used to assign the two methoxy groups and two methyl groups: 
 




Ar-OCH3 (δ 3.95 ppm) and 8-OCH3 (δ 3.94 ppm), 1-CH3 (δ 2.55 ppm) and Ar-CH3 (δ 
2.34 ppm). Analysis of EI mass spectrum of 99 showed a peak at m/z 451, assigned as 
the molecular ion, further confirming the presence of the compound 99. 
Similar to the reaction between 38 and 40 described in section 3.1.3, the Suzuki 
coupling reaction involving less reactive brominated isoquinoline 40 gave the desired 
43 in trace amount only (Entry 2). The more reactive iodo isoquinoline 41 afforded the 
desired naphthylisoquinoline 43 in a much better yield of 51% (Entry 3). By the same 
reaction sequence, naphthylboronic acid 37 and brominated isoquinoline 42 gave 
naphthylisoquinoline 99 as a light brown solid in 75% (Entry 4).  
X-ray quality crystals of 99 and 100 were developed by a slow recrystallization from a 
mixture of CH2Cl2 and hexane. The X-ray structures of naphthylisoquinoline alkaloid 
99 and 100 are shown in Figure 3.5 (see Appendix 2.2 and 2.3 for X-ray 
crystallographic data). Both structures show the naphthyl ring and isoquinoline unit are 
distributed vertically to each other, which significantly reduced the steric hindrance of 
C5 position in the isoquinoline unit during the Suzuki cross-coupling reactions. 
                   
 




Figure 3.2 The crystal structures of naphthylisoquinoline alkaloid 99 (left) and 100 (right). 
Comparing the four Suzuki cross-coupling reactions between naphthylboronic acid 37 
and four different isoquinoline units (39-41), the reaction involving 42 gave the best 
coupling yield (75%), while the brominated isoquinoline 40 with a methoxy group in 
C6 position were inactive in the coupling reaction. Boronic acid 37 showed more 
reactivity in the Suzuki coupling comparing to boronic ester 38 (Table 3.2 and 
Table 3.3). 
3.2 Preparation of michellamine B analogues via oxidative dimerization 
3.2.1 Oxidative dimerization background 
There are a vast number of biaryl natural products with great structural divergence in 
nature. These biaryl molecules, with a broad range of biological activities including 
anti-HIV, anti-malaria, anti-cancer and anti-bacterial activities, are of great importance 
in medicinal chemistry. Numerous synthetic methods have been developed for 
introducing the biaryl linkage into organic compounds.97,98 The popular Suzuki reaction 
and related organometallic methods employ specific functionality directly to the sites of 
reaction.74 Oxidative coupling methods are also well known, where biaryl bonds are 
formed directly at unsubstituted aryl sites, which have been activated either by the aryl 
units themselves or by ring substituents. Compared to organometallic methods, 
oxidative coupling has a clear advantage for the formation of biaryl dimers, as it 
requires no prior functionalisation of the aromatic reaction sites.97,98 
A great number of biaryl compounds have been prepared via oxidative dimerization, 




45 As a necessary precondition for oxidative 
 




coupling reactions, the aromatic portions have to be electron rich (ideally phenolic). 
Multiple products can be obtained from the presence of more than one reactive site in 
the phenolic precursor, depending on the steric and electronic demands.  
The good activities against HIV of the dimeric naphthylisoquinolines michellamines 
have triggered numerous efforts to synthesize these complicated compounds. The initial 
strategy for preparing the dimeric naphthylisoquinolines from monomeric precursors is 
via a Suzuki-Miyaura coupling.56 This multiple step synthesis involved five different 
types of reactions including bromination, borylation, cross coupling, protection and 






















































Scheme 3.4 Preparation of michellamine B via Suzuki-Miyaura coupling strategy. Reactions 
involved (i: protection; ii: bromination; iii: borylation; iv: Suzuki coupling; v: deprotection).  
The introduction of oxidative dimerization strategy reduced the number of the reaction 
steps from five down to only one.102 In this strategy, the phenolic monomeric 
naphthylisoquinoline can be directly transformed to the dimer in one step under the 
oxidative reagent such as Pb(OAc)4. This simple reaction involved a deeply 
 




violet-coloured intermediate diketone 104 (Figure 3.3) which can be reduced into 
desired dimer compound by column chromatography with dichloromethane/methanol as 
the eluent in good yield (Scheme 3.5).  
 
 
Scheme 3.5 Preparation of michellamine A via one-step oxidative dimerization strategy.102 
 
Figure 3.3 Structure of the intermediate diketone 104. 
3.2.2 Synthetic strategy towards the dimeric naphthylisoquinoline alkaloids 
A two-step synthetic strategy towards the dimeric naphthylisoquinoline alkaloids is 
outlined in Scheme 3.6. The first deprotection reaction will afford the phenolic 
intermediate 105. This electron rich phenolic group will significantly activate the 
 




adjacent ArC3 position, allowing the subsequent dimerization reaction to occur. The 
following step is the direct dimerization reaction from the monomeric 
naphthylisoquinoline alkaloid 105 to afford dimeric product 106. 
 
Scheme 3.6 Synthetic strategy towards dimeric naphthylisoquinoline alkaloids. 
All the monomeric and dimeric naphthylisoquinoline alkaloids obtained in this strategy 
will be racemic and directly used for the biological activity testing without further 
separation. The active racemic compound can be further separated by chiral HPLC, 
leading to the active chiral dimeric naphthylisoquinoline. This strategy will significantly 
reduce the synthetic steps for michellamine B analogues compared to the Suzuki 
coupling strategy, as well as avoid synthesizing inactive compounds from the 
multiple-step synthesis. 
3.2.3 Debenzylation of monomeric naphthylisoquinoline alkaloid 
As oxidative coupling reactions required electron rich phenolic protons, debenzylation 
reactions of the monomeric naphthylisoquinoline alkaloids were performed. An efficient 
reduction system of Pd/C/H2 in MeOH/ CH2Cl2 was utilised and the results of the 
deprotection reactions of the three monomeric naphthylisoquinoline alkaloids 43, 100 
and 99 under these conditions are summarized in Table 3.4. 
  
 




Table 3.4 Preparation of unprotected naphthylisoquinolines. 
 
Entry Ar Reactant Product Yield
1 
 
43 44 95% 
2 
 
100 107 94% 
3 
 
99 108 0 
 
The debenzylation reaction was carried out under Pd/C/H2 in MeOH/ CH2Cl2. After 2 h, 
TLC analysis indicated the completion of the reaction. Unprotected 
naphthylisoquinoline 44 was obtained as a brown solid in 95% yield (Entry 1) after a 
short flash silica gel column chromatography. In the 1H NMR spectrum of 44, the 
typical benzyl signals shown in reactant 43 located at the range of δ 7.32-7.62 ppm 
(aromatic ring) and δ 5.22 ppm (ArCH2) cannot be observed, while a new peak located 
at δ 9.48 ppm, with a relative integration of one proton, was assigned to the generated 
phenolic hydroxyl group of 44. The two ortho-split doublets (J = 7.8 Hz) at δ 7.04 ppm 
and δ 6.86 ppm were assigned to the aromatic protons ArH3 and ArH2 in the naphthyl 
ring with the corresponding carbons assigned to the peaks at δ 109.4 ppm (ArC2) and δ 
 




129.9 ppm (ArC3) in the 13C NMR spectrum. Analysis of EI mass spectrum of 44 
showed a peak at m/z 451 assigned as the molecular ion, further confirming the 
completion of the reaction.  
Applying the same conditions, the scaffold 100 produced the phenolic 
naphthylisoquinoline 107 as a brown solid in a high yield (94%) (Entry 2). The high 
resolution mass spectrum (ESI) for 107 showed a peak at m/z 348.1594 assigned as the 
molecular formula (C22H22NO3, calcd. 348.1600). Analysis of the 
1H NMR spectrum 
showed a singlet located at δ 9.44 ppm assigned to the phenolic hydroxyl group, 
indicating that the benzyl protecting group was removed. 
The same reaction conditions were applied to the reaction of 99, however, no compound 
108 was obtained from this reaction (Entry 3). Monitoring of MS spectra during the 
reaction indicated that the reduction of the C, N double bond occurred, leading to the 
compound 109 (Scheme 3.7), before the debenzylation reaction. Phenolic 
naphthylisoquinoline 109, with a free amine group in the isoquinoline unit, was 
obtained in 92% yield. As the impact of this free amine group for biological activity of 
michellamine B analogues could be important information for the SAR study of this 
project, no other alternative debenzylation method was attempted.  
The high resolution mass spectrum (ESI) for 109 showed a peak at m/z 364.1926 
assigned as the molecular formula (C23H26NO3, calcd. 364.1913), confirming the 
presence of 109. As this phenolic naphthylisoquinoline with a free amine group (109) 
obtained relative low solubility in deuterated chloroform, deuterated methanol was used 
in NMR analysis and as expected no signal of phenol hydroxyl or amine can be 
observed in the 1H NMR spectrum of 109. The absence of the typical benzyl signals 
 




shown in reactant 99 located at the range of δ 7.33-7.62 ppm (aromatic ring) and δ 5.23 
ppm (ArCH2) indicated that the benzyl protecting group was removed.  
 
Scheme 3.7 The debenzylation reaction of naphthylisoquinoline 99. 
3.2.4 Synthesis of michellamine B analogues 
In order to prepare the dimeric michellamine B analogues by the oxidative coupling 
method, a trial reaction using phenolic naphthyl 63 was first attempted. Treatment of 
phenolic naphthyl 63 in CH2Cl2 containing 0.2% NEt3 with excessive Ag2O gave the 
deep-violet coloured reaction mixture, due to the formation of diphenoquinone 
intermediate 110. After 18 h stirring in air, the purple coloured diphenoquinone 110 was 
purified from a short silica gel column chromatography (CH2Cl2/methanol: 10/1), and 
then reduced using Pd/C/H2, affording the dimeric compound 111 as a brown solid in 42% 
over two steps (Scheme 3.8).  
 
Scheme 3.8 Preparation of 111 by oxidative dimerization strategy. 
 




Analysis of the 1H NMR spectrum of 111 showed a singlet located at δ 9.59 ppm 
assigned to the phenolic hydroxyl groups. Three sets of singlets (δ 7.21 ppm, δ 7.13 
ppm and δ 6.64 ppm) in the aromatic range were assigned to the six aromatic protons 
(ArH3 and ArH3′, ArH5 and ArH5′, ArH7 and ArH7′) respectively, indicating the 
completion of the dimerization. The high resolution mass spectrum (ESI) for 111 
showed a peak at m/z 575.2647 assigned as the molecular formula (C34H39O8, calcd. 
575.2645), confirming the synthesis of the desired dimer product. 
Besides Ag2O, other oxidants were also attempted in the oxidative dimerization reaction 
of 63, leading to either complete decomposition (Pd(OAc)4) or no reaction 
(Tl(CF3COO)3). 
The oxidative dimerization reactions of the phenolic naphthylisoquinolines (44, 107 and 
109) towards michellamine B analogues were performed using Ag2O as oxidants and 
the results were summarized in Table 3.5.  
Dimeric naphthylisoquinoline 112 (Entry 1) was obtained as a brown solid in 31% 
coupling yield from its corresponding phenolic monomer 44 after purified by flash 
silica gel column chromatography (CH2Cl2/methanol: 10/1). As this michellamine B 
analogue (112) was obtained relative low solubility in deuterated chloroform, deuterated 
methanol was used in NMR analysis and as a result no signal of phenolic hydroxyl 
could be observed in the 1H NMR spectrum of 112. Four sets of singlets located at δ 
7.25 ppm, δ 6.84 ppm, δ 6.83 ppm and δ 6.65 ppm were assigned to the aromatic 
protons (ArH3 and ArH3′, ArH7 and ArH7′, H7 and H7′, ArH5 and ArH5′) in naphthyl 
rings and isoquinolines respectively, indicating the formation of dimer compound. 
gHMBC was used to assign three methoxy singlets δ 4.14 ppm (Ar8-OCH3 and 
 




Ar8′-OCH3), δ 4.09 ppm (8-OCH3 and 8′-OCH3) and δ 3.85 ppm (6-OCH3 and 
6′-OCH3). 
13C NMR spectrum analysis illustrated 24 peaks, consistent with the structure 
of 112. The high resolution mass spectrum (ESI) of 112 showed peaks at m/z 781.3528 
assigned as the molecular formula (C48H48N2O8, calcd. 781.3489), further confirming 
the presence of desired compound. 
Table 3.5 Oxidative dimerization reaction to synthesize michellamine B analogues. 
 
Entry Ar Reactant Product Yield
1 
 
44 112 31% 
2 
 
107 113 35% 
3 
 
109 114 0 
 
The dimeric compound 113 was obtained as a brown solid in 35% yield from 
monomeric naphthylisoquinoline 107 (Entry 2). The high resolution mass spectrum 
(ESI) of 113 showed peaks at m/z 693.2996 assigned as the molecular formula 
(C44H41N2O6, calcd. 693.2965), indicating the presence of desired compound. 
 




Unfortunately, the direct oxidative coupling of phenolic naphthylisoquinoline 109 with 
free amine didn’t succeed for the synthesis of 114, leading to complex reaction mixtures 
instead (Entry 3). The dimerization reaction using Pd(OAc)4 as an oxidising reagent was 
also attempted, since a high coupling yield was reported for the monomer containing 
free amine group using this oxidising system.101 However, no desired compound was 
obtained again. The reason behind the unsuccessful formation was not clear and may be 
attributed to the free amine in the isoquinoline unit. Due to time constraints and 
insufficient material, the protection of amine in 109 and the following dimerization 
reaction could not be conducted. 
A proposed mechanism for the oxidative dimerization of monomeric 
naphthylisoquinoline 105 is outlined in Scheme 3.9. The deprotonation of 105 by base 
first gives phenolate anion 115. The one electron oxidation of 115 by oxidant then 
affords phenoxy radical 116 which can transform the radical to the ortho position, 
leading to 117. The coupling between two phenoxy radical 117 generates intermediate 
118 and subsequent keto-enol tautomerism affords the desired dimeric 
naphthylisoquinoline 119. Over oxidization of 119 leads to diphenoquinone 
intermediate 106 which can be reduced back to 106 under appropriate condition.  
 





Scheme 3.9 Proposed mechanism of the oxidative dimerization reaction to prepare 
michellamine B analogues.  
3.3 Conclusions 
Three monomeric naphthylisoquinolines (96-98) with an ethyl ester substituent in the 
naphthyl ring were prepared in 44%-58% from the naphthylboronic ester (38) and 
halogenated isoquinolines (39-42) via Pd-catalyzed Suzuki cross-coupling, while three 
monomeric naphthylisoquinolines (43, 99-100) with methyl substituent in the naphthyl 
ring were prepared 51%-75% from the naphthyl boronic acid (37) and halogenated 
isoquinolines (39-42). Iodo isoquinoline 41 proved to be more reactive in the Suzuki 
reaction comparing to the brominated isoquinoline 40.  
In order to activate the ArC3 position for the subsequent dimerization, three phenolic 
monomeric naphthylisoquinolines (44, 107 and 109) were obtained 92%-95% via 
debenzylation reactions using Pd/C/H2 reduction system, though the double bond 
 




between C and N in the isoquinoline unit of 99 was reduced during the reaction, leading 
to 109 with free amine.  
Two dimeric naphthylisoquinolines (112 and 113), as michellamine B analogues, were 
synthesized in 31%-35% from the phenolic monomeric naphthylisoquinolines (44 and 
107) via a Ag2O-induced oxidative dimerization strategy, while this oxidative coupling 





Chapter 4: Biological Activities Testing 
4.1 General information 
The synthesized monomeric and dimeric naphthylisoquinolines were evaluated against 
HIV-1 reverse transcriptase through in vitro screening using a Roche colorimetric RT 
assay kit (see Chapter 7). This assay was performed at University of Wollongong by 
the candidate. 
The monomeric naphthylisoquinolines were also screened for their activity against the 
human cancer cell lines NCI-H187 (small cell lung cancer), KB (oral cavity cancer) and 
MCF-7 (breast cancer) as well as malaria (Plasmodium falciparum, K1 strain) and Vero 
cell (cytotoxicity). These assays were conducted by Dr. Rachada Haritakun at the 
National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand. 
The monomeric naphthylisoquinolines were also tested for bacterial growth inhibition 
activity against a primary panel including Escherichia coli, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus 
(MRSA). The biological testing was conducted by Dr. Alysha Elliott in the Worldwide 
Antibiotic Discovery Initiative (WADI), Brisbane. 
4.2 HIV RT testing 
4.2.1 Testing methods and principle 
A colorimetric Reverse Transcriptase assay was used to quantitatively determine 
retroviral reverse transcriptase activity. The testing takes advantage of the ability of 
reverse transcriptase to synthesize DNA using the hybrid poly (A) × oligo (dT)15 as a 
 




template and primer. Digoxigenin- and biotin-labeled nucleotides in an optimized ratio 
are incorporated into the same DNA molecule by the RT activity. The detection and 
quantification of the synthesized DNA as a parameter for RT activity follows a 
sandwich ELISA protocol: biotin-labeled DNA binds to the surface of 
streptavidin-coated microplate modules. In the next step, an antibody to digoxigenin, 
conjugated to peroxidase (anti-DIG-POD), is added and bound to the 
digoxigenin-labeled nucleotides. In the final step, the peroxidase substrate ABTS is 
added. The peroxidase enzyme catalyzes the cleavage of the substrate to produce a 
coloured reaction product. The absorbance of the samples is determined using a 
microplate reader, and is directly correlated to the level of RT activity in the sample 
(Figure 4.1).103 
 
Figure 4.1 The testing principle of the colorimetric RT assay (modified from reference 103). 
The percentage inhibition of RT is calculated by subtracting the absorbance value of 
negative control (sample that does not contain RT, n) from absorbance of Sample (vi) 
and compared to the value from absorbance of positive control (sample that does not 
contain an inhibitor, p) subtracting absorbance of negative control (Formula 4.1).103 
 
 











Formula 4.1 The calculation of the percentage inhibition of RT in the colorimetric assay. 
4.2.2 Testing results 
The percentage inhibition of all compounds was obtained at the potential inhibitory 
concentrations of 50.0 μM and 10.0 μM. Subsequently, the six most promising 
compounds were selected and their inhibitory activity was obtained at additional four 
concentrations (100.0 μM, 75.0 μM, 25 μM and 5 μM).  
IC50 values of these promising inhibitors were determined using linear regression via 
Excel software. Concentrations (X) and inhibitions (Y) were plotted and a straight line 
(linear regression) was fitted the data. IC50 value is then estimated using the fitted line, 
i.e., 
Y = a * X + b, 
IC50 = (0.5 - b)/a. 
The percentage inhibition of each sample was measured in duplicate experiments and 










Table 4.1. The HIV-RT inhibitory results for the monomeric naphthylisoquinolines and dimeric 
naphthylisoquinolines. 
Entry Compound # 
% RT inhibition (μM)* IC50 
(μM) 100 75 50 25 10 5 
1 
 
99 - - 1.8 - 3.6 - - 
2 
 
43 71.2 30.2 35.6 28.1 10.2 23.5 80.8 
3 
 
100 44.6 28.3 26.0 27.4 36.6 13.0 164.6
4 
 
96 49.1 30.0 22.7 25.1 18.8 0 113.1 
5 
 
97 - - 0 - 14.7 -  
 




Entry Compound # 
% RT inhibition (μM)* IC50 
(μM) 100 75 50 25 10 5 
6 
 








108 - - 0 - 0 - - 
8 
 
44 50.5 42.8 34.6 41.5 36.8 18.6 101.8 
9 
 









111 - - 0 - 12.2 - - 
 




Entry Compound # 
% RT inhibition (μM)* IC50 
(μM) 100 75 50 25 10 5 
11 112 - - 2.6 - 8.1 - - 
12 
 
113 - - 7.3 - 6.9 - - 
*Shown is the average % inhibition of duplicate experiments.  
Analysis of the RT inhibition results for monomeric naphthylisoquinolines (Entries 1-9) 
revealed weak to mild activities against the enzyme with a percentage inhibition from 
1.1% to 71.2%. The only exception was compound 108 (Entry 7) featuring both a 
phenol hydroxyl group and a free amine group which showed no activity against the 
enzyme. The activities of these monomeric naphthylisoquinolines (Entries 1-6, 8-9) are 
significantly higher than the inhibition activities reported for korupensamine analogues 
(Figure 4.2), while the korupensamines obtaining three phenol hydroxyl groups and a 
free amine group showed no anti-HIV activity.44 The inactivity of 109 may be attributed 
to the structural similarity to korupensamines. 
The introduction of carbonyl group in the isoquinoline unit increased the activity 
 




significantly and all the monomeric naphthylisoquinolines obtaining this group (100, 98 
and 107) showed mild activities with IC50 values from 61.3 μM to 164.4 μM (Entry 3, 6 
and 9). Compound 107 (Entry 9) featuring the phenol hydroxyl group and carbonyl 
group gave the best IC50 value (61.3 μM) among all the testing compounds.  
Compound 43 (Entry 2) with benzyl protecting group and two methoxy groups in the 
isoquinoline unit obtained the highest inhibition (71.2%) at the concentration of 100 μM 
among all the testing compounds. Its deprotected product 44 (Entry 8) with phenol 
hydroxyl group exhibited slightly weaker activity with an IC50 of 101.8 μM reduced 
from 80.8 μM of 43. These results showed that the removal of phenol hydroxyl groups 
both in the naphthyl ring and isoquinoline unit can increase the anti-HIV activity of the 
monomeric naphthylisoquinolines. 
The impact of the ester group in the naphthyl ring to the activity was still unclear from 
the testing results. The activity increased dramatically from compound 99 (Entry 1) with 
methyl substituent to compound 96 (Entry 4) with ethyl ester substituent, whereas 
decreasing trends were observed from the other two pairs (43 and 97, Entry 2 and 5, 100 
and 98, Entry 3 and 6). 
Weak inhibitory activity was observed for the dimeric naphthylisoquinolines (112 and 
113, Entry 11 and 12) with a maximum inhibition of only 8.1% at the concentration of 
10 μM, which is dramatically weaker compared to the reported EC50 value (10 μM) of 
michellamine B.42 Comparing the structure of 112 and michellamine B (Figure 4.2), the 
only difference is the isoquinoline units. There are two hydroxyl groups and a free 
amine in the isoquinoline unit of the michellamine B, there are two methoxy groups and 
a C, N double bond in the isoquinoline unit of 112, while there is a carbonyl group but 
 




no other substituents in the isoquinoline unit of 113. The introduction of carbonyl group 
in the isoquinoline unit of 113 showed no increase in the inhibition against the RT. The 
absence of hydroxyl groups and free amine in the isoquinoline unit decrease the activity 
against RT significantly comparing to the activity (EC50: 10 μM) of michellamine B 
reported. These groups might be essential to bind with the enzyme as well as keep the 
hydrophilicity of the molecules. 
 
Figure 4.2 Chemical structures of michellamine B and korupensamine A. 
The RT inhibitory activities of these testing compounds can be summarised in the 
following SAR points: 
 Monomeric naphthylisoquinoline derivative with similar structure as 
korupensamines are not active against RT enzyme. 
 The introduction of carbonyl group in the isoquinoline unit in monomeric 
naphthylisoquinolines increased the activity against HIV RT but decrease the 
activity of dimeric naphthylisoquinolines. 
 The removal of phenol hydroxyl groups in isoquinoline unit can increase the 
 




anti-HIV activity of monomeric naphthylisoquinolines but decrease the activity 
of dimeric naphthylisoquinolines. 
 The ethyl ester group in the naphthyl ring of monomeric naphthylisoquinolines 
has impact in the activity, but the pattern was unclear. 
4.3 Anti-malarial and cytotoxicity testing 
The testing results of the monomeric naphthylisoquinolines against malaria 
(Plasmodium falciparum) and Vero cell (cytotoxicity) are summarized in Table 4.2. 
Table 4.2 The IC50 values of the monomeric naphthylisoquinolines against Plasmodium 
falciparum and Vero cell. 
Entry Compound # 
Plasmodium falciparum 








99 4.34 3.27 
2 
 
43 2.94 1.95 
3 
 
100 inactive 16.08 
 




Entry Compound # 
Plasmodium falciparum 








96 inactive 9.14 
5 
 
97 2.83 3.08 
6 
 
98 inactive 15.56 
7 
 
109 2.66 2.22 
8 
 
44 3.13 7.33 
9 
 
107 inactive 30.09 
 




*IC50 of positive control: Dihydroartemisinine = 2.52 nM, Mafloquine= 0.0290 M 
§IC50 of positive control: Ellipticine = 1.83 mg/mL 
From Table 4.2, monomeric naphthylisoquinolines (99, 43, 97, 109 and 44) exhibited 
weak activity against Plasmodium falciparum (2.66-4.34 g/mL) in comparison to the 
positive controls Dihydroartemisinine (2.52 nM) and Mafloquine (0.0290 M), while 
compound 100, 96, 98 and 107 didn’t show any activity. Analysis of the chemical 
structures of these inactive compounds revealed that all the compounds containing 
carbonyl group in the isoquinoline unit are inactive against P. falciparum. 
Compound 109 (Entry 7), featuring a phenol hydroxyl group in the naphthyl ring and a 
free amine group in the isoquinoline unit, obtained the best anti-malaria activity with an 
IC50 value of 2.66 g/mL. However, this result is still significantly weaker than the 
reported activity of korupensamine B (0.18 g/mL, Figure 4.3) tested under similar 
conditions. Analysis of these two structures indicated that the absence of two phenol 
hydroxyl groups in the isoquinoline unit may decrease the activity of compound 109. 
All the testing compounds showed high cytotoxicity (1.95-30.09 g/mL) compared with 
the positive control Ellipticine (1.83 mg/mL). The compounds with carbonyl group in 
the isoquinoline unit (100, 98 and 107) exhibited less cytotoxicity with IC50 values up to 
30.09 g/mL (107, Entry 9) compared to the other tested compounds. 
 
 





Figure 4.3 Chemical structure and anti-malaria activity of korupensamine B.  
The anti-malaria and cytotoxicity activities of these derivatives can be summarised in 
the following SAR points: 
 Monomeric naphthylisoquinolines containing a carbonyl group in the 
isoquinoline unit are inactive against P. falciparum, but have less cytotoxicity in 
Vero cell compared to the other tested compounds. 
 The absence of phenol hydroxyl group in the isoquinoline unit may decrease the 
activity against P. falciparum. 
 The introduction of C, N double bond in the isoquinoline unit decrease the 
anti-malaria activity. 
4.4 Anti-cancer testing 
A random screening testing of the monomeric naphthylisoquinolines were conducted 
and these compounds were tested against the three cell lines KB (oral cavity cancer), 
MCF-7 (breast cancer) and NCI-H187 (small cell lung cancer). All the compounds 
showed cell growth inhibition in micromolar concentrations. The testing results are 
summarised in Table 4.3. 
 
 




Table 4.3 The IC50 values of the monomeric naphthylisoquinolines against three cancer cell 
lines KB (oral cavity cancer), MCF-7 (breast cancer) and NCI-H187 (small cell lung cancer). 














99 14.44 14.99 5.71 
2 
 
43 4.99 6.41 5.54 
3 
 
100 11.7 34.28 16.85 
4 
 
96 29.08 35.29 7.03 
5 
 
97 12.84 15.71 6.15 
 


















98 17.67 30.27 17.11 
7 
 
109 7.44 8.51 6.23 
8 
 
44 37.95 45.62 10.55 
9 
 
107 17.2 17.5 18.03 
 *IC50 of positive control: Ellipticine = 1.47 μg/mL, Doxorubicin = 0.600 μg/mL 
§IC50 of positive control: Tamoxifen = 6.13 μg/mL, Doxorubicin = 7.51 μg/mL 
£IC50 of positive control: Ellipticine = 2.47 μg/mL, Doxorubicin = 0.064 μg/mL 
From Table 4.3, all the monomeric naphthylisoquinolines exhibited moderate to low 
activities against the three cell lines KB (oral cavity cancer), MCF-7 (breast cancer) and 
NCI-H187 (small cell lung cancer). Compound 43 (Entry 2) with two methoxy groups 
and a C, N double bond in the isoquinoline unit showed best activity against breast 
cancer among all the testing compounds with an IC50 value of 6.41 μg/mL which is 
slightly better than that of positive control Doxorubicin (7.51 μg/mL). The activities 
 




against oral cavity cancer and small cell lung cancer of 43 (Entry 2) are also superior to 
those of other compounds with IC50 values of 4.99 μg/mL and 6.41 μg/mL respectively, 
which are both in the same order of magnitude as corresponding positive controls.  
Compound 99 (Entry 1) with a methoxy group and a C, N double bond in the 
isoquinoline unit showed decreased activity in all three cell lines KB (14.44 μg/mL), 
MCF-7 (14.99 μg/mL) and NCI-H187 (5.71 μg/mL) comparing to 43 due to the absence 
of one methoxy group in isoquinoline unit. 
Compound 109 (Entry 7) obtaining unprotected phenol and amine groups also exhibited 
moderate activities against all three cell lines, with an IC50 value of 7.44 μg/mL against 
oral cavity cancer, an IC50 value of 8.51 μg/mL against breast cancer and an IC50 value 
of 6.23 μg/mL against small cell lung cancer.  
4.4 Anti-microbial testing 
A high throughput screening testing for anti-bacterial activity of the monomeric 
naphthylisoquinolines were conducted. These compounds were tested for bacterial 
growth inhibition activity against a primary panel including Escherichia coli, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus 
aureus (MRSA). The MIC (Minimum Inhibitory Concentration) values of all the testing 









Table 4.4 Antimicrobial activity results of the monomeric naphthylisoquinolines. 





























99 >32 >32 >32 >32 32 
2 
 
43 >32 >32 >32 >32 16 
3 
 
100 >32 >32 >32 >32 >32 
4 
 
96 >32 >32 >32 >32 >32 
5 
 
97 >32 >32 >32 >32 >32 
 

































98 >32 >32 >32 >32 >32 
7 
 
109 >32 >32 >32 >32 32 
8 
 
44 >32 >32 >32 >32 >32 
9 
 
107 >32 >32 >32 >32 >32 




































1 Colistin 0.06 ≤0.015-0.03 0.03 ≤0.25 - 
2 Polymyxin B 0.03 ≤0.015 ≤0.015 ≤0.25 - 
3 Vancomycin - - - - 0.5-1 
4 Daptomycin - - - - 1 
 
From Table 4.4, all the monomeric naphthylisoquinolines showed no activities against 
Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas 
aeruginosa, while three compounds (99, 43 and 109, Entry 1, 2 and 7) without carbonyl 
group and ester group exhibited low activity against Staphylococcus aureus with MIC 
values from 16 to 32 µg/mL (Entry 1, 2 and 7). 
4.5 Conclusions 
The synthesized monomeric and dimeric naphthylisoquinolines were tested in vitro 
against the HIV-1 RT enzyme showing weak to moderate inhibitory activities. The 
monomeric naphthylisoquinolines exhibited better anti-HIV activity than 
korupensamines with percentage inhibition from 1.1% to 71.2%. Compound 107 
obtaining phenol and carbonyl group demonstrated best activity with an IC50 value of 
 




61.3 μM, while 43 with benzyl protecting group obtained the highest inhibition (71.2%) 
at the concentration of 100 μM among all the testing compounds. Mild inhibitory 
activity was observed for the dimeric naphthylisoquinolines (112 and 113) with a 
maximum inhibition of only 8.1% at the concentration of 10 μM. 
Five monomeric naphthylisoquinolines (99, 43, 97, 109 and 44) exhibited moderate 
activity against Plasmodium falciparum (2.66-4.34 μg/mL). Compound 97, featuring 
two methoxy groups in the isoquinoline unit and an ester group in naphthyl ring, 
obtained best anti-malaria activity with an IC50 value of 5.76 μM. All the testing 
compounds showed high cytotoxicity (1.95-30.09 μg/mL). 
All the monomeric naphthylisoquinolines exhibited moderate to low activities against 
the three cell lines KB (oral cavity cancer), MCF-7 (breast cancer) and NCI-H187 
(small cell lung cancer). Moderate activity against small cell lung cancer was obtained 
for 99 (IC50 = 5.71 μg/mL), whereas compound 43 with two methoxy groups in the 
isoquinoline unit showed best activity against breast cancer among all the testing 
compounds with an IC50 value of 6.41 μg/mL. 
All the monomeric naphthylisoquinolines showed no activities against Escherichia coli, 
Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, while 
three compounds (99, 43 and 109) exhibited low activity against Staphylococcus aureus 
with MIC values from 16 µg/mL to 32 µg/mL. 
  
 








Chapter 5: Design and Synthesis of Analogues of 
Marine Bioluminescent Substrate Coelenterazine 
In a separate project, analogues of marine bioluminescent substrate coelenterazine were 
designed, synthesized and used as the inhibitors to bind with the bioluminescent 
coelenterazine-utilizing luciferase. As the exact bioluminescent enzymatic mechanism 
has yet to be uncovered due to the instability of coelenterazine, to elucidate the 
enzymatic mechanism, it is of significant importance to obtain structural information of 
the luciferases binding with either the substrate, or an inhibitor that closely resembles 
the substrate. Herein, these synthesized coelenterazine-like inhibitors will be used for 
future crystallography work and for the study of the luciferase's enzymatic kinetics. 
5.1 Background of coelenterazine and its analogues 
5.1.1 Coelenterazine and its properties 
Bioluminescence, a beautiful light emission phenomenon from living organisms, has 
captured the attention of scientists, leading to the discovery of the natural substrate 
coelenterazine (120, Figure 5.1) in the jellyfish Aequorea victoria, amongst 
others.104,105 This imidazo[1,2-a]pyrazine-based chromophore was isolated and its 




Figure 5.1 Chemical structure of coelenterazine. 
 




Coelenterazine (120) plays a key role in bioluminescence by binding covalently to 
luciferase which is activated to bioluminescence by reaction with calcium ions.107 This 
sensitive system has been used for the detection of calcium ions in cells.107 Luciferase is 
also widely employed in molecular biology as a reporter gene in cell culture 
experiments and small animal imaging due to its ability to emit light.108  
Apart from its light-emitting property, further interest in this heterocyclic compound has 
arisen due to discovery of its potent antioxidant properties109 with reports of chemical 
reactivity assays with singlet oxygen,110 radical anion superoxide111 and the inhibition of 
lipid peroxidation.112,113 These results show that the imidazo[1,2-a]pyrazine-based 
coelenterazine derivatives are a new family of antioxidants.114-117 These diverse 
applications make coelenterazine a useful molecule for both medical and molecular 
biological use. 
5.1.2 Synthesis of coelenterazine 
Coelenterazine (120) was synthesized in 1989118 by a condensation between an α-oxo 
aldehyde and a fully substituted 2-aminopyrazine; the pyrazine was prepared by another 
condensation reaction between an α-amino nitrile and an α-nitroso ketone.118 On the 
basis of this pioneering work, improvements to this strategy using organometallic 
coupling developed a more flexible and convergent preparation.119-123 Another attractive 
synthetic approach towards coelenterazine is via a biomimetic and modular peptide 
synthesis method, which is based on a double intermolecular dehydration.124 
5.1.3 Coelenterazine-like imidazo[1,2-a]pyridine-based inhibitor 
Coelenterazine (120) is not stable and reacts with O2 to emit light catalysed by 
luciferase.125 In this reaction, the substrate coelenterazine firstly binds reversibly to the 
 




enzyme, forming the enzyme-substrate complex (Michaelis complex). The enzyme then 
catalyzes the chemical step and releases the product. In order to characterize the 
luciferase bioluminescent mechanism, it is essential to obtain the crystal structure of 
Michaelis complex in this transition state. However, the instability of coelenterazine and 
the rapid catalytic rate of this bioluminescence reaction has made it extremely difficult 
to observe and characterize the Michaelis complex.  
An enzyme inhibitor is a molecule that binds to an enzyme and prevents it from 
working in the normal manner. An ideal inhibitor will closely resemble enzyme 
substrate in structure and be chemically stable. Due to the structural similarity, such an 
inhibitor can bind to the enzyme leading to inhibitor-enzyme Michaelis complex 
without transforming to the product, giving the chance to observe the bindings in the 
active sites of the enzyme.126  
The acidic proton in N7 position in the pyrazine ring of coelenterazine (120, Figure 5.1) 
enable this structure transform to several resonant structures, and the proposed first step 
in the mechanism of the bioluminescent reaction of coelenterazine is the deprotonation 
of this acidic proton.127 Therefore, in order to trap the Michaelis complex from 
transforming to the products, the design of the potential inhibitor should remove this 
acidic proton in N7 position. Eligible scaffolds, such as imidazopyridine, 
imidazooxazine and imidazopyridazine, became the candidates of the inhibitors 
(Figure 5.2).  
 






































Figure 5.2 Structural analogues of the coelenterazine. 
The imidazo[1,2-a]pyridine ring system was first introduced by Tschitschibabin128 in 
1925. The pharmacological properties of this skeleton are currently the object of 
renewed interest as illustrated by the number of patents containing this scaffold.129 The 
synthesis of 3-hydroxyimidazo[1,2-a]pyridine derivatives was first achieved via a 
condensation of 2-aminopyridine 1-oxide and phenacyl bromides,130 before a more 
efficient methodology using 2-aminopyridine and phenylglyoxals for the condensation 
was developed.131-133 The imidazo[1,2-a]pyridine analogue 121 was selected as the 
potential inhibitor target in this project after the evaluation of the synthetic feasibility. 
5.2 Synthetic strategy towards imidazo[1,2-a]pyridine-based inhibitor 121 
The synthesis of coelenterazine-like inhibitor 121 involves a key step to prepare the 
central aromatic ring 3-hydroxyimidazo[1,2-a]pyridine 123 (Figure 5.3). It is reported 
that the structurally similar ring imidazo[1,2-a]pyrazine 122 (Figure 5.3) can be 
synthesized from a condensation between 2-aminopyrazine and benzylglyoxal. 
Compared to the extensively studied imidazo[1,2-a]pyrazine (122), the 
 




imidazo[1,2-a]pyridine heterocycle is still poorly investigated, especially the 
3-hydroxyimidazo[1,2-a]pyridine variation (123). There is no report about the 
condensation between 2-aminopyridine and benzylglyoxals, but this strategy will be 
adopted towards the synthesis of 3-hydroxyimidazo[1,2-a]pyridine derivatives in this 
project. 
 
Figure 5.3 Structures of imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyridine.  
The proposed synthesis of imidazo[1,2-a]pyridine-based inhibitor 121 is illustrated in 
Scheme 5.1. Two key precursors, 2-aminopyridine 126 and benzylglyoxal 129, are 
required for the final condensation to prepare 121. The synthesis of 126 will start from 
the commercially available 2-aminonicotinic acid 124. Bromination followed by a 
two-step Weinreb ketone synthesis, should produce intermediate 125. With a 
subsequent Suzuki coupling and Wolff-Kishner reduction will give the 2-aminopyridine 
126. Synthesis of benzylglyoxal 129 will require a bromination and oxidation from the 
commercially available 1-(4-hydroxyphenyl)propan-2-one (127). The final 
condensation between 2-aminopyridine and benzylglyoxal will afford the desired 
imidazo[1,2-a]pyridine 121.  
 





Scheme 5.1 Synthetic strategy towards imidazo[1,2-a]pyridine 121. 
Imidazo[1,2-a]pyridine 121 will be used to bind with luciferase for the study of its 
bioluminescent catalytic mechanism. The potential antioxidant activity of this 
coelenterazine-like compound (121) will also be evaluated. 
5.3 Synthesis of coelenterazine analogues 
5.3.1 Synthesis of 2-aminopyridine derivative 126 
Starting from commercially available 2-aminonicotinic acid (124), bromination with Br2 
in glacial acetic acid provided 130 as a white crystalline needle in 97% yield after 
recrystallized from methanol (Scheme 5.2).134 Analysis of 1H NMR of 130 showed two 
meta-split doublets (J = 2.5 Hz) at δ 8.44 ppm and δ 8.33 ppm assigned to the aromatic 











Scheme 5.2 Reagents and conditions: (i) Br2, HOAc, rt, 20 h, 97%; (ii) CH3NHOCH3·HCl, 
HBTU, HOBt, DMF, rt, 5 h, 74%; (iii) C6H5MgBr, −50 
oC, THF, 5 h, 95%; 
(iv) 4-methoxyphenylboronic acid, Pd(dppf)Cl2, NaHCO3, toluene, reflux, 12 h, 85%; (v) EtSH, 
NaH, DMF, 100 oC, 15 h, 82%; (vi) 4-hydroxyphenylboronic acid, PdCl2(PPh3)2, Na2CO3, 
1,4-dioxane, reflux, 20 h, 91%; (vii) NH2NH2·H2O, KOH, ethanediol, 240 
oC, 3 h, 86%. 
Conversion of this compound into the desired phenylmethanone 125 required a two-step 
Weinreb ketone synthesis involving the preparation of Weinreb amide 131 and a 
subsequent Grignard reaction. Three different coupling reactions were attempted to 
obtain 2-amino-5-bromo-N-methoxy-N-methylnicotinamide (131). Reaction of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) with 
1-hydroxybenzotriazole hydrate (HOBt) resulted in a 24% yield of 131. The use of 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) gave a 
better yield of 46%, while HOBt and N,N,N′,N′-tetramethyl-O- 
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) provided the best 









Table 5.1 Attempted reaction conditions for coupling reaction. 
 Coupling reagents Solvent Yield 
1 EDC·HCl, HOBt, N,N-diisopropylethylamine DMF 24% 
2 PyBOP, N-methylmorpholine CH2Cl2 46% 
3 HOBt, HBTU, N,N-diisopropylethylamine DMF 74% 
 
The reaction of 131 with phenylmagnesium bromide afforded the ketone 125 as a 
yellow crystalline solid in 95% yield.134 Analysis of the 13C NMR spectrum of 125 
showed absence of methyl (δ 33.4 ppm) and methoxy peaks (δ 61.5 ppm), indicating the 
synthesis of the desired 125.  
In order to obtain the novel biaryl intermediate 133, a direct Suzuki coupling of 125 
with 4-methoxyphenylboronic acid using Pd(dppf)Cl2 as a catalyst gave the novel biaryl 
intermediate 132 in 85% yield, followed by a demethylation with sodium ethanethiolate 
which provided 133 as a pale yellow solid in 82% yield. However, the more direct 
Suzuki coupling of 125 with 4-hydroxyphenylboronic acid to give compound 133 was 
also investigated. Comparing to the two-step synthesis above, a higher yield of 91% was 
achieved group during this Suzuki reaction involving active phenol hydroxyl group. 
This improved method not only avoided the use of the unpleasant reagent ethanethiol, 
but also reduced one synthetic step and increased overall yield from 70% (with two 
steps) to 91%.  
Analysis of the EI mass spectrum of 133 showed a peak at m/z 290 assigned as the 
molecular ion of 133. In the 1H NMR spectrum, a singlet at δ 9.46 ppm, with the 
relative integration of one, was assigned to the phenol hydroxyl proton. Two singlets at 
 




δ 8.50 ppm and δ 7.60 ppm were assigned to the aromatic protons ArH4 and ArH6 in 
the pyridine ring respectively. Analysis of the 1H NMR spectrum of 133 showed peaks 
located at δ 7.30 ppm and δ 6.79 ppm which were assigned to the aromatic protons of 
phenol. 
Finally, Wolff-Kishner reduction of 133 using hydrazine hydrate and KOH furnished 
the new aminopyridine derivative 126 as a white solid in 86% yield after separation 
using flash silica gel column chromatography (hexane/ethyl acetate: 50/50) (Scheme 
5.2). Analysis of 1H NMR spectrum of 126 showed a peak at δ 4.02 ppm assigned to the 
methylene (ArCH2) generated from the reduction, with the corresponding carbon 
assigned to the peak at δ 34.5 ppm in the 13C NMR spectrum, indicating the completion 
of the reaction. Analysis of the EI mass spectrum of 126 showed a peak at m/z 276 and 
was assigned as the molecular ion. 
5.3.2 Synthesis of benzylglyoxal 
5.3.2.1 Attempted reactions towards -bromoketone intermediate 
The synthesis of benzylglyoxal requires a key -bromoketone intermediate and there 
are three different reported methods to prepare it.120,122,135 
The direct bromination from 1-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-2-one 
(134) was first attempted to afford the target intermediate 137, as a similar reaction was 
reported (Scheme 5.3).135 However, a mixture of dibrominated (136) and two 
monobrominated (135 and 137) products was obtained, as identified by EI mass 
spectrometry and 1H NMR spectral analysis. TLC analysis of the reaction mixture 
showed only a single spot due to the similar polarity, indicating that compound 137 is 
not able to be separated from the mixture with the other two species. 
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Scheme 5.3 Attempted direct bromination of phenylpropan-2-one 134. 
The second reported method for the synthesis of 140 was an organozinc method122 and 
was then attempted (Scheme 5.4). The addition of 4-(chloromethyl)phenyl acetate 138 to 
commercial Zn dust in the presence of LiCl at 25 °C afforded the organozinc complex 
within 24 h. Trapping with bromoacetyl chloride after transmetalation with 
CuCN·2LiCl furnished the desired -bromoketone intermediate 140. However, a low 
yield (12%) was obtained for 140 from this reaction. A homo-coupling occurred during 
the reaction producing the side product 139 in 75%. 
 
Scheme 5.4 Attempted organozinc reaction towards the -bromoketone intermediate 140. 
The third reported method120 required use of the sensitive and explosive diazomethane 
and was not attempted, as a simpler, more practical synthetic route, involving a 








5.3.2.2 Synthesis of benzylglyoxal via an epichlorohydrin ring-opening strategy 
This designed synthetic route (Scheme 5.5) has not previously been used to synthesize 
the benzylglyoxal fragment required, however, all the proposed methodologies involved 
are reliable. 
A grignard reagent was firstly prepared from the tert-butyldimethylsilyl protected 
4-bromophenol 141, followed by a ring-opening reaction of commercially available 
epichlorohydrin to afford 143 (80%).136 Dess-Martin periodinate oxidation of the 
alcohol 143 gave the ketone 145 (91%),137 which was then treated with LiBr in acetone 
yielding -bromoketones 137.138 The reactive -bromoketone 137 was treated with 
AgNO3 in acetonitrile overnight, which gave the nitrate ester 148 as a yellow oil in 89% 
yield. The esterification reaction from 145 directly to nitrate ester 148 was also 
attempted under the same condition described above, however no reaction was observed. 
Finally, reaction of 148 with NaOAc in DMSO at room temperature for one hour 
furnished the novel 4-hydroxylbenzylglyoxal 129 as a colourless solid in 87% yield 
(Scheme 5.5).122  
 
 





Scheme 5.5 (i) Mg, THF, rt, 2 h; (ii) epichlorohydrin, THF, 0 oC, 8 h; (iii) Dess-Martin reagent, 
CH2Cl2, rt, 12 h; (iv) LiBr, acetone, rt, 24 h; (v) AgNO3, MeCN, rt, 18 h; (vi) NaOAc, DMSO, 
rt, 1 h. 
The 1H NMR spectrum of 129 displayed a broad singlet at δ 9.45 ppm assigned to the 
alkene hydroxyl group with the corresponding carbon assigned to a resonance at the 
relatively low shift of δ 149.2 ppm in the 13C NMR spectrum, clearly indicating that 129 
existed entirely in the enol form. 
By the same reaction sequence, benzylglyoxal 150, without the phenolic hydroxyl group, 
was prepared with an overall yield of 59%. Benzylglyoxal 150 was spectroscopically 
identical to that reported in the literature.122 
5.3.3 Condensation reaction between 2-aminopyridines and benzylglyoxals 
The key condensation reaction between the 2-aminopyridines and benzylglyoxals has 
not been previously reported. Therefore, the condensation of aminopyridine 126 and 
benzylglyoxals 129 was initially attempted using 1,4-dioxane as the solvent with a 
catalytic amount of hydrochloric acid at room temperature under an N2 atmosphere, 
however no reaction was observed. Increasing the temperature to reflux gave a new, 
 




highly fluorescent compound as indicated by TLC analysis (UV light visualisation at 
365 nm). Upon reaction quenching with water, the resulting brown precipitate was 
filtered and recrystallization from methanol/ether afforded the imidazo[1,2-a]pyridine 
121 as a yellow solid in 62% yield (Scheme 5.6). Coelenterazine analogue 121 were 
both air- and light-sensitive, and had low solubility even in methanol. 
 
Scheme 5.6 Condensation of aminopyridine and arylglyoxals to produce the 
imidazo[1,2-a]pyridine-based coelenterazine derivatives. 
The high resolution mass spectrum (ESI) for 121 showed a peak at m/z 423.1706 
assigned as the molecule formula (C27H23N2O3, calcd. 423.1709), indicating the 
presence of 121. Analysis of the 1H NMR spectrum of 121 (Figure 5.4) showed two 
singlets at δ 4.21 ppm and δ 4.02 ppm, assigned to the two sets of benzyl methylene 
protons ArCH2. The aromatic doublets at δ 7.07 ppm and δ 6.69 ppm associated with 
typical phenyl ortho-coupling (J = 8.0 Hz) were assigned to the protons (ArH2′ and 
ArH6′, ArH3′ and ArH5′) in the benzyl substituent with phenolic group. The two 
ortho-coupling peaks (J = 8.1 Hz) at δ 7.40 ppm and δ 6.86 ppm were assigned to the 
protons (ArH2′′ and ArH6′′, ArH3′′ and ArH5′′) in the phenol substituent. The singlet at 
δ 8.31 ppm was assigned to the aromatic proton ArH5 next to nitrogen atom in the 
pyridine ring. No signals of the three phenolic hydroxyl protons can be observed as 
 




deuterated methanol was used as solvent for 1H NMR analysis. No 13C NMR spectrum 
of 121 was obtained due to the low solubility and poor stability. 
 
Figure 5.4 1H NMR spectrum (500 MHz, CD3OD) of 121. 
Under the same condensation conditions, commercially available 
4-hydroxylphenylglyoxal (151) and phenylglyoxal (152) were synthesized, as well as 
the synthesized benzylglyoxal 150, and were used to react with aminopyridine 126, 
affording the imidazo[1,2-a]pyridine analogues 153-155 as yellow solids in the yields 
of 67-83% (Scheme 5.6).  
The proposed mechanism of condensation between aminopyridine 126 and 
benzylglyoxal 129 has been outlined in Scheme 5.7. The lone pair electrons of the 
amine in 126 first attack the aldehyde giving the intermediate 156 which then takes 
place a Chapman-like rearrangement, leading to intermediate 157. A cyclization of 156 
affords the 158 which eventually leads to imidazo[1,2-a]pyridine 121 after dehydration. 
 




































Scheme 5.7 Proposed mechanism of condensation to prepare imidazo[1,2-a]pyridine 121. 
Four new coelenterazine analogues (121, 153-155) based on the 
3-hydroxyimidazo[1,2-a]pyridine scaffold were eventually prepared in 33%-44% yield 
over 6 linear steps and will be used for the biological activity testing. 
5.4 Optical properties of imidazo[1,2-a]pyridines 
The UV absorption maxima, fluorescent emission maxima, Stokes shift and quantum 
yields were measured for imidazo[1,2-a]pyridines (121, 153-155) in methanol solution 
and the data are summarized in Table 5.2.  
The compounds (154-155), with phenyl substituent in the C2 position of the 
imidazo[1,2-a]pyridine ring, exhibited slightly larger UV absorption maxima (277 nm) 
compared to the compounds (121, 153) with corresponding benzyl substituents (276 
nm, Figure 5.5). Compounds (121, 154) possessing phenolic hydroxyl group in Ar′ 
substituent ring showed higher UV absorbance than the compounds without such group 
 




(153, 155), with decadic molar attenuation coefficients (lg) 5.3 L·mol-1·cm-1 and 5.4 
L·mol-1·cm-1 respectively. 











121 276 5.3 392 116 0.25 
153 276 5.0 388 112 0.075 
154 277 5.4 390 113 0.19 
155 277 5.2 393 116 0.042 
    * Values were obtained by the peak height and tryptophan was used as standard. 
 
Figure 5.5 UV absorption spectra of imidazo[1,2-a]pyridines (121, 153-155) in CH3OH 
(c = 1.0×105 mol/L). 
The fluorescent emission spectra, exited by the wavelength of corresponding absorption 
maxima, are showed in Figure 5.6. The Stocks shifts, calculated from subtracting 
 




emission maxima and absorption maxima, ranged from 112 nm (153) to 116 nm (121, 
155). The quantum yields, measured in methanol solution and using tryptophan as a 
standard, ranged from 0.042 (155) to 0.25 (121). The results indicated that compound 
121, with a moderate quantum yield of 0.25, is potential fluorescent material. 
 
Figure 5.6 Fluorescent emission spectra of imidazo[1,2-a]pyridines (121, 153-155) in CH3OH 
(c = 1.0×105 mol/L). 
5.5 Antioxidant activities 
It is reported that the imidazo[1,2-a]pyrazine-based coelenterazine possessed potent 
antioxidant properties.109 Due to the structural similarity of imidazo[1,2-a]pyridine and 
imidazo[1,2-a]pyrazine, impetus was provided to test the prepared coelenterazine-like 
imidazo[1,2-a]pyridines for their antioxidant activity. 
The in vitro antioxidant abilities of the imidazo[1,2-a]pyridines (121, 153-155) and the 
two intermediate aminopyridines 132 and 126 were analysed using 
2,2-diphenyl-1-picrylhydrazyl (DPPH) assays139 with the moderate antioxidant reagent 
 




L-ascorbic acid as a standard.c Their abilities to scavenge DPPH radicals were studied 
both on reaction rates and inhibition. The reaction of DPPH with compounds 121, 154 
and 155 were fast, reaching peaks within 20 minutes, whereas compounds 6, 126 and 
153 were relatively slow in comparison (Figure 5.4). Compounds 121, 154 and 155 
demonstrated a higher percentage of inhibition compared to 132, 126 and 153 at 30 min, 
while the value is similar with the standard L-ascorbic acid (Figure 5.5). Table 5.2 
illustrates that imidazo[1,2-a]pyridine 155 had the highest inhibition of 97% in 30 
minutes, which was higher than that of the standard. The IC50 values of 121, 154 and 
155 ranged from 58.7 μM to 72.8 μM, indicating that these three 
imidazo[1,2-a]pyridines possessed moderate antioxidant abilities. The IC50 values of the 
imidazo[1,2-a]pyridines were in the same order of magnitude as that of the standard 
L-ascorbic acid and therefore are potential antioxidant candidates. 
 
Figure 5.4 Time course of scavenging DPPH radicals by compounds 132, 126, 121, 153, 154, 
155 and L-ascorbic acid. The reaction mixture (200 μL) in methanol contained DPPH (37.5 μM) 
in the presence of the target antioxidant (25 μM). The absorbance was measured at 515 nm. 
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Figure 5.5 Inhibition percentages at 30 min in the concentration of 100 μM. The reaction 
mixture (200 μL) in methanol contained DPPH (37.5 μM) in the presence of 132 (25 μM), 126 
(25 μM), 121 (25 μM), 153 (25 μM), 154 (25 μM), 155 (25 μM) or L-ascorbic acid (25 μM). 
The reaction mixtures were kept at 30 oC for 30 minutes and the absorbance was measured at 
515 nm. 
Table 5.2 Inhibition percentage and IC50 values of 132, 126, 121, 153, 154, 155 and L-ascorbic 
acid.a 
Compound Inhibition (%) IC50 (μM) 
132 43 >100 
126 46 >100 
121 86 58.7 
153 24 >100 
154 77 72.8 
154 97 60.6 
L-ascorbic acid 95 36.6 
aThe reaction mixture (200 μL) in methanol contained DPPH (37.5 μM) in 
the presence of the target antioxidant (25 μM). The reaction mixtures were 




















132 126 121 153 154 155 L‐ascorbic acid
 





Coelenterazine-like imidazo[1,2-a]pyridines, as inhibitors of bioluminescent luciferase 
for the study of its enzymatic kinetics, were synthesized via a highly convergent and 
adaptable synthesis route. This simple synthesis involves 11 steps in total with only six 
linear steps, proceeding in respectable 33-44% overall yields from commercially 
available 2-aminonicotinic acid. The antioxidant abilities of four new coelenterazine 
analogues (121, 153-155) were evaluated, showing moderate activities with IC50 values 
from 58.7 μM to 72.8 μM. Their optical properties, including UV absorption, 




Chapter 6: Conclusions and Future Directions 
6.1 Preparation of as precursors for subsequent Suzuki cross-coupling  
6.1.1 Synthesis of naphthylboronic acid 37 and naphthylboronic ester 38 
Naphthylboronic acid 37 was prepared via a Diels-Alder method starting from 
commercially available 3,3-dimethylacrylic acid 59. Key steps include a Diels-Alder 
reaction between prepared diene 51 and 1,4-benzoquinone (84%), a selective protection 
of phenol group in a diphenol intermediate (87%) and a Miyaura borylation reaction to 
give the boronic ester 66 (92%). This developed strategy gave naphthylboronic acid 37 
in 37% over 8 steps and allowed scalable access to these precursors in a time-efficient 
and inexpensive manner. 
Naphthylboronic ester 38 with an ethyl ester substituent was successfully synthesized 
by a Wittig method over 7 steps with an overall yield of 43%. Key steps include a 
Wittig reaction to prepare intermediate 48 (71%), a cyclisation to give naphthyl ring 56 
(98%) and a Miyaura borylation reaction to give the boronic ester 38 (91%). 
Both naphthylboronic acid 37 and naphthylboronic ester 38 were used for the 
subsequent Suzuki cross-coupling to prepare the monomeric naphthylisoquinolines. 
6.1.2 Synthesis of halogenated 3,4-dihydroisoquinolines (39-42) 
The synthesis of four dihydroisoquinolines 39-42 was achieved in four or five steps 
starting from the appropriate benzaldehyde derivative. The challenging step was the 
cyclization of the halogenated phenylethyl acetamide intermediates (83-84, 90) which 
were achieved using a mixture of P2O5 and POCl3 affording the dihydroisoquinoline 
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derivatives (39-41) in 86%-90% yields. On the other hand, the synthesis of 
3,4-dihydroisoquinolin-1(2H)-one 42 was achieved through the cyclisation of key 
intermediate isocyanate 69 (31%).  
All these dihydroisoquinolines 39-42 were used for the subsequent Suzuki 
cross-coupling for the preparation of a variety of monomeric naphthylisoquinoline 
alkaloids derivatives. 
6.1.3 Suggested synthesis of halogenated isoquinolines 
The HIV RT testing result indicated that the phenol hydroxyl group and carbonyl group 
in the isoquinoline unit gave a significant impact to activity against enzyme. In order to 
further explore the importance of these two groups in the isoquinoline unit for the 
biological activity of michellamine B analogues, a series of isoquinoline derivatives can 
be designed (Figure 6.1) and used for the subsequent Suzuki cross-coupling to prepare 
the michellamine B analogues. The designed units aim to investigate the role that may 
be played for the RT inhibition activity.  
 
 









































Figure 6.1 Examples for isoquinoline units that may be incorporated into the synthesis of 
michellamine B analogues. X refers to a suitable handle, such as Br, I and OTf. 
The synthesis of the designed units can be achieved by adopting a similar procedure to 
that used for the synthesis of 42 (Chapter 2). In addition, the reduction reaction of the 












Scheme 6.1 The proposed synthesis of the 1,2,3,4-tetrahydroisoquinoline derivatives via 
reduction of compound 42. 
6.2 Preparation of michellamine B analogues 
6.2.1 Synthesis of monomeric naphthylisoquinoline alkaloid via Suzuki 
cross-coupling 
Three monomeric naphthylisoquinolines (96-98) with an ethyl ester substituent in the 
naphthyl ring were prepared in 44%-58% yields from the naphthylboronic ester (38) 
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and halogenated isoquinolines (39-42) via Pd-catalyzed Suzuki cross-coupling, while 
three monomeric naphthylisoquinolines (43, 99-100) with methyl substituent in the 
naphthyl ring were prepared in 51%-75% yields from the naphthyl boronic acid (37) 
and halogenated isoquinolines (39-42). Iodo isoquinoline 41 proved to be more reactive 
in the Suzuki reaction comparing to the brominated isoquinoline 40.  
6.2.2 Synthesis of michellamine B analogues via oxidative dimerization 
In order to activate the ArC3 position for the subsequent dimerization, three phenolic 
monomeric naphthylisoquinolines (44, 107 and 109) were obtained via debenzylation 
reactions using Pd/C/H2 reduction system in 92%-95% yields, though the double bond 
between C and N in the isoquinoline unit of 109 was reduced. Two dimeric 
naphthylisoquinolines (112 and 113), as michellamine B analogues, were synthesized in 
31%-35% from the phenolic monomeric naphthylisoquinolines (44 and 107) via a 
Ag2O-induced oxidative dimerization strategy, while this oxidative coupling of 
naphthylisoquinoline 109 with free amine was unsuccessful for the corresponding 
dimer. 
6.2.3 Biological activities of the naphthylisoquinolines 
The synthesised monomeric and dimeric naphthylisoquinolines were tested in vitro 
against the HIV-1 RT enzyme showing weak to mild inhibitory activities. The 
monomeric naphthylisoquinolines exhibited better anti-HIV activity than 
korupensamines with % inhibition ranging from 1.1% to 71.2%. Compound 107, 
bearing a phenol and carbonyl group demonstrated best activity with an IC50 value of 
61.3 μM, while 43 with benzyl protecting group obtained the highest inhibition (71.2%) 
at the concentration of 100 μM among all the testing compounds. Weak inhibitory 
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activity was observed for the dimeric naphthylisoquinolines (112 and 113) with a 
maximum inhibition of only 8.1% at the concentration of 10 μM. 
Five monomeric naphthylisoquinolines (99, 43, 97, 109 and 44) exhibited weak activity 
against Plasmodium falciparum (2.66-4.34 μg/mL). Compound 97, featuring two 
methoxy groups in the isoquinoline unit and an ester group in naphthyl ring, obtained 
best anti-malaria activity with an IC50 value of 5.76 μM. All the tested compounds 
showed high cytotoxicity (1.95-30.09 μg/mL). 
All the monomeric naphthylisoquinolines exhibited moderate to low activities against 
the three cell lines KB (oral cavity cancer), MCF-7 (breast cancer) and NCI-H187 
(small cell lung cancer). Moderate activity against small cell lung cancer was obtained 
for 99 (IC50 = 5.71 μg/mL), whereas compound 43 with two methoxy groups in the 
isoquinoline unit showed best activity against breast cancer among all the testing 
compounds with an IC50 value of 6.41 μg/mL. 
All the monomeric naphthylisoquinolines showed no activities against Escherichia coli, 
Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, while 
three compounds (99, 43 and 109) exhibited low activity against Staphylococcus aureus 
with MIC values from 16 µg/mL to 32 µg/mL. 
6.2.4 Suggested synthesis of michellamine B analogues via binaphthyl core units 
In order to obtain HIV RT inhibitors with a potentially better inhibitory activity, a range 
of novel isoquinoline substituted dimeric naphthylisoquinoline targets can be 
synthesized to obtain more data in terms of structure-activity relationship. In this 
manner, the importance of the isoquinoline substitutes for HIV-RT activity could be 
further investigated. Since the final dimerization step from the monomeric 
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naphthylisoquinolines obtained low yields, a new strategy applying di-coupling method 
in the last step can be adopted to increase the overall yield of the synthesis. From the 
dinaphthyl intermediate 111, diboronic acid 160 can be synthesized over 5 steps by 
following a similar synthetic route of boronic acid 37. A subsequent di-Suzuki 























Ar: designed isoquinoline units
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Scheme 6.2 Proposed alternative synthesis of the novel isoquinoline substituted dimeric 
naphthylisoquinoline via di-coupling strategy. 
6.3 Synthesis of analogues of marine bioluminescent substrate coelenterazine 
6.3.1 Synthesis of coelenterazine analogues 
A highly convergent and adaptable synthesis of the coelenterazine-like 
imidazo[1,2-a]pyridines was achieved. This simple synthesis involves 11 steps in total 
with only six linear steps, proceeding in respectable 33-44% overall yields from 
commercially available 2-aminonicotinic acid. Four new coelenterazine analogues (121, 
153-155) based on the 3-hydroxyimidazo[1,2-a]pyridine scaffold were prepared and 
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tested for their antioxidant ability – three compounds showed moderate activities with 
IC50 values from 58.7 μM to 72.8 μM. Their optical properties, including UV absorption, 
fluorescent emission, Stocks shift and quantum yields, were also studied. 
6.3.2 Potential study of luciferase’s enzymatic kinetics 
The crystal structural information of coelenterazine binding with the luciferase 
(Michaelis complex) in transition state is very important for characterization of  the 
luciferase bioluminescent mechanism. Because of the instability of coelenterazine and 
the rapid catalytic rate of this bioluminescence reaction, it is extremely difficult to 
observe and characterize the Michaelis complex. Due to the structural similarity, the 
synthesized inhibitor 121, which closely resembles coelenterazine and is chemically 
stable, can bind to the enzyme to form a pseudo-Michaelis complex without 
transforming to the product, thus allowing the “trapped” transition state to be 
characterized. The development of the crystals of luciferase binding with 121 for the 
study of the luciferase's enzymatic kinetics can be achieved in near future. 
  
 







Chapter 7: Experimental 
7.1 Synthesis 
7.1.1 General procedure 
7.1.1.1 Reagents and Solvents 
Dry THF, Et2O and CH2Cl2 were obtained from a Pure Solv MD-5 solvent purification 
system. Alternatively, THF was distilled from Na/benzophenone under N2. Anhydrous 
DMF and DMSO were purchased and used without further purification. HPLC grade 
CH2Cl2 was used for extractions and column chromatography. H2O was obtained from a 
Millipore purification system. N2 was dried by passing through a CaCl2 tube. Grignard 
reagents were prepared with Mg turnings that were washed with 2 M HCl and Et2O 
before being dried under high vacuum. Na was purchased as lumps in oil and was 
washed with hexanes before use. NaH was weighed and used as a 60% suspension in 
mineral oil. LiBr were dried in a 110 oC oven for at least 24 h and cooled under N2 
before use. All other reagents and solvents were purchased reagent grade and used 
without further purification or drying unless otherwise stated. All aqueous solutions 
stated with a percentage are dissolved in H2O and refer to g/100 mL (eg: 10% Na2SO3 = 
10 g/100 mL). All organic solvent mixtures stated are in v/v proportions. 
7.1.1.2 Reactions and Purifications 
All reactions were performed in acetone washed and oven dried glassware with 
magnetic stirring under a positive pressure of N2 unless specified that the reaction was 
carried out in air. Anhydrous and/or air sensitive liquids were introduced into the 
reaction vessel through a rubber septum with a syringe. The majority of other liquid 
 
Chapter 7    Experimental 
115 
 
reagents were weighed analytically and mixed with the appropriate solvent before being 
added to the reaction vessel. Air sensitive and/or hygroscopic solid reagents were 
handled under N2 and weighed either directly into the reaction vessel or transferred as a 
solution in the appropriate solvent. 
All reactions performed at −40 and −78 oC used liquid N2/CH3CN and liquid N2/EtOAc 
slush baths, respectively. Thermal heating of reactions was carried out with paraffin oil 
bath or sand bath. Microwave reactions were performed using a Discover CEM Focused 
Microwave Synthesis System in 10 mL closed vessels under N2 (unless stated 
otherwise) with a power setting of 100 W. 
Reactions heated either thermally or under microwave irradiation were cooled to rt 
before quenching and work-up, or crystallisation/precipitation at lower temperatures 
than ambient. All organic extracts were dried with anhydrous MgSO4 or Na2SO4 and 
gravity filtered. All solvents were evaporated under reduced pressure on a rotary 
evaporator and products dried under high vacuum (~1 mbar) at rt unless otherwise 
stated.  
Purification by column chromatography was performed using Flash Merck Silica Gel 60 
(63-200 mesh) under a positive pressure of air. In cases where deactivated silica 
required, silica was deactivated by addition of specific amount of Et3N to the eluting 
solvent. Preparative Thin Layer Chromatography (PTLC) was performed using 
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7.1.1.3 Analysis and Characterisation 
Thin Layer Chromatography (TLC) was performed using Merck Silica Gel F254 
pre-coated aluminium plates. Visualisation was accomplished using UV light and/or an 
iodine/silica stain. Melting points (Mp.) were determined using a Gallenkamp (Griffin) 
melting point apparatus or Büchi melting point M-560 apparatus. Temperatures are 
expressed in degrees Celsius (oC). 
Infrared (IR) spectra were recorded with neat liquid or solid samples using a Shimadzu 
IR Affinity-1 FTIR spectrometer in combination with the Single Reflection Horizontal 
Attenuated Total Reflectance (HATR) accessory MIRacle 10, fitted with a 1.5 mm 
round diamond crystal. IR data was recorded as number of wavelength per unit distance 
(υmax) in cm
-1 with peak intensity assigned as weak (w), medium (m) or strong (s). 
Proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded 
at 500 and 126 MHz respectively on a Varian Inova 500 MHz spectrometer or a 
VNMRS PS54 500 MHz spectrometer. Alternatively, 1H and 13C NMR spectra were 
recorded at 300 and 75 MHz respectively on a Varian Mercury 300 MHz spectrometer. 
NMR spectra were acquired in CDCl3 with chemical shifts () reported in parts per 
million (ppm) relative to TMS (1H:  = 0 ppm) and CDCl3 (13C:  = 77.16 ppm). 
Alternatively, where stated, spectra were acquired in (CD3)2SO with  values reported 
relative to (CH3)2SO (
1H:  = 2.50 ppm) and (CD3)2SO (13C:  = 39.52), or in CD3OD 
with  values relative to (CH3)OH (1H:  = 3.31 ppm) and (CD3)OD (13C:  = 49.00 
ppm). Coupling constants (J) are reported in Hertz (Hz). J values listed in 1H NMR 
spectral data refer to coupling between hydrogen nuclei. Multiplicities are reported as 
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singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd), triplet (t), quartet 
(q), triplet of doublet (td) or multiplet (m). 
Low resolution mass spectra were obtained by electrospray ionisation (ESI) mass 
spectrometry on a Micromass Platform LCZ spectrometer or a Shimadzu LC-2010EV 
spectrometer by injecting the samples as a solution in MeOH. In some cases 1% formic 
acid was added to suppress dimerization and or aid in protonation. Alternatively, 
electron impact (EI) mass spectra were performed using a Shimadzu QP-5050 
spectrometer with compounds dissolved in CH2Cl2. High resolution mass spectrometry 
(HRMS) was performed using either electrospray ionisation (ESI) technique on a 
Waters QTOF Xevo spectrometer or electron impact technique (EI) on a Micromass 
Autospec Premier spectrometer. Ion mass charge (m/z) values of molecular ions (M), 
fragment peaks and adducts are stated with their relative abundances in parentheses. For 
compounds with more than one major isotope all significant isotopic peaks are reported. 
X-ray diffraction data sets were collected on a Nonius Kappa-CCD area-detector 
diffractometer equipped with IFG capillary X-ray focusing collimators and an Oxford 
Cryosystems crystal cooling device. Calculations were performed using maXus, 
Crystals and Reals software packages. 
7.1.1.4 Other Considerations 
All compounds prepared as racemic mixtures are drawn flat without showing the 
stereogenic atoms/axis. 
Where a known compound was prepared according to literature procedures or by a new 
or modified method, notation and reference appeared in the text. The 1H and 13C NMR 
spectral data of known compounds is included within and is in agreement with that 
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previously reported unless otherwise noted. Some manuscripts however did not contain 
complete (or any) physical and spectral data and/or were published before modern 
characterisation techniques were available. Therefore, the additional data is included 
herein and noted where appropriate. 
7.1.2 Synthesis of michellamine B analogues 
7.1.2.1 Preparation of naphthyl boronic acid 
Methyl 3-methylbut-2-enoate (62) 
This is a known compound and it was prepared according to the known 
procedure.56 A solution of methanol (130 mL), 3,3-dimethylacrylic acid 
(35.0 g) and concentrated sulphuric acid (2 mL) were heated at reflux for 16 h. H2O (50 
mL) was added and the reaction mixture extracted with Et2O (3 ×  150 mL). The 
combined organic layers were washed with saturated aqueous Na2CO3 solution, dried 
(MgSO4) and concentrated. Distillation gave the ester 62 (33.4 g, 83%) as a colourless 
oil. 1H NMR (500 MHz, CDCl3) δ 5.68 (s, 1H, H2), 3.68 (s, 3H, OCH3), 2.17 (s, 3H, 
H4a), 1.90 (s, 3H, H4b). 13C NMR (126 MHz, CDCl3) δ 167.2 (C=O), 156.8 (C3), 115.9 
(C2), 50.8 (OCH3), 27.4 (C4a), 20.3 (C4b). MS (EI): m/z 149 (M
+, 20%), 83 (100%). 
((1-Methoxy-3-methylbuta-1,3-dien-1-yl)oxy)trimethylsilane (51) 
This is a known compound and it was prepared according to the known 
procedure.56 To a stirring solution of diisopropylamine (2.00 mL, 14.5 
mmol) in THF (10 mL) was added n-BuLi (7.30 mL, 14.5 mmol) dropwise at −78 oC 
over 1 h. The mixture was warmed to rt over 1 h, then cooled to −78 oC. A solution of 
62 (1.50 g, 13.2 mmol) in THF (5 mL) was added dropwise to the mixture over 30 min. 
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After being stirred for 1 h at −78 oC, TMSCl (2.00 mL, 15.8 mmol) was added slowly 
over 1 h and the mixture was stirred at −78 oC for 30 min, and then allowed to warm to 
rt over 1 h. The solvent was removed under reduced pressure and the slurry was 
suspended with hexane (20 mL), filtered and concentrated to afford the crude product 
51 as a light yellow liquid (2.43 g, 98%) and used without further purification. 1H NMR 
(500 MHz, CDCl3) δ 4.78 (s, 1H, H4a), 4.54 (s, 1H, H4b), 4.26 (s, 1H, H2), 3.57 (s, 3H, 
OCH3), 1.93 (s, 3H, CH3), 0.23 (s, 9H, Si-CH3). 
13C NMR (126 MHz, CDCl3) δ 157.8 
(C1), 140.5 (C3), 107.6 (C4), 80.9 (C2), 55.2 (OCH3), 23.8 (CH3), 0.5 (Si-CH3). 
5-Methoxy-7-methylnaphthalene-1,4-dione (52) 
This is a known compound and it was prepared according to the known 
procedure.56 To a solution of 51 (2.40 g, 12.9 mmol) in CH2Cl2 (120 mL) 
was added slowly benzoquinone (2.80 g, 25.8 mmol) at rt. After stirred 
for 20 h, AcOH (1.60 mL, 28.4 mmol) was added to the above solution, the mixture was 
stirred at rt for 30 min. The mixture was concentrated and the residue was recrystallized 
from MeOH to afford 52 (2.44 g, 84%) as yellow crystals. 1H NMR (500 MHz, CDCl3) 
δ 7.54 (s, 1H, H8), 7.10 (s, 1H, H6), 6.83 (s, 2H, H2, H3), 3.99 (s, 3H, OCH3), 2.48 (s, 
3H, CH3). 
13C NMR (126 MHz, CDCl3) δ
 185.6 (C1), 184.2 (C4), 160.0 (C5), 146.5 
(C7), 141.1 (C2), 136.2 (C3), 134.0 (C8a), 120.2 (C8), 118.5 (C6), 117.8 (C4a), 56.5 
(OCH3), 22.4 (CH3). MS (EI): m/z 202 (M
+, 100%). 
4-Hydroxy-5-methoxy-7-methylnaphthalen-1-yl pivalate (63) 
This is a known compound and it was prepared according to the known procedure.56 To 
a mixture of 52 (589 mg, 2.91 mmol) and Na2S2O4.2H2O (5.00 g, 23.8 mmol) at rt was 
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before the two phases were separated. The aqueous layers were 
further extracted with CH2Cl2 (3 × 50 mL). The combined CH2Cl2 
layer was dried (MgSO4) and concentrated to provide the crude 
reduction product (582 mg, 2.90 mmol) which was used directly without further 
purification. To a solution of the aforementioned crude product (582 mg, 2.90 mmol) in 
CH2Cl2 (20 mL) at 0 
oC under N2 was added Et3N (0.44 mL, 3.20 mmol) and pivaloyl 
chloride (0.39 mL, 3.17 mmol). After stirred at rt for 2.5 h, the mixture was 
concentrated and subjected to flash silica gel column chromatography (hexanes/EtOAc: 
20/1) to afford 63 (731 mg, 87% over two steps) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 9.17 (s, 1H, OH), 7.11 (s, 1H, ArH8), 7.01 (d, J = 8.3 Hz, 1H, ArH2), 6.75 (d, 
J = 8.3 Hz, 1H, ArH3), 6.61 (s, 1H, ArH6), 4.01 (s, 3H, OCH3), 2.43 (s, 3H, Ar-CH3), 
1.46 (s, 9H, 3×CH3). 
13C NMR (126 MHz, CDCl3) δ 177.5 (C=O), 156.4 (ArC5), 152.5 
(ArC4), 138.6 (ArC1), 136.5 (ArC7), 129.7 (ArC8a), 120.1 (ArC2), 114.1 (ArC8), 
114.0 (ArC4a), 108.7 (ArC3), 106.9 (ArC6), 56.3 (OCH3), 39.5 (C2), 27.5 (3×CH3), 
22.5 (Ar-CH3). MS (EI): m/z 288 (M
+, 40%), 204 (100%). 
4-(Benzyloxy)-5-methoxy-7-methylnaphthalen-1-yl pivalate (64) 
This is a known compound and it was prepared according to the 
known procedure.56 To a solution of 63 (2.00 g, 6.94 mmol) in 
DMF (15 mL) at 0 oC was charged NaH (60%, 0.330 g, 8.32 mmol). 
The mixture was stirred at 0 oC under N2 for 10 min before BnBr 
(0.86 mL, 7.30 mmol) was added. The resulting mixture was 
allowed to warm to rt over 1 h and then filtered, then washed with H2O (5 mL) and Et2O 
(1 mL) to afford 64 (2.58 g, 93%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.28 
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J = 7.5 Hz, ArH4′), 7.15 (s, 1H, ArH8), 7.03 (d, 1H, J = 8.0 Hz, ArH2), 6.81 (d, 1H, 
J = 8.0 Hz, ArH3), 6.71 (s, 1H, ArH6), 5.12 (s, 2H, Ar′-CH2), 3.93 (s, 3H, OCH3), 2.46 
(s, 3H, Ar-CH3), 1.48 (s, 9H, 3×CH3). 
13C NMR (126 MHz, CDCl3) δ 177.5 (C=O), 
157.4 (ArC5), 154.1 (ArC4), 140.4 (ArC1), 137.8 (ArC7), 137.2 (ArC1′), 130.6 
(ArC8a), 128.5 (ArC3′), 127.7 (ArC4′), 127.2 (ArC2′), 118.5 (ArC2), 117.3 (ArC4a), 
112.8 (ArC8), 109.0 (ArC6), 107.3 (ArC3), 72.1 (Ar′-CH2), 56.4 (OCH3), 39.5 (C2), 
27.5 (3×CH3), 22.5 (Ar-CH3). MS (EI): m/z 378 (M
+, 60%), 203 (100%). 
4-(Benzyloxy)-5-methoxy-7-methylnaphthalen-1-yl trifluoromethanesulfonate (65)d 
This is a known compound and it was prepared according to the 
known procedure.56 A solution of 64 (10.0 g, 26.4 mmol) and KOH 
(5.93 g, 106 mmol) in MeOH (300 mL) and H2O (100 mL) was 
stirred at 50 oC under N2 for 3 h. After the mixture cooled to rt, H2O 
(150 mL) and CH2Cl2 (200 mL) was added. HCl (1 M) aqueous 
solution was added to acidify the mixture until the pH of the aqueous layer reached 5~6. 
The organic layer was separated and the aqueous layer was further extracted with 
CH2Cl2 (2 ×  50 mL). The combined organic layers were dried (Na2SO4) and 
concentrated and the residue was re-dissolved in CH2Cl2 (200 mL). To this solution at 
−78 oC under N2 was charged Et3N (18.40 mL, 132 mmol) and Tf2O (5.00 mL, 29.00 
mmol). The mixture was stirred at −78 oC for 0.5 h and then concentrated. The residue 
was subjected to flash silica gel column chromatography (hexanes/EtOAc: 20/1) to 
provide 65 (10.1 g, 89%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.57 (d, 
J = 7.4 Hz, 2H, ArH2′, ArH6′), 7.42 (t, J = 7.3 Hz, 2H, ArH3′, ArH5′), 7.36 (s, 1H, 
ArH8), 7.31-7.35 (m, 1H, ArH4′), 7.30 (d, J = 8.6 Hz, 1H, ArH2), 6.77 (s, 1H, ArH6), 
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6.75 (d, J = 8.8 Hz, 1H, ArH3), 5.18 (s, 1H, Ar′-CH2), 3.94 (s, 2H, OCH3), 2.52 (s, 2H, 
CH3). 
13C NMR (75 MHz, CDCl3) δ 157.5 (ArC5), 156.2 (ArC4), 139.2 (ArC1), 139.1 
(ArC1′), 137.1 (ArC8), 130.2 (ArC8a), 128.6 (ArC3′), 127.9 (ArC4′), 127.0 (ArC2′), 
121.0 (CF3), 118.7 (ArC2), 117.2 (ArC4a), 112.3 (ArC8), 109.6 (ArC6), 105.3 (ArC3), 
71.5 (Ar-CH2), 56.3 (OCH3), 22.5 (CH3). MS (EI): m/z 426 (M
+, 50%), 293 (100%). 
2-(4-(Benzyloxy)-5-methoxy-7-methylnaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2- 
dioxaborolane (66)e 
This is a known compound and it was prepared according to the 
known procedure.56 A mixture of 65 (7.00 g, 16.4 mmol), KOAc 
(4.83 g, 49.2 mmol), bispinacolatodiboron (6.25 g, 24.6 mmol), 
Pd(dppf)Cl2 (401 mg, 3 mol%), and 
1,1'-bis(diphenylphosphino)ferrocene (dppf, 273 mg, 3 mol%) in 
dioxane (100 mL) was stirred in a sealed tube at 100 oC under N2 for 7 h. H2O (100 mL) 
and EtOAc (50 mL) was added to quench the reaction. The organic layer was separated, 
washed with water (3 × 50 mL), brine (50 mL), dried (Na2SO4), concentrated, and the 
residue was subjected to flash silica gel column chromatography (hexanes/EtOAc: 
100/1) to provide 66 (6.10 g, 15.1 mmol, 92%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 8.16 (s, 1H, ArH8), 7.95 (d, J = 7.7 Hz, 1H, ArH2), 7.59 (d, J = 7.4 Hz, 2H, 
ArH2′, ArH6′), 7.39 (t, J = 7.3 Hz, 2H, ArH3′, ArH5′), 7.31 (t, J = 7.2 Hz, 1H, ArH4′), 
6.84 (d, J = 7.8 Hz, 1H, ArH3), 6.70 (s, 1H, ArH6), 5.22 (s, 2H, Ar′-CH2), 3.92 (s, 3H, 
OCH3), 2.49 (s, 3H, Ar-CH3), 1.40 (s, 12H, 4×CH3). 
13C NMR (126 MHz, CDCl3) 
δ 159.1 (ArC5), 157.3 (ArC4), 141.5 (ArC7), 137.6 (ArC1′), 137.4 (ArC2), 136.8 
(ArC8a), 128.5 (ArC3′), 127.6 (ArC4′), 127.0 (ArC2′), 120.6 (ArC8), 116.1 (ArC4a), 
                                                              
e ArC1 didn’t show any signal in 13C NMR spectrum. 
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108.5 (ArC6), 106.4 (ArC3), 83.5 (C1), 70.9 (Ar′-CH2), 56.4 (OCH3), 25.1 (4×CH3), 
22.5 (Ar-CH3). MS (EI): m/z 404 (M
+, 100%).  
(4-(Benzyloxy)-5-methoxy-7-methylnaphthalen-1-yl)boronic acid (37)f 
This is a known compound and it was prepared according to the 
known procedure.56 To a solution of 66 (2.00 g, 4.95 mmol) in 
THF/H2O (40 mL/10 mL) was added NaIO4 (3.18 g, 14.9 mmol). 
The mixture was stirred at rt for 30 min and then HCl solution (1 M, 
2.5 mL) was added. The resulting mixture was stirred at rt for 12 h, then H2O (50 mL) 
was added to the mixture and extracted with EtOAc (2 × 30 mL). The combined organic 
phases were washed sequentially with water (40 mL) and brine (20 mL), dried (Na2SO4), 
concentrated, and recrystallized from EtOAc/hexane to afford 37 (1.32 g, 82%) as a 
gray solid. 1H NMR (300 MHz, CD3OD) δ 7.61 (d, J = 7.4 Hz, 2H, ArH2′, ArH6′), 
7.47-7.26 (m, 4H, ArH2, ArH3′, ArH4′, ArH5′), 7.08 (s, 1H, ArH8,), 6.95 (d, J = 7.7 Hz, 
1H, ArH3), 6.80 (s, 1H, ArH6), 5.19 (s, 2H, Ar′-CH2), 3.92 (s, 3H, OCH3), 2.46 (s, 3H, 
CH3). 
13C NMR (126 MHz, CD3OD) δ 158.7 (ArC5), 158.1 (ArC4), 140.6 (ArC7), 
139.1 (ArC1′), 137.8 (ArC8a), 132.2 (ArC2), 129.3 (ArC3′), 128.5 (ArC4′), 128.1 
(ArC2′), 121.1 (ArC8), 117.3 (ArC4a), 109.5 (ArC6), 108.4 (ArC3), 72.2 (Ar′-CH2), 
56.7 (OCH3), 22.0 (CH3). MS (EI): m/z 322 (M
+, 40%), 278 (100%).  
Ethyl 8-bromo-5-isopropoxy-4-methoxy-2-naphthoate (49) 
This is a known compound and it was prepared according to the known 
procedure.49,60,140 Iodomethane (0.16 mL, 0.37 g, 2.61 mmol) was added to a suspension 
of 56 (0.23 g, 0.653 mmol) and potassium carbonate (0.37 g, 2.66 mmol) in acetone and 
                                                              
f ArC1 didn’t show any signal in 13C NMR spectrum. 
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heated at reflux for 18 h. The reaction mixture was concentrated 
under reduced pressure, diluted with H2O (10 mL) and extracted 
with chloroform (3 × 10 mL). The combined organic layers were 
washed with 2 M NaOH (10 mL), brine (25 mL), dried (Na2SO4), filtered, evaporated 
and recrystallized from CH2Cl2/hexane to give 49 (0.220 g, 92%) as a light yellow solid. 
1H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 1.6 Hz, 1H, ArH1), 7.70 (d, J = 8.2 Hz, 1H, 
ArH7), 7.46 (bs, 1H, ArH3), 6.87 (d, J = 8.2 Hz, 1H, ArH6), 4.57-4.49 (m, 1H, 
CH(CH3)2), 4.45 (q, J = 7.1 Hz, 2H, CH2CH3), 4.01 (s, 3H, OCH3), 1.46 (t, J = 7.1 Hz, 
3H, CH2CH3), 1.40 (d, J = 5.9 Hz, 6H, CH(CH3)2).
 13C NMR (126 MHz, CDCl3) δ 
166.5 (C=O), 157.6 (ArC4), 155.0 (ArC5), 134.4 (ArC8a), 131.1 (ArC2), 129.2 (ArC7), 
122.7 (ArC1), 122.6 (ArC4a), 115.5 (ArC8), 114.9 (ArC3), 105.8 (ArC6), 73.4 
(C(CH3)2), 61.3 (CH2CH3), 56.4 (OCH3), 21.9 (CH(CH3)2), 14.4 (CH2CH3).
 MS (EI): 
m/z 369 (M+, 81Br, 100%), 367 (M+, 79Br, 100%). 
Ethyl 5-isopropoxy-4-methoxy-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2- 
naphthoae (38) 
This is a known compound and it was prepared according to the 
known procedure.70 A mixture of 49 (0.350 g, 1.36 mmol), KOAc 
(0.270 g, 2.73 mmol), and PdCl2(dppf) (0.060 g, 10 mol%) in dry 
THF (5 mL) was heated at reflux in a sealed tube overnight. The 
reaction mixture was concentrated under reduced pressure, diluted with H2O and 
extracted with chloroform (3 × 10 mL). The combined organic layers were washed with 
brine (25 mL), dried (Na2SO4), filtered, evaporated and the residue was subjected to 
flash silica gel column chromatography (hexane/EtOAc: 5/95) to give the boronic ester 
38 (0.26 g, 91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.20 (d, J = 0.8 Hz, 1H, 
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ArH1), 7.99 (d, J = 7.8 Hz, 1H, ArH7), 7.39 (bs, 1H, ArH3), 6.98 (d, J = 7.9 Hz, 1H, 
ArH6), 4.69-4.60 (m, 1H, CH(CH3)2), 4.42 (q, J = 7.1 Hz, 2H, CH2CH3), 3.98 (s, 3H, 
OCH3), 1.46 (t, J = 7.1 Hz, 3H, CH2CH3), 1.42 (d, J = 3.6 Hz, 6H, CH(CH3)2), 1.26 (s, 
12H, 2×C(CH3)2).
 13C NMR (126 MHz, CDCl3) δ 167.3 (C=O), 158.1 (ArC4), 157.7 
(ArC5), 140.6 (ArC8a), 137.3 (ArC7), 128.2 (ArC4a), 124.6 (ArC1), 121.2 (ArC8), 
112.5 (ArC6), 105.2 (ArC3), 83.7 (C(CH3)2), 83.6 (C(CH3)2), 72.4 (CH(CH3)2), 61.0 
(CH2CH3), 56.5 (OCH3), 25.1 (C(CH3)2), 25.0 (C(CH3)2), 22.1 (CH(CH3)2), 14.4 
(CH2CH3).
 MS (EI): m/z 414 (M+, 40%) 372 (100%). 
7.1.2.2 Preparation of halogenated isoquinolines 
General procedure 1: preparation of (2-nitrovinyl)benzene derivatives 
To a solution of benzaldehyde derivative (20 mmol) in acetic acid (10 mL) was added 
nitromethane (12.2 g, 200 mmol) and Al(OAc)3 (770 mg, 10 mmol). The reaction 
mixture was heated at reflux for 5 h. The resulting solution was poured into saturated 
NaHCO3 aqueous solution (25 mL) slowly and extracted with EtOAc (3 × 30 mL). The 
combined organic layers were dried (Na2SO4), concentrated, and the residues were 
crystallized from MeOH to afford the nitrostyrene product. 
(E)-1-Methoxy-3-(2-nitrovinyl)benzene (79) 
This is a known compound and it was prepared according to the known 
procedure.80 Using General procedure 1, 3-methoxybenzaldehyde 77 
(2.70 g, 20.0 mmol) gave 79 (3.20 g, 91%) as yellow crystals. 1H NMR (500 MHz, 
CD3Cl) δ 7.95 (d, J = 14.0 Hz, 1H, H2), 7.56 (d, J = 14.0 Hz, 1H, H1), 7.36 (dd, J = 8.0, 
8.5 Hz, 1H, ArH5), 7.13 (d, J = 8.0 Hz, 1H, ArH4), 7.04 (m, 2H, ArH2, ArH6), 3.85 (s, 
3H, OCH3). 
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131.3 (ArC3), 130.4 (ArC5), 121.7 (ArC4), 117.9 (ArC6), 113.9 (ArC2), 55.4 (CH3). 
MS (EI): m/z 179 (M+, 100%). 
(E)-1,3-dimethoxy-5-(2-nitrovinyl)benzene (80) 
This is a known compound and it was prepared according to the 
known procedure.80 Using General procedure 1, 
3,5-dimethoxybenzaldehyde 78 (3.30 g, 20.0 mmol) gave the nitrostyrene derivative 80 
(4.00 g, 96%) as yellow crystals. 1H NMR (500 MHz, CD3Cl) δ 7.90 (d, J = 14.0 Hz, 
1H, H2), 7.54 (d, J =14.0 Hz, 1H, H1), 6.66 (d, J = 1.8 Hz, 2H, ArH4, ArH6), 6.58 (bs, 
1H, ArH2), 3.82 (s, 6H, 2×OCH3). 
13C NMR (126 MHz, CD3Cl) δ 161.3 (ArC1, ArC3), 
139.1 (C1), 137.5 (C2), 131.7 (ArC5), 107.0 (ArC4, ArC6), 104.1 (ArC2), 55.5 
(2×OCH3). MS (EI): m/z 209 (M
+, 100%). 
General procedure 2: Preparation of N-phenethylacetamide derivatives 
Step 1 
A solution of the nitrostyrene derivative (15 mmol) in anhydrous THF (40 mL) was 
added dropwise to a stirred solution of LiAlH4 (60 mmol) in THF (100 mL) at 0 
oC. The 
reaction mixture was allowed to warm to rt and was then heated at reflux for 5 h. The 
resulting mixture was cooled to 0 oC and treated with an excess of 30% NaOH aqueous 
solution. The liquid layer was decanted and extracted with EtOAc (3 × 50 mL). The 
combined organic layers were dried (Na2SO4), and concentrated to afford the 
corresponding amine, which was used in Step 2 without further purification. 
Step 2 
To a stirred solution of the crude amine in CH2Cl2 (25 mL) at 0 
oC was added Et3N 
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(15 mmol) and acetyl chloride (15 mmol). The mixture was allowed to warm to rt and 
stirred for 15 min. The resulting suspension was diluted with water (20 mL) and the 
layers were separated. The organic layer was washed with dilute HCl (15 mL), saturated 
NaHCO3 (15 mL) followed by brine (15 mL), then dried (Na2SO4), concentrated, and 
the resulting residue was subjected to flash silica gel column chromatography 
(hexanes/EtOAc: 30/70 containing 5% Et3N) to afford the desired acetamide derivative. 
N-(3-Methoxyphenethyl)acetamide (81) 
This is a known compound and it was prepared according to the 
known procedure.80 Using the General procedure 2, 
(E)-(2-nitrovinyl)benzene 79 (2.20 g, 15.0 mmol) gave 81 (1.60 g, 56% over two steps) 
as a brown oil. 1H NMR (500 MHz, CDCl3) δ 7.20 (m, 1H ArH5), 6.73-6.78 (m, 3H, 
ArH2, ArH4, ArH6), 6.24 (bs, 1H, NH), 3.77 (s, 3H, OCH3), 3.47 (td, J = 7.5 Hz, 
6.5 Hz, 2H, H2), 2.77 (t, J = 7.5 Hz, 2H, H1), 1.92 (s, 3H, CH3). 
13C NMR (126 MHz, 
CDCl3) δ 170.2 (C=O), 159.7 (ArC3), 140.4 (ArC1), 129.4 (ArC5), 120.8 (ArC6), 114.2 
(ArC2), 111.6 (ArC4), 54.9 (OCH3), 40.4 (C2), 35.4 (C1), 22.9 (CH3). MS (ESI): 
m/z 194 ([M+H]+). 
N-(3,5-Dimethoxyphenethyl)acetamide (82) 
This is a known compound and it was prepared according to the 
known procedure.80 Using the General procedure 2, 
(E)-1,3-dimethoxy-5-(2-nitrovinyl)benzene 80 (3.10 g, 15.0 
mmol) gave 82 (2.10 g, 63% over two steps) as a brown oil. 1H NMR (500 MHz, CDCl3) 
δ 6.34 (s, 3H, ArH2, ArH4, ArH6), 5.64 (bs, 1H, NH), 3.78 (s, 6H, 2×OCH3), 3.50 (td, 
J = 6.9 Hz, 6.0 Hz, 2H, H2), 2.75 (t, J = 6.9 Hz, 2H, H1), 1.94 (s, 3H, CH3). 
13C NMR 
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(126 MHz, CDCl3) δ 170.1 (C=O), 160.9 (ArC3, ArC5), 141.2 (ArC1), 106.7 (ArC2, 
ArC6), 98.3 (ArC4), 55.2 (2×OCH3), 40.4 (C2), 35.8 (C1), 23.3 (CH3). MS (EI): 
m/z 223 (M+, 30%), 164 (100%). 
General procedure 3: Bromination of N-phenethylacetamide derivatives 
To a solution of the acetamide derivative (5.20 mmol) in CH2Cl2 (20 mL) was added 
bromine solution (0.900 g, 5.7 mmol) in CH2Cl2 (10 mL) dropwise at 0 ºC. The reaction 
mixture was allowed to warm up to rt and stirred for 2 h. The resulting mixture was 
diluted with H2O (20 mL) and the layers were separated. The organic layer was washed 
successively with NaHCO3 (15 mL), 10% Na2S2O5 solution (15 mL) and brine (15 mL), 
then dried (Na2SO4), concentrated, and the resulting residue was subjected to flash silica 
gel column chromatography (hexanes/EtOAc: 30/70 containing 5% Et3N) to afford the 
corresponding bromo derivative. 
N-(2-Bromo-5-methoxyphenethyl)acetamide (83) 
This is a known compound and it was prepared according to the 
known procedure.80 Using General procedure 3, 
N-(3-methoxyphenethyl)acetamide 81 (1.00 g, 5.20 mmol) and 
bromine (0.900 g, 5.70 mmol) gave 83 (1.20 g, 87%) as a light brown solid. 1H NMR 
(500 MHz, CDCl3) δ 7.40 (d, J = 8.5 Hz, 1H, ArH3), 6.78 (d, J = 3.0 Hz, 1H, ArH6), 
6.64-6.67 (dd, J = 8.7, 2.9 Hz, 1H, ArH4), 5.96 (bs, 1H, NH), 3.77 (s, 3H, OCH3), 3.50 
(td, J = 7.0 Hz, 6.5 Hz, 2H, H2), 2.92 (t, J = 7.0 Hz, 2H, H1), 1.95 (s, 3H, CH3). 
13C NMR (126 MHz, CDCl3) δ 170.2 (C=O), 158.9 (ArC5), 139.2 (ArC1), 
133.3 (ArC3), 116.3 (ArC4), 114.8 (ArC2), 113.9 (ArC6), 55.4 (OCH3), 39.2 (C2), 35.8 
(C1), 23.2 (CH3). MS (ESI): m/z 272 ([M+H]














This is a known compound and it was prepared according to the 
known procedure.80 Using General procedure 3, 
N-(3,5-dimethoxyphenethyl) acetamide 82 (1.20 g, 5.20 mmol) 
and bromine (0.900 g, 5.70 mmol) gave the 84 (1.40 g, 89%) as a light brown solid. 1H 
NMR (500 MHz, CDCl3) δ 6.40 (d, J = 2.5 Hz, 1H, ArH6), 6.36 (d, J = 2.5 Hz, 1H, 
ArH4), 5.71 (bs, 1H, NH), 3.84 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.52 (td, J = 7.0 Hz, 
6.5 Hz, 2H, H2), 2.95 (t, J = 7.0 Hz, 2H, H1), 1.94 (s, 3H, CH3). 
13C NMR (126 MHz, 
CDCl3) δ 170.1 (C=O), 159.6 (ArC5), 156.8 (ArC3), 140.2 (ArC1), 106.9 (ArC6), 104.8 
(ArC2), 98.1 (ArC4), 56.3 (OCH3), 55.5 (OCH3), 39.3 (C2), 36.1 (C1), 23.3 (CH3). 
MS (EI): m/z 303 (M+, 20%, 81Br), 301 (M+, 20%, 79Br), 222 (100%). 
N-(2-Iodo-3,5-dimethoxyphenethyl)acetamide (90) 
To a solution of N-(3,5-dimethoxyphenethyl)acetamide 89 
(1.00 g, 4.48 mmol) was added Ag2SO4 (4.21g, 13.5 mmol), and 
then a solution of iodine (1.14 g, 4.48 mmol) in ethanol (20 mL) 
was added dropwise. After stirring for 30 min, the inorganic salts were removed by 
filtration, and the residue was subjected to flash silica gel column chromatography 
(CH2Cl2/EtOAc: 1/2 containing 5% Et3N) to afford 90 (1.36g, 87%) as a white solid. 
Mp. 118-119 oC. IR (neat) υmax 3338 (w), 2933 (w), 1640 (m), 1579 (m), 1547 (m), 
1453 (w), 1407 (w), 1332 (w), 1319 (w), 1293 (w), 1280 (w), 1204 (s), 1161 (s), 
1101 (w), 1049 (w), 1009 (w), 847 (w), 820 (w), 701 (w), 603 (w). 1H NMR (500 MHz, 
CDCl3) δ 6.46 (d, J = 2.5 Hz, 1H, ArH6), 6.33 (d, J = 2.5 Hz, 1H, ArH4), 5.58 (bs, 1H, 
NH), 3.86 (s, 3H, Ar3-OCH3), 3.80 (s, 3H, Ar5-OCH3), 3.51 (td, J = 7.0, 6.5 Hz, 2H, 
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N-CH2), 3.00 (t, J = 7.0 Hz, 2H, Ar-CH2), 1.96 (s, 3H, CH3). 
13C NMR (126 MHz, 
CDCl3) δ 170.3 (C=O), 161.2 (ArC3), 159.2 (ArC5), 143.8 (ArC1), 107.1 (ArC6), 
97.4 (ArC4), 82.0 (ArC2), 56.6 (Ar3-OCH3), 55.7 (Ar5-OCH3), 40.7 (N-CH2), 
39.7 (Ar-CH2), 23.5 (CH3). MS (EI): m/z 349 (M
+, 20%), 222 (100%). HRMS (ESI) 
calcd for C12H17INO3: 350.0253, found 350.0258. 
General procedure 4: Preparation of isoquinolines by cyclization reaction. 
To a solution of the acetamide derivative (2.50 mmol) in CH3CN (20 mL) was added 
POCl3 (32.0 mmol) and P2O5 (2.50 mmol) and the resulting mixture was heated at 
reflux for 6 h. The solvent was evaporated under reduced pressure and the resulting 
residue was diluted with CH2Cl2 (10 mL) followed by stirring in aqueous KOH (30 mL, 
1 M) for 10 min. The layers were separated and the aqueous layer was extracted with 
EtOAc (3 × 10 mL). The combined organic layers were washed with brine (25 mL), 
dried (Na2SO4), concentrated, and the residue subjected to flash silica gel column 
chromatography (hexane/ethyl acetate: 60/40 containing 5% Et3N) to give the 
isoquinoline. 
5-Bromo-8-methoxy-1-methyl-3,4-dihydroisoquinoline (39) 
This is a known compound and it was prepared according to the known 
procedure.80 Using General procedure 4, 
N-(2-bromo-5-methoxyphenethyl)acetamide 83 (548 mg, 2.00 mmol) gave 
39 (447 mg, 88%) as a brown solid. 1H NMR (300 MHz, CDCl3) δ 7.87 (d, J = 9.1 Hz, 
1H, H6), 7.00 (d, J = 9.1 Hz, 1H, H7), 4.01 (s, 3H, OCH3), 3.85 (t, J = 7.2 Hz, 2H, H3), 
3.13 (t, J = 7.5 Hz, 2H, H4), 3.02 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 175.2 
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(OCH3), 40.1 (C3), 26.8 (C4), 24.2 (CH3). MS (EI): m/z 253 (M
+, 79Br, 100%) 255 (M+, 
81Br, 97%). 
5-Bromo-6,8-dimethoxy-1-methyl-3,4-dihydroisoquinoline (40) 
This is a known compound and it was prepared according to the known 
procedure.80 Using General procedure 4, 
N-(2-bromo-3,5-dimethoxyphenethyl)acetamide 84 (1.51g, 5.00 mmol) 
gave 40 (1.30 g, 90%) as a brown solid. 1H NMR (500 MHz, CD3OD) δ 6.81 (s, 1H, 
H7), 4.09 (s, 6H, OCH3), 3.73 (t, J = 7.3 Hz, 2H, H3), 3.20 (t, J = 7.5 Hz, 2H, H4), 2.77 
(s, 3H, CH3). 
13C NMR (126 MHz, CD3OD) δ 176.3 (C1), 165.7 (C8), 165.6 (C6), 
142.1 (C4a), 110.7 (C8a), 106.0 (C5), 96.9 (C7), 57.9 (8-OCH3), 57.3 (6-OCH3), 41.3 
(C4), 28.3 (C3), 24.7 (CH3). MS (EI): m/z 283 (M
+, 79Br, 100%) 285 (M+, 81Br, 97%). 
5-Iodo-6,8-dimethoxy-1-methyl-3,4-dihydroisoquinoline (41) 
Using General procedure 4, 90 (1.05g, 3.00 mmol) gave 41 (0.850 g, 
86%) as a yellow solid. Mp. 205-206 oC. IR (neat) υmax 2651 (m), 1632 
(m), 1566 (s), 1425 (w), 1354 (w), 1317 (w), 1280 (s), 1224 (s), 1123 
(w), 1084 (w), 1016 (w), 916 (w), 840 (w), 739 (w). 1H NMR (500 MHz, CD3OD) 
δ 6.76 (s, 1H, H7), 4.09 (s, 6H, OCH3), 3.71 (t, J = 7.1 Hz, 2H, H3), 3.19 (t, J = 7.4 Hz, 
2H, H4), 2.76 (s, 3H, CH3). 
13C NMR (126 MHz, CD3OD) δ 176.1 (C1), 167.7 (C8), 
166.7 (C6), 146.0 (C4a), 111.1 (C8a), 96.0 (C7), 83.3 (C5), 58.0 (8-OCH3), 57.1 
(6-OCH3), 41.8 (C4), 34.0 (C3), 24.4 (CH3). MS (EI): m/z 331 (M
+, 100%). HRMS (ESI) 





















This is a known compound and it was prepared according to the known 
procedure.82 To a solution of 1-bromo-2-(2-isocyanatopropyl)benzene 
(76) (1.93 g, 8.01 mmol) in tetrachloroethylene (20 mL) in a flask 
equipped with a reflux condenser was added aluminium chloride (2.24 g, 16.8 mmol) 
and the reaction mixture was heated at 80 °C for 3 h. Upon heating, the reaction mixture 
turned black. The reaction mixture was quenched with 3 M aq. HCl (2.92 mL), diluted 
with CH2Cl2 (100 mL) and filtered. The filter cake was washed with CH2Cl2 (100 mL), 
the filtrate dried (MgSO4), filtered, evaporated and the residue was subjected to flash 
silica gel column chromatography (CH2Cl2/ethyl acetate: 8/2) yielded the desired 
3,4-dihydroisoquinolinone 42 as a yellowish solid (612 mg, 31%). 1H NMR (500 MHz, 
CDCl3) δ 8.00 (1H, d, J = 8.0 Hz, H8), 7.72 (1H, d, J = 8.5 Hz, H6), 7.68 (1H, bs, NH), 
7.28 (1H, t, J = 8.0 Hz, H7), 3.80- 3.87 (1H, m, H3), 3.18 (1H, dd, J = 16.0, 4.5 Hz, 
H4b), 2.69 (1H, dd, J = 16.8, 10.5 Hz, H4a), 1.37 (3H, d, J = 6.6 Hz, CH3). 13C NMR 
(126 MHz, CDCl3) δ 164.6 (C1), 138.3 (C4a), 135.9 (C6), 131.5 (C5), 128.4 (C7), 
127.3 (C8), 123.0 (C8a), 46.3 (C3), 36.1 (C4), 20.9 (CH3). MS (EI): m/z 241 (M+, 81Br, 
30%), 239 (M+, 79Br, 32%). 
7.1.2.3 Preparation of naphthylisoquinoline alkaloids by Suzuki coupling 
General Procedure 5: Suzuki coupling of naphthyl boronic acid and halogenated 
isoquinolines 
A mixture of 37 (1.10 mmol), halogenated isoquinoline (1.00 mmol), Pd (PPh3)4 
(5 mol%) and 2 M Na2CO3 aqueous solution (8.00 mmol) in dioxane (20 mL) in a 
sealed tube under N2 was heated and stirred at reflux for 18 h. The mixture was cooled 
to rt, diluted with H2O (10 mL) and extracted with EtOAc (3 × 20 mL). The combined 
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organic layers were washed with brine (25 mL), dried (Na2SO4), filtered, evaporated 
and the residue was subjected to flash silica gel column chromatography (hexane/ethyl 
acetate: 60/40 containing 5% Et3N) to give the target monomer. 
5-(4-(Benzyloxy)-5-methoxy-7-methylnaphthalen-1-yl)-8-methoxy-1-methyl-3,4-dihydroi
soquinoline (99) 
Using the General Procedure 5, 37 (142 mg, 0.440 mmol) and 39 
(101 mg, 0.400 mmol) gave 99 (102 mg, 57%) as a light brown solid. 
Mp. 148 oC. IR (neat) υmax 3741 (w), 2940 (w), 2839 (w), 2360 (m), 
1618 (w), 1574 (s), 1455 (w), 1369 (w), 1321 (w), 1274 (s), 1181 (w), 
1143 (w), 1081 (s), 972 (w), 836 (m), 738 (m), 691 (m). 1H NMR 
(500 MHz, CDCl3) δ 7.62 (d, J = 7.5 Hz, 2H, ArH2′, ArH6′), 7.42 (t, J = 7.6 Hz, 2H, 
ArH3′, ArH5′), 7.33 (t, J = 7.3 Hz, 1H, ArH4′), 7.27 (d, J = 8.5 Hz, 1H, H6), 7.14 (d, 
J = 7.8 Hz, 1H, ArH2), 6.95 (d, J = 8.5 Hz, 1H, H7), 6.89 (d, J = 7.9 Hz, 1H, ArH3), 
6.76 (s, 1H, ArH8), 6.71 (s, 1H, ArH6), 5.23 (s, 2H, Ar′-CH2), 3.95 (s, 3H, Ar-OCH3), 
3.94 (s, 3H, 8-OCH3), 3.32-3.36 (m, 2H, H3), 2.55 (s, 3H, 1-CH3), 2.34 (s, 3H, Ar-CH3), 
2.18 (t, J = 7.0 Hz, 2H, H4). 13C NMR (126 MHz, CDCl3) δ 164.8 (C1), 157.5 (ArC5), 
156.7 (C8), 155.9 (ArC4), 140.3 (ArC4a), 137.8 (ArC1′), 136.6 (ArC8a), 136.2 (ArC7), 
133.6 (C6), 131.8 (C5), 130.6 (ArC1), 128.5 (ArC3′, ArC5′), 128.2 (ArC2), 127.6 
(ArC4′), 127.1 (ArC2′, ArC6′), 119.4 (C8a), 117.9 (ArC8), 116.4 (ArC4a), 109.8 (C7), 
108.6 (ArC6), 107.2 (ArC3), 71.5 (Ar′-CH2), 56.4 (Ar′-OCH3), 55.5 (8-OCH3), 46.8 
(C3), 27.9 (1-CH3), 25.0 (C4), 22.2 (Ar-CH3). MS (EI): m/z 451 (M
+, 80%), 360 (100%). 


















Using the General Procedure 5, 37 (256 mg, 0.790 mmol) and 41 
(238 mg, 0.720 mmol) gave 43 (175 mg, 51%) as a light brown solid. 
Mp. 149-150 oC. IR (neat) υmax 2935 (w), 2835 (w), 2361 (w), 
1615 (w), 1578 (s), 1452 (w), 1433 (w), 1370 (w), 1347 (w), 1304 
(w), 1269 (m), 1233 (w), 1207 (m), 1180 (w), 1145 (w), 1088 (s), 
1023 (w), 826 (w), 737 (m), 697 (m). 1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 7.5 Hz, 
2H, ArH2′, ArH6′), 7.42 (t, J = 7.6 Hz, 2H, ArH3′, ArH5′), 7.32 (t, J = 7.3 Hz, 1H, 
ArH4′), 7.10 (d, J = 7.9 Hz, 1H, ArH2), 6.91 (d, J = 7.9 Hz, 1H, ArH3), 6.69 (s, 1H, 
ArH8), 6.68 (s, 1H, ArH6), 6.52 (s, 1H, H7), 5.22 (s, 2H, Ar′-CH2), 3.97 (s, 3H, 
8-OCH3), 3.94 (s, 3H, Ar-OCH3), 3.69 (s, 3H, 6-OCH3), 3.40-3.17 (m, 2H, H3), 2.51 (s, 
3H, 1-CH3), 2.33 (s, 3H, Ar-CH3), 2.19-1.96 (m, 2H, H4). 
13C NMR (126 MHz, CDCl3) 
δ 164.4 (C1), 160.1 (C6), 158.6 (C8), 157.5 (ArC5), 155.9 (ArC4), 142.1 (C4a), 138.0 
(ArC1′), 136.5 (ArC8a), 136.4 (ArC7), 128.8 (ArC2), 128.4 (ArC3′, ArC5′), 127.6 
(ArC4′), 127.1 (ArC2′, ArC6′), 126.4 (ArC1), 120.3 (C5), 117.5 (ArC8), 116.6 (ArC4a), 
113.1 (C8a), 108.7 (ArC6), 107.4 (ArC3), 93.9 (C7), 71.4 (Ar′-CH2), 56.4 (Ar-OCH3), 
55.9 (6-OCH3), 55.6 (8-OCH3), 46.7 (C3), 27.9 (1-CH3), 25.2 (C4), 22.2 (Ar-CH3). 
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gave 100 (66 mg, 75%) as a light brown solid. Mp. 221 oC. IR (neat) 
υmax 3190 (w), 3063 (w), 2925 (w), 2362 (w), 1668 (m), 1621 (w), 
1578 (s), 1452 (w), 1396 (w), 1370 (m), 1322 (m), 1268 (m), 
1240 (w), 1182 (w), 1147 (w), 1111 (w), 1086 (m), 1030 (w), 964 
(w), 827 (m), 733 (s), 693 (w), 635 (w), 615 (w). 1H NMR 
(500 MHz, CDCl3) δ 8.17 (d, J = 6.9 Hz, 1H, H8), 7.63 (d, J = 7.4 Hz, 2H, ArH2′, 
ArH6′), 7.47-7.38 (m, 4H, ArH3′, ArH5′, H6, H7), 7.38-7.32 (m, 1H, ArH4′), 7.19 (d, 
J = 7.8 Hz, 1/2H, ArH2), 7.12 (d, J = 7.8 Hz, 1/2H, ArH2), 6.92 (d, J = 7.8 Hz, 1H, 
ArH3), 6.77 (s, 1/2H, ArH8), 6.73 (d, J = 4.5 Hz, 1H, ArH6), 6.60 (s, 1/2H, ArH8), 6.04 
(d, J = 4.5 Hz, 1H, NH), 5.25 (s, 2H, ArCH2), 3.97 (s, 3H, OCH3), 3.73-3.63 (m, 1H, 
H3), 2.58-2.38 (m, 2H, H4), 2.35 (s, 3/2H, Ar7-CH3), 2.33 (s, 3/2H, Ar7-CH3), 1.15 (d, 
J = 3.0 Hz, 3/2H, 3-CH3), 1.13 (d, J = 3.0 Hz, 3/2H, 3-CH3). 
13C NMR (126 MHz, 
CDCl3) δ 166.7 (C=O), 157.5 (ArC5), 156.2 (ArC4), 140.1 (C5), 137.7 (ArC8a), 
137.0 (ArC7), 135.9 (C4a), 134.8 (C6), 134.6 (ArC1′), 130.4 (ArC3′, ArC5′), 128.8 
(ArC2′, ArC6′), 128.7 (ArC4′), 128.5 (ArC2), 127.7 (C8a), 127.3 (ArC1), 127.1 (C7), 
126.8 (C8), 117.9 (ArC8), 116.2 (ArC4a), 108.7 (ArC6), 107.0 (ArC3), 71.5 (Ar′CH2), 
56.4 (OCH3), 46.9 (C3), 33.7 (C4), 22.2 (Ar7-CH3), 21.4 (3-CH3). MS (EI): m/z 437 
(M+, 90%), 91 (100%). HRMS (ESI) calcd for C29H28NO3: 438.2069, found 438.2066. 
General procedure 6: Debenzylation of naphthylisoquinoline alkaloids 
Benzyl protected naphthylisoquinoline alkaloid (0.10 mmol) was dissolved in 
MeOH/CH2Cl2 (10 mL/5 mL), followed by addition of Pd/C (10 mol%, 5 mg). The 
resulting mixture was stirred at rt under 1 atm of H2 for 2 h and then filtered. The filtrate 
was concentrated and the residue was subjected to flash silica gel column 
chromatography (hexane/ethyl acetate: 70/30 containing 5% Et3N) to afford the target 
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compound as a light brown solid. 
8-Methoxy-4-(8-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-6-methylnaphtha
len-1-ol (109) 
Using the General procedure 6, 99 (93 mg, 0.20 mmol) gave 109 
(67 mg, 92%) as a brown solid. Mp. 184 oC (decomp.). IR (neat) υmax 
3401 (w), 2944 (w), 2362 (m), 1669 (w), 1615 (w), 1583 (s), 1453 (w), 
1436 (w), 1397 (m), 1262 (s), 1126 (w), 1110 (w), 1083 (w), 1034 (w), 
957 (w), 820 (m), 733 (w), 637 (w), 613 (w). 1H NMR (500 MHz, CD3OD) δ 7.19-6.99 
(m, 3H, H6, ArH3, H7), 6.82-6.71 (m, 2H, ArH5, ArH2), 6.63 (s, 1H, ArH7), 4.90-4.86 
(m, 1H, H1), 4.07 (s, 3H, Ar8-OCH3), 3.95 (s, 3H, 8-OCH3), 3.43-3.21 (m, 2H, H3), 
2.82-2.55 (m, 2H, H4), 2.31 (s, 3H, Ar6-CH3), 1.68 (m, 3H, 1-CH3). 
13C NMR 
(126 MHz, CD3OD) δ 157.9 (ArC8), 156.6 (C8), 155.6 (ArC1), 137.7 (C4a), 136.5 
(ArC4a), 134.7 (ArC6), 132.4 (C5), 132.2 (C6), 130.3 (ArC3), 129.2 (C8a), 123.4 
(ArC4), 119.4 (ArC5), 114.6 (ArC8a), 110.0 (ArC2), 109.8 (C7), 107.6 (ArC7), 56.8 
(Ar8-OCH3), 56.2 (8-OCH3), 48.3 (C1), 37.2 (C3), 24.5 (C4), 22.2 (Ar6-CH3), 18.1 
(1-CH3). MS (EI): m/z 363 (M
+, 30%), 348 (100%). HRMS (ESI) calcd for C23H26NO3: 
364.1913, found 364.1926. 
4-(6,8-Dimethoxy-1-methyl-3,4-dihydroisoquinolin-5-yl)-8-methoxy-6-methylnaphthale
n-1-ol (44) 
Using the General procedure 6, 43 (48 mg, 0.10 mmol) gave 44 (37 mg, 95%) as a 
brown solid. Mp. 179 oC (decomp.). IR (neat) υmax 3739 (w), 3396 (w), 2571 (w), 2363 
(w), 1644 (w), 1621 (w), 1580 (s), 1430 (m), 1360 (m),1321 (m), 1284 (m), 1257 (m), 
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(300 MHz, CDCl3) δ 9.48 (s, 1H, OH), 7.04 (d, J = 7.8 Hz, 1H, 
ArH3), 6.86 (d, J = 7.8 Hz, 1H, ArH2), 6.66 (s, 1H, ArH5), 6.57 (s, 
1H, ArH7), 6.54 (s, 1H, H7), 4.10 (s, 3H, Ar8-OCH3), 4.08 (s, 3H, 
8-OCH3), 3.81 (s, 3H, 6-OCH3), 3.64-3.40 (m, 2H, H3), 3.01 (s, 3H, 
1-CH3), 2.60-2.39 (m, 2H, H4), 2.35 (s, 3H, Ar6-CH3). 
13C NMR (75 MHz, CDCl3) 
δ 173.9 (C1), 166.1 (C6), 163.8 (ArC8), 156.5 (C8), 154.9 (ArC1), 140.7 (ArC4a), 
136.7 (ArC6), 135.0 (C4a), 129.9 (ArC3), 121.9 (ArC4), 121.4 (C8a), 117.3 (ArC7), 
113.5 (C5), 109.4 (ArC2), 108.4 (C8a), 106.6 (ArC5), 94.0 (ArC7), 56.26 (OCH3), 
56.23 (OCH3), 56.15 (OCH3), 39.9 (C3), 24.5 (C4), 24.2 (1-CH3), 22.3 (Ar-CH3). 




Using the General procedure 6, 100 (88 mg, 0.20 mmol) gave 107 
(76 mg, 94%) as a brown solid. Mp. 210-211 oC. IR (neat) υmax 3421 
(w), 3200 (w), 2962 (w), 1671 (s), 1616 (w), 1588 (w), 1433 (m), 1397 
(m), 1258 (s), 1175 (w), 1130 (m), 1097 (w), 1032 (w), 957 (w), 824 
(m), 755 (w), 614 (m). 1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1H, OH), 8.15 (d, 
J = 6.6 Hz, 1H, H8), 7.51-7.34 (m, 2H, H7, H6), 7.18 (d, J = 7.8 Hz, 1/2H, ArH2), 7.11 
(d, J = 7.8 Hz, 1/2H, ArH2), 6.86 (d, J = 7.6 Hz, 1H, ArH3), 6.79 (s, 1/2H, ArH8), 6.71 
(bs, 1H, NH), 6.66 (s, 1H, ArH6), 6.62 (s, 1/2H, ArH8), 4.08 (s, 3H, OCH3), 3.73-3.61 
(m, 1H, CH), 2.56-2.39 (m, 2H, H4), 2.34 (s, 3/2H, Ar7-CH3), 2.33 (s, 3/2H, Ar7-CH3), 
1.15 (d, J = 5.4 Hz, 3H, 3-CH3). 
13C NMR (126 MHz, CDCl3) δ 156.5 (C=O), 154.61 
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(C6), 128.9 (ArC2), 128.2 (C8a), 127.8 (ArC1), 127.3 (C8), 126.6 (C7), 118.7 (ArC8), 
113.4 (ArC4a), 109.3 (ArC3), 106.7 (ArC6), 56.4 (OCH3), 46.8 (C3), 33.7 (C4), 22.2 
(Ar7-CH3), 21.3 (3-CH3). MS (ESI): m/z 348 ([M+H]
+, 100%). HRMS (ESI) calcd for 
C22H22NO3: 348.1600, found 348.1594. 
General procedure 7: Suzuki coupling of naphthyl boronic ester and halogenated 
isoquinolines 
A mixture of boronic ester 38 (0.10 mmL), halogenated isoquinoline (0.10 mmol), 
K2CO3 (0.40 mmol) and PdCl2(dppf) (5 mol%) in dry dioxane (30 mL) was heated at 
reflux in a sealed tube under N2 for 24 h. The mixture was cooled to rt, diluted with 
H2O (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers 
were washed with brine (25 mL), dried (Na2SO4), filtered, evaporated and the residue 
subjected to flash silica gel column chromatography (hexane/ethyl acetate: 50/50 
containing 5% Et3N) to give the target naphthylisoquinoline alkaloids.  
Ethyl 5-isopropoxy-4-methoxy-8-(8-methoxy-1-methyl-3,4-dihydroisoquinolin-5-yl)-2- 
naphthoate (96) 
Using the General procedure 7, 38 (62 mg, 0.15 mmol) and 39 
(38 mg, 0.15 mmol) gave 96 (40 mg, 58%) as a brown semi-solid. 
IR (neat) υmax 2934 (w), 2858 (w), 1713 (s), 1617 (w), 1585 (m), 
1460 (w), 1369 (m), 1275 (s), 1224 (m), 1195 (s), 1030 (m), 949 
(w), 916 (w), 835 (w), 762 (m), 692 (w). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 1.0 
Hz, 1H, ArH1), 7.39 (bs, 1H, ArH3), 7.28 (d, J = 8.5 Hz, 1H, H6), 7.25 (d, J = 7.9 Hz, 
1H, ArH7), 7.06 (d, J = 7.9 Hz, 1H, ArH6), 6.97 (d, J = 8.5 Hz, 1H, H7), 4.66-4.54 (m, 
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8-OCH3), 3.40-3.29 (m, 2H, H3), 2.54 (s, 3H, 1-CH3), 2.16 (t, J = 7.0 Hz, 2H, H4), 1.45 
(d, J = 1.4 Hz, 6H, CH(CH3)2), 1.33 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (75 MHz, 
CDCl3) δ 166.8 (C=O), 164.9 (C1), 157.8 (ArC4), 156.9 (C8), 154.7 (ArC5), 140.2 
(C4a), 135.3 (ArC8a), 133.7 (C6), 132.8 (ArC8), 130.8 (C5), 128.9 (ArC7), 128.1 
(ArC2), 121.8 (ArC1), 121.4 (ArC4a), 119.4 (C8a), 114.2 (ArC6), 109.9 (C7), 105.1 
(ArC3), 73.3 (CH(CH3)2), 61.2 (CH2CH3), 56.5 (Ar4-OCH3), 55.6 (8-OCH3), 46.5 (C3), 
27.8 (1-CH3), 25.2 (C4), 24.9 (CH2CH3), 22.3 (CH(CH3)2), 22.2 (CH(CH3)2). MS (EI): 




Using the General procedure 7, 38 (133 mg, 0.40 mmol) and 41 
(132 mg, 0.40 mmol) gave 97 (87 mg, 44%) as a brown solid. Mp. 
57-58 oC. IR (neat) υmax 3743 (w), 2974 (w), 1713 (m), 1616 (w), 
1579 (s), 1515 (w), 1455 (m), 1373 (w), 1345 (w), 1304 (w), 
1275 (m), 1230 (s), 1116 (s), 1086 (s), 1024 (m), 927 (w), 817 (w), 766 (w), 721 (w). 1H 
NMR (500 MHz, CDCl3) δ 7.71 (s, 1H, ArH1), 7.37 (s, 1H, ArH3), 7.20 (d, J = 7.7 Hz, 
1H, ArH7), 7.06 (d, J = 7.8 Hz, 1H, ArH6), 6.52 (s, 1H, H7), 4.65-4.56 (m, 1H, CH), 
4.37-4.28 (m, 2H, CH2CH3), 4.01 (s, 3H, Ar4-OCH3), 3.97 (s, 3H, 8-OCH3), 3.68 (s, 3H, 
6-OCH3), 3.41-3.17 (m, 2H, H3), 2.51 (s, 3H, 1-CH3), 2.19-1.94 (m, 2H, H4), 1.45 (d, 
J = 5.5 Hz, 6H, CH(CH3)2), 1.33 (t, J = 6.8 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, 
CDCl3) δ 166.8 (C=O), 164.4 (C1), 160.0 (C8), 158.9 (ArC4), 157.8 (C6), 154.7 (ArC5), 
141.9 (ArC8a), 135.6 (C4a), 129.6 (ArC7), 128.6 (ArC8), 128.0 (ArC2), 121.74 (ArC1), 
121.70 (ArC4a), 119.4 (C5), 114.1 (ArC6), 113.2 (C8a), 105.2 (ArC3), 94.1 (C7), 73.0 
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(CH), 61.0 (CH2CH3), 56.6 (Ar4-OCH3), 55.8 (8-OCH3), 55.6 (6-OCH3), 46.6 (C3), 
27.8 (1-CH3), 25.3 (C4), 22.3 (2 × CH3), 14.4 (CH2CH3). MS (EI): m/z 491 (M
+, 90%), 
434 (100%). HRMS (ESI) calcd for C29H34NO6: 492.2386, found 492.2403. 
Ethyl 5-isopropoxy-4-methoxy-8-(3-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-5-yl)- 
2-naphthoate (98) 
 Using the General procedure 7, 38 (104 mg, 0.25 mmol) and 42 
(60 mg, 0.25 mmol) gave 98 (60 mg, 54%) as a brown solid. Mp. 
203-204 oC. IR (neat) υmax 2975 (w), 1715 (m), 1669 (s), 1583 (s), 
1444 (w), 1372 (s), 1331 (w), 1275 (s), 1227 (s), 1191 (w), 1119 (s), 
1018 (m), 918 (w), 817 (w), 762 (m), 727 (m), 687 (w). 1H NMR 
(500 MHz, CDCl3) δ 8.19 (t, J = 6.5 Hz, 1H, H8), 7.78 (s, 1/2H, ArH1), 7.60 (s, 1/2H, 
ArH1), 7.49-7.39 (m, 3H, H6, H7, ArH3), 7.28 (d, J = 8.1 Hz, 1/2H, ArH7), 7.23 (d, 
J = 7.9 Hz, 1/2H, ArH7), 7.07 (dd, J = 7.9, 2.7 Hz, 1H, ArH6), 6.26 (s, 1/2H, NH), 6.20 
(s, 1/2H, NH), 4.64 (m, 1H, CH(CH3)2), 4.38-4.27 (m, 2H, CH2CH3), 4.03 (s, 3H, 
OCH3), 3.79-3.63 (m, 1H, H3), 2.54-2.30 (m, 2H, H4), 1.47 (d, J = 5.9 Hz, 6H, 
CH(CH3)2), 1.30 (m, 3H, CH2CH3), 1.15 (t, J = 5.9 Hz, 3H, 3-CH3). 
13C NMR 
(126 MHz, CDCl3) δ 166.7 (C=O), 166.5 (C1), 158.0 (ArC4), 155.2 (ArC5), 139.3 
(ArC8a), 137.4 (C5), 135.1 (C4a), 134.6 (C6), 132.4 (ArC8), 129.1 (C8a), 128.6 (ArC7), 
128.4 (ArC2), 127.7 (C8), 126.9 (C7), 121.5 (ArC4a), 121.3 (ArC1), 113.7 (ArC6), 
105.4 (ArC3), 73.1 (CH(CH3)2), 61.2 (CH2CH3), 56.5 (OCH3), 46.8 (C3), 34.3 (C4), 
22.3 (2×CH3), 21.4 (CH2CH3), 14.4 (3-CH3). MS (EI): m/z 447 (M
+, 70%), 390 (100%). 
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7.1.2.4 Preparation of michellamine B analogues by oxidative dimerization 
General procedure 8: Oxidative dimerization of the naphthylisoquinoline alkaloids 
A solution of naphthylisoquinoline (0.010 mmol) in dry CH2Cl2 (10 mL) containing 0.2% 
NEt3 was treated with Ag2O (116 mg, 0.50 mmol). After 18 h stirring at rt in air, the 
solvent was removed and the residue was subjected to a short flash silica gel column 
chromatography (CH2Cl2/methanol: 50:1) to afford the deep-violet coloured 
intermediate. The intermediate was hydrogenated using a hydrogen balloon in ethanol 
(3 mL) in the presence of Pd/C 10% (5 mg) for 1 h. After evaporation of the solvent, the 
residue subjected to a flash silica gel column chromatography (CH2Cl2/methanol: 10/1) 
to afford the target michellamine analogues as a brown solid. 
1,1'-Dihydroxy-8,8'-dimethoxy-6,6'-dimethyl-[2,2'-binaphthalene]-4,4'-diyl 
bis(2,2-dimethylpropanoate) (111) 
Using the General procedure 8, 63 (29 mg, 0.10 mmol) 
gave the 111 (12 mg, 42%) as a brown solid. Mp. 246-247 
oC. IR (neat) υmax 3744 (w), 3363 (w), 2967 (w), 1748 (m), 
1625 (w), 1459 (m), 1403 (m), 1354 (w), 1280 (w), 1250 
(w), 1112 (s), 1039 (m), 958 (w), 902 (w), 830 (w), 762 (w), 620 (w). 1H NMR (500 
MHz, CDCl3) δ 9.59 (s, 2H, 2 × OH), 7.21 (s, 2H, ArH3, ArH3′), 7.13 (s, 2H, ArH5, 
ArH5′), 6.64 (s, 2H, ArH7, ArH7′), 4.01 (s, 6H, 2×OCH3), 2.46 (s, 6H, 2×CH3), 1.46 (s, 
18H, 3×CH3). 
13C NMR (126 MHz, CDCl3) δ 177.5 (2×C=O), 156.5 (ArC8, ArC8′), 
149.4 (ArC1, ArC1′), 138.1 (ArC4, ArC4′), 136.3 (ArC6, ArC6′), 129.4 (ArC4a, 
ArC4a′), 123.1 (ArC3, ArC3′), 118.1 (ArC2, ArC2′), 114.11 (ArC5, ArC5′), 114.08 












Chapter 7    Experimental 
142 
 
(CH3). MS (EI): m/z 574 (M




Using the General procedure 8, 107 (11 mg, 0.030 mmol) 
gave the 113 (3.6 mg, 35%) as a brown solid. Mp. 236-237 
oC. IR (neat) υmax 3744 (w), 3363 (w), 2967 (w), 1748 (m), 
1625 (w), 1459 (w), 1403 (m), 1354 (m), 1280 (w), 1250 
(w), 1112 (s), 1039 (m), 958 (w), 902 (w), 830 (w), 762 (w), 
620 (w). 1H NMR (500 MHz, CD3OD) δ 7.98 (bs, 2H, H8, 
H8′), 7.39-7.17 (m, 6H, H6, H6′, H7, H7′, ArH3, ArH3′), 6.79 (s, 2H, ArH5, ArH5′), 
6.72 (s, 1H, ArH7, ArH7′), 6.60 (s, 1H, ArH7, ArH7′), 4.04 (s, 3H, Ar8-OCH3), 4.03 (s, 
3H, Ar8′-OCH3), 3.63-3.46 (m, 2H, H3, H3′), 2.64-2.34 (m, 4H, H4, H4′), 2.30 (s, 6H, 
Ar6-CH3, Ar6′-CH3), 1.08-1.02 (m, 6H, 3-CH3, 3′-CH3). 
13C NMR (126 MHz, CD3OD) 
δ 158.0 (C=O), 152.4 (ArC8, ArC8′), 152.3 (ArC1, ArC1′), 141.5 (C5, C5′), 139.0 
(ArC4a, ArC4a′), 137.7 (C4a, C4a′), 136.1 (C6, C6′), 135.6 (ArC6, ArC6′), 133.8 (ArC3, 
ArC3′), 129.9 (C8a, C8a′), 128.2 (ArC4, ArC4′), 127.7 (C7, C7′), 127.5 (C8, C8′), 119.6 
(ArC2, ArC2′), 119.1 (ArC7, ArC7′), 114.7 (ArC8a, ArC8a′), 107.9 (ArC5, ArC5′), 56.9 
(OCH3), 47.6 (C3, C3′), 34.7 (C4, C4′), 21.08 (Ar7-CH3, Ar7′-CH3), 20.97 (3-CH3, 
3′-CH3).  MS (ESI): m/z 693 ([M+H]
+, 80%). HRMS (ESI) calcd for C44H41N2O6: 









Using the General procedure 8, 44 (10 mg, 0.025 mmol) 
gave the 112 (3.0 mg, 31%) as a brown solid. Mp. 215 oC 
(decomp.).  IR (neat) υmax 3743 (w), 3364 (w), 2967 (w), 
1750 (w), 1654 (s), 1585 (s), 1455 (w), 1402 (s), 1358 (m), 
1262 (m), 1158 (m), 1100 (s), 1023 (m), 959 (w), 902 (w), 
830 (m), 757 (m), 612 (w). 1H NMR (500 MHz, CD3OD) 
δ 7.26 (s, 1H, ArH3 or ArH3′), 7.25 (s, 1H, ArH3 or ArH3′), 6.84 (s, 2H, ArH7 or ArH7′ 
or H7 or H7′), 6.83 (s, 2H, ArH7 or ArH7′ or H7 or H7′), 6.65 (s, 2H, ArH5 or ArH5′), 
4.14 (s, 6H, Ar8-OCH3, Ar8′-OCH3), 4.09 (s, 6H, 8-OCH3, 8′-OCH3), 3.85 (s, 3H, 
6-OCH3 or 6′-OCH3), 3.84 (s, 3H, 6-OCH3 or 6′-OCH3), 3.61-3.43 (m, 4H, H3, H3′), 
2.81 (s, 3H, 1-CH3 or 1′-CH3), 2.80 (s, 3H, 1-CH3 or 1′-CH3), 2.55-2.42 (m, 4H, H4, 
H4′), 2.33 (s, 6H, Ar6-CH3, Ar6′-CH3). 
13C NMR (126 MHz, CD3OD) δ 176.0 (C1, C1′), 
168.2 (C6, C6′), 166.0 (ArC8, ArC8′), 158.1 (C8, C8′), 152.6 (ArC1, ArC1′), 142.2 (C4a, 
C4a′), 137.8 (ArC6, ArC6′), 136.0 (ArC4a, ArC4a′), 134.5 (ArC3, ArC3′), 123.0 (ArC4, 
ArC4′), 122.7 (ArC2, ArC2′), 119.9 (C5, C5′), 118.7 (ArC5, ArC5′), 114.9 (ArC8a, 
ArC8a′), 109.6 (C8a, C8a′), 108.0 (ArC7, ArC7′), 95.8 (C7, C7′), 57.1 (Ar8-OCH3, 
Ar8′-OCH3 or 8-OCH3, 8′-OCH3), 57.0 (Ar8-OCH3, Ar8′-OCH3 or 8-OCH3, 8′-OCH3), 
56.9 (6-OCH3, 6′-OCH3), 41.7 (C3, C3′), 25.74 (C4, C4′ or 1-CH3, 1′-CH3), 25.72 (C4, 
C4′ or 1-CH3, 1′-CH3), 22.1 (Ar6-CH3, Ar6′-CH3). MS (ESI): m/z 781 ([M+H]
+, 40%). 
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7.1.3 Preparation of coelenterazine analogues 
7.1.3.1 Synthesis of substituted 2-aminopyridine  
2-Amino-5-bromonicotinic acid (130)  
This is a known compound but not fully characterized, and it was 
prepared according to the known procedure.141 To a suspension of 
2-aminonicotinic acid 124 (7.50 g, 54 mmol) in glacial acetic acid (30 mL) was added a 
solution of bromine (3.60 mL, 69 mmol) in glacial acetic acid (5 mL) and the mixture 
stirred at rt for 20 h. The resulting precipitate was filtered and washed with glacial 
acetic acid until the filtrate remained colourless. The remaining solid was air dried and 
then recrystallized from boiling methanol to afford 130 (11.3 g, 97%) as a white 
crystalline needle. Mp. 247-249 oC. IR (neat) υmax 3301 (m), 2942 (w), 2871 (w), 2013 
(w), 1704 (s), 1635 (m), 1522 (m), 1451 (m), 1361 (m), 1305 (s), 1239 (m), 1036 (s), 
879 (m), 796 (m), 703 (s) cm-1. 1H NMR (500 MHz, DMSO) δ 8.44 (d, J = 2.5 Hz, 1H, 
ArH4), 8.33 (d, J = 2.5 Hz, 1H, ArH6), 7.67 (bs, 2H, NH2). 
13C NMR (126 MHz, 
DMSO) δ 166.1 (C=O), 155.2 (ArC2), 147.3 (ArC6), 145.5 (ArC4), 110.9 (ArC3), 
103.6 (ArC5). MS (EI): m/z 216 (M+, 79Br, 100%) 218 (M+, 81Br, 100%). HRMS (ESI): 
calcd for C6H6N2O2
79Br 216.9613, found 216.9612. 
2-Amino-5-bromo-N-methoxy-N-methylnicotinamide (131) 
This is a known compound but not fully characterized, and it was 
prepared by a new procedure.142 To a solution of 
2-amino-6-chloronicotinic acid 130 (4.99 g, 29.0 mmol) in anhydrous DMF (50 mL) 
was added 1-hydroxybenzotriazole hydrate (HOBt) (6.21 g, 40.6 mmol) and 
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) 
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(15.4 g, 40.6 mmol). A solution of N,O-dimethylhydroxylamine hydrochloride (306 mg, 
3.15 mmol) in anhydrous DMF (15 mL) was treated with N,N-diisopropylethylamine 
(8.28 g, 64.1 mmol) and immediately added to the reaction. The mixture was stirred at 
0 oC for 10 min and then at rt for 5 h. The reaction was diluted with EtOAc (150 mL) 
and H2O (100 mL) and the aqueous layer was then extracted with EtOAc (3 x 150 mL). 
The combined organic layers were washed with H2O, brine, then concentrated and the 
residue subjected to flash silica gel column chromatography (hexane/ethyl acetate: 
80/20) to give 131 (4.72 g, 74%) as a light yellow solid. Mp. 82-83 oC. IR (neat) υmax 
3420 (m), 3275 (w), 3140 (m), 1626 (s), 1557 (s), 1448 (m), 1376 (s), 1240 (m), 1199 
(m), 1164 (w), 1131 (w), 1052 (m), 977 (s), 908 (m), 838 (m), 781 (m), 738 (m), 677 
(m), 627 (m) cm-1. 1H NMR (500 MHz, CDCl3) δ 8.15 (s, 1H, ArH4), 7.89 (s, 1H, 
ArH6), 5.78 (s, 2H, NH2), 3.57 (s, 3H, OCH3), 3.35 (s, 3H, NCH3). 
13C NMR (126 MHz, 
CDCl3) δ 167.1 (C=O), 156.7 (ArC2), 151.3 (ArC6), 140.0 (ArC4), 111.8 (ArC3), 106.1 
(ArC5), 61.5 (OCH3), 33.4 (NCH3). MS (EI): m/z 259 (M
+, 79Br, 20%), 261 (M+, 81Br, 
20%), 199 (100%), 201 (100%). HRMS (ESI): calcd for C8H11N3O2
79Br 260.0035, 
found 260.0025. 
(2-Amino-5-bromopyridin-3-yl)(phenyl)methanone (125)  
This is a known compound but not fully characterized, and it was 
prepared according to the known procedure.143 A suspension of 
2-amino-5-bromo-N-methoxy-N-methyl-nicotinamide 131 (1.00 g, 
3.38 mmol) in anhydrous THF (50 mL) was cooled to −50 °C under N2 and a 1.0 M 
solution of phenylmagnesium bromide in ether (13.50 mL, 13.50 mmol) was added 
rapidly affording an orange solution. The mixture was stirred and slowly warmed to rt 
over 1 h. The resulting yellow-orange solution was diluted with a 10% (w/w) aqueous 
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citric acid solution (75 mL) and EtOAc (200 mL). The organic phase was separated and 
washed with a 10% (w/w) aqueous citric acid solution (75 mL) and saturated aqueous 
NaHCO3 (75 mL). The organic phase was then dried (Na2SO4) and concentrated to 
afford 125 (936 mg, 95%) as a yellow crystalline solid without any further purification 
required. Mp. 145-146 oC. IR (neat) υmax 3417 (m), 3272 (w), 3126 (m), 1631 (s), 1569 
(w), 1537 (m), 1448 (m), 1390 (m), 1347 (w), 1293 (m), 1222 (s), 1148 (m), 1072 (w), 
1031 (w), 1002 (w), 946 (m), 917 (w), 844 (m), 803 (w), 769 (m), 746 (w), 700 (s), 650 
(s) cm-1. 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J = 2.0 Hz, 1H, ArH4), 7.85 (d, J = 1.9 
Hz, 1H, ArH6), 7.64-7.55 (m, 3H, ArH2′, ArH4′, ArH6′), 7.51 (t, J = 7.5 Hz, 2H, ArH3′, 
ArH5′), 6.79 (bs, 2H, NH2). 
13C NMR (126 MHz, CDCl3) δ 196.8 (C=O), 158.3 (ArC2), 
154.6 (ArC6), 144.3 (ArC4), 138.5 (ArC1′), 132.1 (ArC4′), 129.1 (ArC2′, ArC6′), 128.7 
(ArC3′, ArC5′), 114.1 (ArC3), 105.4 (ArC5). MS (EI): m/z 276 (M+, 79Br, 100%), 278 
(M+, 81Br, 100%). HRMS (ESI): calcd for C12H10N2O
79Br 276.9976, found 276.9975. 
(2-Amino-5-(4-methoxyphenyl)pyridin-3-yl)(phenyl)methanone (132) 
A mixture of (2-amino-5-bromopyridin-3-yl)(phenyl) 
-methanone 125 (200 mg, 0.72 mmol), 4-methoxyphenyl 
-boronic acid (164 mg, 1.1 mmol), Pd(dppf)Cl2 (26 mg, 
0.036 mmol) and NaHCO3 (185 mg, 2.2 mmol) in toluene (20 mL) was heated at reflux 
for 12 h under N2. The mixture was cooled to rt, diluted with H2O (10 mL) and 
extracted with EtOAc (3 × 20 mL). The combined organic layers were dried (MgSO4) 
and concentrated, and the residue subjected to flash silica gel column chromatography 
(hexane/ethyl acetate: 60/40) to give 132 (187 mg, 85%) as a yellow solid. Mp. 156-157 
oC. IR (neat) υmax 3388 (m), 3145 (w), 1619 (m), 1546 (m), 1511 (m), 1456 (m), 1442 
(m), 1387 (w), 1328 (w), 1303 (w), 1227 (s), 1178 (m), 1142 (w), 1029 (m), 956 (m), 
 
Chapter 7    Experimental 
147 
 
926 (m), 854 (m), 823 (m), 807 (m), 772 (m), 702 (m), 657 (m) cm-1. 1H NMR (500 
MHz, CDCl3) δ 8.48 (s, 1H, ArH6), 7.93 (s, 1H, ArH4), 7.67 (d, J = 8.0 Hz, 2H, ArH2′, 
ArH6′), 7.57 (t, J = 7.0 Hz, 1H, ArH4′), 7.49 (t, J = 7.5 Hz, 2H, ArH3′, ArH5′), 7.34 (d, 
J = 9.0 Hz, 2H, ArH2′′, ArH6′′), 6.94 (d, J = 8.5 Hz, 2H, ArH3′′, ArH5′′), 6.82 (bs, 2H, 
NH2), 3.82 (s, 3H, OCH3). 
13C NMR (126 MHz, CDCl3) δ 196.0 (C=O), 159.3 (ArC4′′), 
158.6 (ArC2), 152.1 (ArC6), 140.8 (ArC4), 139.3 (ArC1′), 131.9 (ArC4′), 130.1 
(ArC1′′), 129.3 (ArC2′, ArC6′), 128.7 (ArC3′, ArC5′), 127.5 (ArC2′′, ArC6′′), 125.7 
(ArC5), 114.7 (ArC3′′, ArC5′′), 112.9 (ArC3), 55.6 (OCH3). MS (EI): m/z 304 (M
+, 
100%). HRMS (ESI): calcd for C19H17N2O2 305.1290, found 305.1286. 
(2-Amino-5-(4-hydroxyphenyl)pyridin-3-yl)(phenyl)methanone (133) 
Strategy 1  
A mixture of (2-amino-5-(4-methoxyphenyl)pyridin-3-yl) 
-(phenyl)methanone 132 (304 mg, 1.0 mmol) and sodium 
ethanethiolate (494 mg, 5 mmol) in DMF (5 mL) was heated at 
100 °C for 20 h under N2 atmosphere. The resulting mixture was then quenched with a 
saturated aqueous NH4Cl solution (20 mL), extracted with EtOAc (5 × 50 mL) and the 
combined organic layers were washed with brine (25 mL), dried (Na2SO4), filtered, 
evaporated and the residue subjected to flash silica gel column chromatography 
(hexane/ethyl acetate: 60/40) to give 133 (238 mg, 82%) as a pale yellow solid. Mp. 
215-216 oC. IR (neat) υmax 3489 (w), 3343 (m), 1640 (m), 1612 (w), 1600 (w), 1576 (m), 
1550 (w), 1512 (m), 1441 (m), 1349 (w), 1325 (w), 1265 (m), 1231 (s), 1173 (m), 956 
(m), 833 (m), 773 (m), 708 (m), 694 (m) cm-1. 1H NMR (500 MHz, DMSO) δ 9.46 (s, 
1H, OH), 8.50 (s, 1H, ArH4), 7.60 (s, 1H, ArH6), 7.61-7.66 (m, 3H, ArH2′, ArH4′, 
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ArH6′), 7.54-7.57 (m, 4H, ArH3′, ArH5′, NH2), 7.30 (d, J = 8.0 Hz, 2H, ArH2′′, ArH6′′), 
6.79 (d, J = 8.5 Hz, 2H, ArH3′′, ArH5′′). 13C NMR (126 MHz, DMSO) δ 197.1 (C=O), 
158.3 (ArC4′′), 156.7 (ArC2), 151.7 (ArC6), 139.2 (ArC4), 138.9 (ArC1′), 131.6 
(ArC4′), 128.8 (ArC2′, ArC6′), 128.5 (ArC2′′, ArC6′′), 127.7 (ArC1′′), 126.8 (ArC3′, 
ArC5′), 123.9 (ArC5), 115.8 (ArC3′′, ArC5′′), 111.3 (ArC3). MS (EI): m/z 290 (M+, 
100%). HRMS (ESI): calcd for C18H15N2O2 291.1134, found 291.1135. 
Strategy 2  
A mixture of (2-amino-5-bromopyridin-3-yl)(phenyl)methanone 125 (1.50 g, 5.40 
mmol), 4-hydroxylphenylboronic acid (1.12 g, 8.10 mmol), PdCl2(PPh3)2 (190 mg, 
0.270 mmol) and Na2CO3 (1.72 g, 16.2 mmol) in dioxane (40 mL) under N2 was heated 
and stirred at reflux for 18 h. The mixture was cooled to rt, diluted with H2O (10 mL) 
and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with 
brine (25 mL), dried (Na2SO4), filtered, evaporated and the residue subjected to flash 
silica gel column chromatography (hexane/ethyl acetate: 60/40) to give 133 (1.43 g, 
91%) as a yellow solid. 
4-(6-Amino-5-benzylpyridin-3-yl)phenol (126) 
A stirred mixture of (2-amino-5-(4-hydroxyphenyl) 
-pyridin-3-yl)(phenyl)methanone 133 (290 mg, 1.0 mmol), 
ethylene glycol (2 mL) and hydrazine hydrate (0.5 mL) was 
heated at 100 °C for 1 h and then allowed to cool to rt. KOH pellets (500 mg) were 
added and the resulting mixture was heated in a sand bath at 240 °C for 1 h. After 
cooling to rt, the reaction mixture was diluted with H2O (20 mL) and extracted with 
EtOAc (5 × 50 mL). The combined organic layers were washed with dilute aqueous 
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HCl solution (30 mL), dried (MgSO4), concentrated and the residue subjected to flash 
silica gel column chromatography (hexane/ethyl acetate: 50/50) to give 126 (237 mg, 
86%) as a white solid. Mp. 195-196 oC. IR (neat) υmax 3241 (w), 3194 (w), 1653 (s), 
1614 (s), 1574 (m), 1519 (m), 1451 (m), 1342 (m), 1269 (m), 1230 (m), 1177 (m), 823 
(s), 741 (s), 697 (m), 627 (m) cm-1. 1H NMR (500 MHz, DMSO) δ 9.73 (s, 1H, OH), 
8.14 (s, 1H, ArH6), 8.03 (s, 1H, ArH4), 7.80 (s, 2H, NH2), 7.42 (d, J = 8.4 Hz, 2H, 
ArH2′′, ArH6′′), 7.38-7.29 (m, 4H, ArH2′, ArH3′, ArH5′, ArH6′), 7.28-7.19 (m, 1H, 
ArH4′), 6.85 (d, J = 8.3 Hz, 2H, ArH3′′, ArH5′′), 4.02 (s, 2H, ArCH2). 
13C NMR 
(126 MHz, DMSO) δ 157.7 (ArC4′′), 151.7 (ArC2), 141.2 (ArC6), 137.5 (ArC1′), 130.9 
(ArC4), 128.8 (ArC2′, ArC6′), 128.6 (ArC3′, ArC5′), 127.2 (ArC2′′, ArC6′′), 126.7 
(ArC4′), 125.3 (ArC1′′), 125.2 (ArC5), 125.1 (ArC3), 116.0 (ArC3′′, ArC5′′), 34.5 
(ArCH2). MS (EI): m/z 276 (M
+, 100%). HRMS (ESI): calcd for C18H17N2O 277.1341, 
found 277.1349. 
7.1.3.2 Preparation of benzylglyoxals 
General Procedure 9: The preparation of chlorohydrins  
To a mixture of Mg (35 mmol) and a catalytic amount of I2 in dry THF (30 mL) was 
added bromobenzene (30 mmol) dropwise under N2, maintaining a gentle reflux. Once 
the magnesium had been consumed, the reagent was transferred to a dry flask with CuI 
(2.5 mmol) in dry THF (2.5 mmL). The solution was cooled to −60 oC and 
epichlorohydrin (30 mmol) in THF (10 mL) was added dropwise. The reaction mixture 
was then warmed to 0 oC and stirred for 1 h. The reaction mixture was quenched by 
saturated NH4Cl (50 mL) and extracted with EtOAc (3 × 25 mL). The combined organic 
layers were washed with H2O (3 × 25 mL), brine (25 mL), dried (MgSO4), concentrated 
and the residue subjected to flash silica gel column chromatography (hexane/ethyl 
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acetate: 90/10) to yield the chlorohydrin. 
1-Chloro-3-phenylpropan-2-ol (144) 
This is a known compound and it was prepared according to the known 
procedure.144 Using the General Procedure 9, bromobenzene (4.71 g, 
30 mmol) and epichlorohydrin (2.78 g, 30.0 mmol) gave 144 (4.60 g, 90%) 
as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.32 (t, J = 7.5 Hz, 2H, ArH3, ArH5), 
7.23-7.27 (m, 3H, ArH2, ArH4, ArH6), 4.09-4.02 (m, 1H, H2), 3.62 (dd, 1H, J = 4.0, 
11.1 Hz, H1a), 3.50 (dd, J = 4.0, 11.1 Hz, 1H, H1b), 2.89 (d, J = 7.0 Hz, 2H, H3), 2.19 (d, 
J = 5.0 Hz, 1H, OH). 13C NMR (75 MHz, CDCl3) δ 137.1 (ArC1), 129.5 (ArC3, ArC5), 
128.9 (ArC2, ArC6), 127.0 (ArC4), 72.4 (C2), 49.4 (C1), 40.8 (C3). MS (EI): m/z 170 
(M+, 40%), 84 (100%). 
1-(4-((Tert-butyldimethylsilyl)oxy)phenyl)-3-chloropropan-2-ol (143) 
Using the General Procedure 9, 
(4-bromophenoxy)(tert-butyl)-dimethylsilane (6.31 g, 22 mmol) and 
epichlorohydrin (2.04 g, 22.0 mmol) gave 143 (5.20 g, 80%) as a 
colourless oil. IR (neat) υmax 2933 (w), 2859 (w), 1609 (w), 1509 (m), 
1467 (w), 1256 (s), 1171 (w), 1045 (w), 912 (s), 836 (s), 780 (m), 693 (m) cm-1. 1H 
NMR (500 MHz, CDCl3) δ 7.08 (d, J = 8.3 Hz, 2H, ArH3, ArH5), 6.79 (d, J = 8.3 Hz, 
2H, ArH2, ArH6), 3.97-4.04 (m, 1H, H2), 3.60 (dd, J = 4.0, 11.1 Hz, 1H, H1a), 3.49 (dd, 
J = 6.0, 11.1 Hz, 1H, H1b), 2.82 (d, J = 6.6 Hz, 2H, H3), 2.18 (d, J = 5.1 Hz, 1H, OH), 
0.98 (s, 9H, CCH3), 0.19 (s, 6H, SiCH3). 
13C NMR (126 MHz, CDCl3) δ 154.6 (ArC1), 
130.3 (ArC4), 129.5 (ArC3, ArC5), 120.5 (ArC2, ArC6), 72.3 (C2), 49.1 (C1), 39.8 
(C3), 25.7 (SiC), 18.2 (CH3), -4.4 (SiCH3). MS (EI): m/z 300 (M
+, 60%), 199 (100%). 
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HRMS (ESI): calcd for C15H26O2SiCl 301.1391, found 301.1387. 
General Procedure 10: The preparation of chloropropanones 
1-Chloro-3-phenylpropan-2-ol (1.0 mmol) was dissolved in CH2Cl2 (40 mL) at 0 
oC and 
treated with Dess-Martin periodinane (1.0 mmol). The reaction was allowed to warm to 
rt and stirred for 4 h. The reaction mixture was concentrated and the residue subjected to 
flash silica gel column chromatography (hexane/ethyl acetate: 90/10) to yield the target 
compound. 
1-Chloro-3-phenylpropan-2-one (146) 
This is a known compound and it was prepared according to the known 
procedure.145 Using the General Procedure 10, 
1-chloro-3-phenylpropan-2-ol 144 (170 mg, 1.00 mmol) and Dess-Martin 
periodinane (424 mg, 1.00 mmol) gave 146 (148 mg, 88%) as a yellowish oil. 1H NMR 
(300 MHz, CDCl3) δ 7.22-7.42 (m, 5H, ArH), 4.12 (s, 2H, H1), 3.89 (s, 2H, H3). 
13C NMR (75 MHz, CDCl3) δ 200.1 (C=O), 133.0 (ArC1), 129.6 (ArC2, ArC6), 129.0 
(ArC3, ArC5), 127.5 (ArC4), 47.7 (C1), 46.9 (C3). MS (EI): m/z 168 (M+, 40%), 91 
(100%). 
1-(4-((Tert-butyldimethylsilyl)oxy)phenyl)-3-chloropropan-2-one (145) 
Using the General Procedure 10, 1-(4-((tert-butyldimethylsilyl)oxy) 
-phenyl)-3-chloropropan-2-ol 143 (4.80 g, 16.0 mmol) and Dess-Martin 
periodinane (6.78 g, 16.0 mmol) gave 145 (3.50 g, 91%) as a yellow oil. 
IR (neat) υmax 2955 (w), 2932 (w), 2859 (w), 1733 (m), 1609 (m), 1509 
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(s), 692 (m) cm-1. 1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 8.2 Hz, 2H, ArH2, ArH6), 
6.80 (d, J = 8.3 Hz, 2H, ArH3, ArH5), 4.10 (s, 2H, H1), 3.80 (s, 2H, H3), 0.98 (s, 12H, 
CCH3), 0.19 (s, 6H, SiCH3). 
13C NMR (126 MHz, CDCl3) δ 200.2 (C=O), 155.1 (ArC4), 
130.4 (ArC2, ArC6), 125.4 (ArC1), 120.5 (ArC3, ArC5), 47.6 (C1), 46.1 (C3), 25.7 
(CH3), 18.2 (SiC), -4.4 (SiCH3). MS (EI): m/z 298 (M
+, 40%), 205 (100%). HRMS 
(ESI): calcd for C15H24O2SiCl 299.1234, found 299.1228. 
General Procedure 11: The preparation of bromopropanones  
A solution of 1-chloro-3-phenylpropan-2-one (1.0 mmol) was dissolved in acetone (15 
mL) and treated with lithium bromide (8.0 mmol). The mixture was stirred at rt 
overnight. The solvent was evaporated and the resulting solid was dissolved in EtOAc, 
washed with H2O (2 × 25 mL) and brine, dried (MgSO4) and evaporated to dryness. 
1-Bromo-3-phenylpropan-2-one (147) 
This is a known compound and it was prepared according to the known 
procedure.146 Using the General Procedure 11, 
1-chloro-3-phenylpropan-2-one 146 (168 mg, 1.00 mmol) and lithium 
bromide (696 mg, 8.00 mmol) gave 147 (185 mg, 88%) as a yellow-brown oil. 1H NMR 
(500 MHz, CDCl3) δ 7.22-7.36 (m, 5H), 3.94 (s, 2H), 3.91 (s, 2H). 
13C NMR (126 MHz, 
CDCl3) δ 199.5 (C=O), 133.3 (ArC1), 129.6 (ArC2, ArC6), 129.1 (ArC3, ArC5), 127.6 
(ArC4), 46.9 (C3), 33.6 (C1). MS (EI): m/z 212 (M+, 79Br, 40%), 214 (M+, 81Br, 40%), 
91 (100%). 
1-Bromo-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-2-one (137) 
Using the General Procedure 11, 1-(4-((tert-butyldimethylsilyl)oxy) 
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-phenyl)-3-chloropropan-2-one 145 (298 mg, 1.00 mmol) and lithium 
bromide (696 mg, 8.00 mmol) gave 137 (294 mg, 85%) as a 
yellow-brown oil. IR (neat) υmax 2933 (w), 2858 (w), 1723 (m), 1608 (m), 
1508 (s), 1466 (w), 1395 (w), 1257 (s), 1170 (w), 1103 (w), 1047 (w), 911 
(s), 835 (s), 781 (s), 694 (m) cm-1. 1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 8.2 Hz, 
2H, ArH2, ArH6), 6.81 (d, J = 8.2 Hz, 2H, ArH3, ArH5), 3.90 (s, 2H, H1), 3.86 (s, 2H, 
H3), 0.98 (s, 12H, CCH3), 0.19 (s, 6H, SiCH3). 
13C NMR (126 MHz, CDCl3) δ 199.9 
(C=O), 155.3 (ArC4), 130.6 (ArC2, ArC6), 125.8 (ArC1), 120.7 (ArC3, ArC5), 46.2 
(C3), 33.6 (C1), 25.8 (CH3), 18.3 (SiC), -4.3 (SiCH3). MS (EI): m/z 342 (M
+, 79Br, 40%), 
344 (M+, 81Br, 40%), 205 (100%). HRMS (ESI): calcd for C15H24O2Si
79Br 343.0729, 
found 343.0718. 
General Procedure 12: The preparation of phenylpropyl nitrate  
AgNO3 (2.3 mmol) was added to a solution of 1-bromo-3-phenylpropan-2-one 
(1.0 mmol) in dry acetonitrile (2 mL) at rt and the mixture was stirred for 40 h. The 
mixture was filtered through a flash silica pad and concentrated under vacuum to obtain 
the target compound.  
2-Oxo-3-phenylpropyl nitrate (149) 
This is a known compound and it was prepared according to the known 
procedure.147 Using the General Procedure 12, 
1-bromo-3-phenylpropan-2-one 147 (213 mg, 1.00 mmol) and AgNO3 
(391 mg, 2.30 mmol) gave 149 (186 mg, 95%) as a yellow oil. IR (neat) 
υmax 2934 (w), 1736 (m), 1642 (s), 1404 (m), 1282 (s), 1024 (m), 977 (m), 844 (s), 753 
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(s, 2H, H1), 3.78 (s, 2H, H3). 13C NMR (126 MHz, CDCl3) δ 198.8 (C=O), 131.8 
(ArC1), 129.4 (ArC2, ArC6), 129.2 (ArC3, ArC5), 127.8 (ArC4), 73.3 (C1), 46.6 (C3). 
MS (EI): m/z 195 (M+, 40%), 91 (100%). HRMS (ESI): calcd for C9H10NO4 196.0610, 
found 196.0619. 
3-(4-((Tert-butyldimethylsilyl)oxy)phenyl)-2-oxopropyl nitrate (148) 
Using the General Procedure 12, 1-bromo-3-(4-((tert 
-butyldimethylsilyl)oxy)phenyl)propan-2-one 137 (343 mg, 1.00 mmol) 
and AgNO3 (391 mg, 2.30 mmol) gave 148 as a yellow oil (186 mg, 
89%). IR (neat) υmax 2943 (m), 2861 (w), 1735 (m), 1649 (m), 1509 (m), 
1262 (s), 910 (s), 836 (s), 786 (s), 693 (m), 626 (m) cm-1. 1H NMR (500 MHz, CDCl3) δ 
7.08 (d, J = 8.0 Hz, 2H, ArH2, ArH6), 6.82 (d, J = 8.1 Hz, 2H, ArH3, ArH5), 4.94 (s, 
2H, H1), 3.70 (s, 2H, H3), 0.98 (s, 12H, CCH3), 0.20 (s, 6H, SiCH3). 
13C NMR (126 
MHz, CDCl3) δ 199.3 (C=O), 155.5 (ArC4), 130.5 (ArC2, ArC6), 124.5 (ArC1), 120.9 
(ArC3, ArC5), 73.4 (C1), 46.1 (C3), 25.8 (CH3), 18.4 (SiC), -4.3 (SiCH3). MS (EI): m/z 
325 (M+, 40%), 221 (100%). HRMS (ESI): calcd for C15H24NO5Si 326.1424, found 
326.1426. 
General Procedure 13: The preparation of benzylglyoxals  
NaOAc·3H2O (0.80 mmol) was slowly added to a solution of 2-oxo-3-phenylpropyl 
nitrate (0.80 mmol) in DMSO (5 mL). The reaction mixture was stirred at 25 °C for 1 h 
and then poured into ice-water. The resulting mixture was saturated with NaCl and then 
extracted with EtOAc (3 × 25 mL). The organic phase was washed with H2O (25 mL), 
aqueous NaHCO3 (25 mL) and then again with H2O. Removal of the solvent by 
distillation under reduced pressure followed by drying in vacuum afforded the target 
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compound as a colourless solid. 
2-Oxo-3-phenylpropanal (150) 
This is a known compound and it was prepared according to the known 
procedure.147 Using the General Procedure 13, 2-oxo-3-phenylpropyl 
nitrate 149 (156 mg, 0.80 mmol) and NaOAc·3H2O (109 mg, 0.80 mmol) 
gave 150 as a colourless solid (105 mg, 89%). Mp. 98-99 oC. IR (neat) υmax 3207 (m), 
1658 (m), 1631 (m), 1411 (m), 1376 (m), 1328 (w), 1308 (w), 1280 (w), 1207 (m), 1161 
(m), 922 (s), 843 (m), 756 (w), 712 (m), 684 (s) cm-1. 1H NMR (500 MHz, CDCl3) 
δ 9.26 (s, 1H, H1), 7.42 (d, J = 8.0 Hz, 2H, ArH2, ArH6), 7.42 (t, J = 7.5 Hz, 2H, ArH3, 
ArH5), 7.34 (t, J = 8.0 Hz, 1H, ArH4), 6.63 (s, 1H, OH), 6.17 (s, 1H, H3). 13C NMR 
(126 MHz, CDCl3) δ 188.3 (C=O), 148.7 (C2), 133.6 (ArC1), 130.5 (ArC2, ArC6), 
129.4 (ArC3, ArC5), 128.7 (ArC4), 122.8 (C3). MS (EI): m/z 148 (M+, 45%), 91 
(100%). HRMS (ESI): calcd for C9H9O2 149.0603, found 149.0597. 
3-(4-Hydroxyphenyl)-2-oxopropanal (129) 
Using the General Procedure 13, 3-(4-((tert-butyldimethylsilyl)oxy) 
-phenyl)-2-oxopropyl nitrate 148 (782 mg, 2.40 mmol) and NaOAc·3H2O 
(327 mg, 2.40 mmol) gave 129 (342 mg, 87%) as a colourless solid. Mp. 
160-161 oC. IR (neat) υmax 3396 (m), 3139 (m), 1615 (m), 1569 (s), 1506 
(m), 1456 (w), 1376 (m), 1302 (w), 1292 (w), 1240 (m), 1164 (m), 913 (m), 854 (s), 754 
(m), 703 (s) cm-1. 1H NMR (300 MHz, DMSO) δ 9.87 (bs, 1H, ArOH), 9.45 (bs, 1H, 
OH), 9.18 (s, 1H, H1), 7.70 (d, J = 8.5 Hz, 2H, ArH2, ArH6), 6.81 (d, J = 8.5 Hz, 2H, 
ArH3, ArH5), 6.26 (s, 1H, H3). 13C NMR (75 MHz, DMSO) δ 189.2 (C=O), 158.2 
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ArC5). MS (ESI): 163 ([M-H]-). HRMS (ESI): calcd for C9H9O3 165.0552, found 
165.0552. 
7.1.3.3 Preparation of imidazo[1,2-a]pyridin-3-ol analogues 
General Procedure 14: The preparation of imidazo[1,2-a]pyridin-3-ol analogues 
To a degassed solution of pyridin-2-amine (1.0 mmol) and keto aldehyde (1.5 mmol) in 
20% water/dioxane (5 mL) was added 10% (w/w) aqueous HCl solution (1.5 mL) and 
the mixture was stirred under a N2 atmosphere at rt for 5 min, and then heated at reflux 
for 16 h. After cooling, H2O (10 mL) was added at 0 
oC. The resulting precipitate was 
filtered and recrystallized from methanol/ether to provide a yellow solid.  
8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-3-ol (121) 
Using the General Procedure 14, 
4-(6-amino-5-benzylpyridin-3-yl)phenol 126 (83 mg, 
0.30 mmol) and 3-(4-hydroxyphenyl)-2 -oxopropanal 129 
(74 mg, 0.45 mmol) gave 121 as a yellow solid (78 mg, 
62%). Mp. 150 oC (decomp.). IR (neat) υmax 3123 (w), 3116 (w), 1645 (m), 1606 (m), 
1565 (m), 1507 (s), 1452 (m), 1375 (m), 1270 (m), 1235 (s), 1172 (m), 1147 (m), 1098 
(m), 830 (s), 792 (m), 784 (m), 756 (m), 729 (m), 700 (m), 671 (m), 653 (w) cm-1. 1H 
NMR (500 MHz, CD3OD) δ 8.31 (s, 1H, ArH5), 7.40 (d, J = 7.7 Hz, 2H, ArH2′′, 
ArH6′′), 7.34-7.20 (m, 6H, ArH7, ArH2′′′, ArH3′′′, ArH4′′′, ArH5′′′, ArH6′′′), 7.07 (d, 
J = 8.1 Hz, 2H, ArH2′, ArH6′), 6.86 (d, J = 8.1 Hz, 2H, ArH3′′, ArH5′′), 6.69 (d, J = 8.0 
Hz, 2H, ArH3′, ArH5′), 4.21 (s, 2H, ArC8CH2), 4.02 (s, 2H, ArC2CH2). MS (ESI): 















Using the General procedure 14, 4-(6-amino-5- 
benzylpyridin-3-yl)phenol 126 (55 mg, 0.20 mmol) and 
3-phenyl-2-oxopropanal 150 (44 mg, 0.30 mmol) gave 153 
(55 mg, 67%) as a yellow solid. Mp. > 200 oC. IR (neat) υmax 
3316 (w), 1649 (w), 1609 (m), 1572 (m), 1493 (m), 1454 (m), 1393 (m), 1270 (m), 
1242 (w), 1177 (m), 1108 (m), 1033 (w), 918 (m), 832 (m), 735 (m), 700 (m), 669 (w) 
cm-1. 1H NMR (500 MHz, CD3OD) δ 8.38 (s, 1H, ArH5), 7.57 (s, 1H, ArH7), 7.42 (d, 
J = 7.9 Hz, 2H, ArH2′′, ArH6′′), 7.35-7.15 (m, 10H, ArH2′, ArH3′, ArH4′, ArH5′, ArH6′, 
ArH2′′′, ArH3′′′, ArH4′′′, ArH5′′′, ArH6′′′), 6.88 (d, J = 8.0 Hz, 2H, ArH3′′, ArH5′′), 4.28 
(s, 2H, ArC2CH2), 4.22 (s, 2H, ArC8CH2). MS (ESI): m/z 407 ([M+H]
+, 100%). HRMS 
(ESI): calcd for C27H23N2O2 407.1760, found 407.1766. 
4,4'-(8-Benzyl-3-hydroxyimidazo[1,2-a]pyridine-2,6-diyl)diphenol (154) 
Using the General procedure 14, 4-(6-amino-5- 
benzylpyridin-3-yl)phenol 126 (55 mg, 0.20 mmol) and 
4-hydroxyphenylglyoxal 151 (60 mg, 0.30 mmol) gave 154 
(64 mg, 79%) as a yellow solid. Mp. 191-192 oC. IR (neat) υmax 
3138 (w), 1651 (m), 1601 (w), 1569 (m), 1504 (s), 1443 (m), 
1372 (m), 1228 (s), 1169 (s), 1105 (m), 909 (w), 827 (s), 782 (w), 739 (m), 697 (m), 669 
(w), 626 (w), 613 (w) cm-1. 1H NMR (300 MHz, DMSO) δ 9.62 (bs, 3H, OH), 8.24 (s, 
1H, ArH5), 7.94 (s, 1H, ArH7), 7.57-7.13 (m, 9H, ArH3′, ArH5′, ArH3′′, ArH5′′, ArH2′′′, 
ArH3′′′, ArH4′′′, ArH5′′′, ArH6′′′), 6.95-6.73 (m, 4H, ArH2′, ArH2′′, ArH6′′), 4.35 (s, 2H, 
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ArCH2). MS (ESI): m/z 409 ([M+H]
+, 100%). HRMS (ESI): calcd for C26H21N2O3 
409.1552, found 409.1572. 
8-Benzyl-6-(4-hydroxyphenyl)-2-phenylimidazo[1,2-a]pyridin-3-ol (155) 
Using the General procedure 14, 4-(6-amino-5 
-benzylpyridin-3-yl)phenol 126 (55 mg, 0.20 mmol) and 
phenylglyoxal 152 (45 mg, 0.30 mmol) gave 155 (65 mg, 83%) 
as a yellow solid. Mp. > 200 oC. IR (neat) υmax 3261 (m), 3074 
(w), 3033 (w), 2819 (w), 2572 (w), 2163 (w), 1658 (m), 1614 
(m), 1506 (m), 1443 (m), 1364 (m), 1263 (m), 1222 (m), 1170 (m), 1102 (w), 1087 (w), 
919 (w), 822 (m), 757 (m), 696 (s), 644 (s) cm-1. 1H NMR (500 MHz, DMSO) δ 9.80 
(bs, 2H, OH), 8.42 (s, 1H, ArH5), 8.07 (d, J = 7.1 Hz, 2H, ArH2′, ArH6′), 7.64 (s, 1H, 
ArH7), 7.51 (d, J = 7.6 Hz, 2H, ArH2′′, ArH6′′), 7.40-7.45 (m, 4H, ArH3′, ArH4′, ArH5′, 
ArH4′′′), 7.33 (t, J = 7.1 Hz, 2H, ArH2′′′, ArH6′′′), 7.27-7.16 (m, 2H, ArH3′′′, ArH5′′′), 
6.89 (d, J = 7.9 Hz, 2H, ArH3′′, ArH5′′), 4.43 (s, 2H, ArCH2). MS (ESI): m/z 391 
([M-H]-, 100%). HRMS (ESI): calcd for C26H19N2O2 391.1447, found 391.1437. 
7.2 Biological activity testing 
7.2.1 HIV RT testing 
Preparations of working solutions 
Reverse Transcriptase: The lyophilized reverse transcriptase (500 ng) was dissolved in 
autoclaved redistilled water (250 μL) to obtain a final concentration of 2 ng/μL. 
Reaction mixture for using poly (A) × oligo (dT)15: The template was dissolved in 
autoclaved redistilled water (430 μL) and 100 μL of this solution was added to each of 
three vials containing the nucleotides which were each previously diluted with 
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incubation buffer (1 mL). The final concentration of the reaction mixture is 46 mM 
Tris-HCl, 266 mM potassium chloride, 27.5 mM magnesium chloride, 9.2 mM DDT, 10 
μM dUTP/dTTP, template/primer hybrid, 750 mA260 nm/mL. 
Anti-DIG-POD: The lyophilizate anti-DIG-POD was dissolved in autoclaved redistilled 
water (0.5 mL) and conjugate dilution buffer was added to a concentration of 200 
mU/mL. (50 μL antibody solution and 4.95 mL of conjugate dilution buffer). 
Washing buffer: Autoclaved redistilled water (225 mL) was added to the provided 
washing buffer per bottle and the mixture was mixed thoroughly before use. 
ABTS substrate solution: An ATBS tablet was dissolved in substrate buffer and mixed 
thoroughly. 
Prepare testing samples in 1 mL DMSO solutions in the concentrations of 5 mM as a 
stock solution. Then dilute them to 500 μM (10 times using DMSO) and 100 μM. 6 μL 
of each sample added to a PCR plate.A reaction mixture (54 μL) of RT (0.5 ng, supplied 
by adding 0.25 μL of the 2 ng/μL stock solution), lysis buffer (33.75 μL) and the 
reaction mixture for using poly (A) × oligo (dT)15 (20 μL) was added to each sample 
and the PCR plate. Incubated at 37 °C for 1 h and then frozen at −40 °C in the freezer 
for 5 min. The PCR plate was allowed to taw and the samples were added to the 
Streptavidin plate provided by the RT kit, and incubated at 37 °C for 1 h. The solvent 
was discharged and the Streptavidin plate was washed with washing buffer (5 × 200 μL 
for each sample). Anti-DIG-POD (diluted 1 in 100 in conjugate dilution buffer to a 
concentration of 200 mU/mL, 200 μL for each sample) was added and the Streptavidin 
plate was incubated at 37 °C for 1 h. The Streptavidin plate was washed with washing 
buffer (5 × 200 μL for each sample). The ABTS substrate solution (200 μL for each 
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sample) was added and the Streptavidin plate was incubated at room temperature for 
10-30 min until a dark green colour was visible. The absorbance at 405 nm was read 
using a Microplate reader. 
A negative and positive control have been added in the Streptavidin plate. The negative 
control consists of 54 μL of reaction mixture without the RT enzyme. The positive 
control consists of 54 μL of reaction mixture with RT enzyme and without RT inhibitor. 
7.2.2 Testing method of the anti-plasmodial assay 
The compounds were tested in vitro against Plasmodium falciparum, K1CB1 (K1), 
which is a multidrug resistant (chloroquine and antifolate resistant) strain, a generous 
gifts from Professor Sodsri Thaithong, Chulalongkorn University, Bangkok, Thailand. 
The parasites were maintained in human red-blood cells in RPMI 1640 medium 
supplemented with 25 mM HEPES, 0.2% sodium bicarbonate and 8% human serum, at 
37 ºC in a 3% CO2 incubator.
148 Samples were dissolved in DMSO and the in vitro 
anti-malarial activity testing was carried out using the microdilution radioisotope 
technique. The test sample (25 μL, in the culture medium) was placed in triplicate in a 
96-well plate where parasitized erythrocytes (200 μL) with a cell suspension (1.5%) of 
parasitemia (0.5-1%) were then added to the wells. The ranges of the final 
concentrations of the samples were varied from 2 × 10-5 to 1 × 10-7 M with 0.1% of 
solvent. The plates were then cultured under standard conditions for 24 h after which 
3H-hypoxanthine (25 μL, 0.5 mCi) was added. The culture was incubated for 18-20 h 
after which the DNA from the parasite was harvested from the culture onto glass fiber 
filters and a liquid scintillation counter used to determine the amount of 
3H-hypoxanthine incorporation.149,150 The inhibitory concentration of the sample was 
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determined from its dose-response curves or by calculation. The assay was performed in 
at least three replicates. Dihydroartemisinine and mefloquine were used as positive 
controls. 
7.2.3 Testing method of the anti-cancer assay 
The cancer growth inhibition assays of the three human-cell lines KB (epidermoid 
carcinoma of oral cavity, ATCC CCL-17), MCF-7 (breast adenocarcinoma, ATCC 
HTB-22) and NCI-H187 (small cell lung carcinoma, ATCC CRL-5804) and the Vero 
cell assay were performed using the Resazurin Microplate Assay (REMA) method.151 In 
brief, cells at a logarithmic growth phase were harvested and diluted (e.g. to 2.2 × 104 
cells/mL for KB and to 3.3 × 104 cells/mL for NCI-H187) in fresh medium. 
Successively, 5 μl of test sample diluted in 5% DMSO, and 45 μL of cell suspension 
were added to 384-well plates, incubated at 37 °C in a 5% CO2 incubator. After the 
incubation period (e.g. three days for KB, and five days for NCI-H187), 12.5 μL of 
62.5 μg/mL resazurin solution was added to each well and the plates were then 
incubated at 37 °C for 4 hours. The fluorescence signal was measured using a 
SpectraMax M5 multi-detection microplate reader (Molecular Devices, USA) at the 
excitation and emission wavelengths of 530 nm and 590 nm. The % inhibition of cell 
growth was calculated by the following equation:  
% inhibition = [1-(FUT / FUC)] × 100% 
FUT and FUC are the mean fluorescent unit from treated and untreated conditions, 
respectively. Dose response curves were plotted from 6 concentrations of 3-fold serially 
diluted test compounds and the sample concentrations that inhibit cell growth by 50% 
(IC50) been derived using the SOFTMax Pro software (Molecular Devices, USA). 
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Ellipticine, doxorubicin and tamoxifen were used as a positive control, and 0.5% 
DMSO and water were used as a negative control.151 
7.2.4 Testing method of the anti-microbial assay 
7.2.4.1 Purpose 
Tested for bacterial growth inhibition activity against a primary panel including 
Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Staphylococcus aureus (MRSA) 
7.2.4.2 Compound preparation 
Dry weights of the testing compounds were supplied. Namfon Pantarat prepared stock 
solutions at 10 mg/mL in DMSO, according to the weight reported for each compound. 
Gentle heating and sonication was required to solubilise the compounds. The highest 
concentration tested for each compound was 32 μg/mL. 
7.2.4.3 Single point bacterial inhibition assay 
The primary bacteria panel, including Escherichia coli ATCC 25922 (GN_001), 
Klebsiella pneumoniae ATCC 700603 (GN_003), Acinetobacter baumannii ATCC 
19606 (GN_034), Pseudomonas aeruginosa ATCC 27853 (GN_042) and 
Staphylococcus aureus ATCC 43300 (MRSA) (GP_020) were cultured in Muller 
Hinton broth (MHB) at 37 °C overnight. A sample of each culture was then diluted 
40-fold in fresh MHB broth and incubated at 37 °C for 1.5-3 hrs. The compounds were 
plated at a single test concentration of 64 μg/mL. Colistin, Polymyxin B, Vancomycin 
and Daptomycin were serially diluted two-fold across the wells, with compound 
concentrations ranging from 0.5 to 64 μg/mL, as controls of bacterial inhibitors. The 
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resultant mid-log phase cultures were diluted to the final concentration of 5×105 
CFU/mL, then 50 μL was added to each well of the compound containing 96-well plates 
(Corning; Cat. No 3641, NBS), giving a final compound concentration range of 0.25 
μg/mL to 32 μg/mL for control inhibitors and 32 μg/mL for test compounds. All the 
plates were covered and incubated at 37 °C for 24 h. 
Inhibition of bacterial growth was determined visually and was recorded at 32 μg/mL 
were 100% inhibition was identified. 
7.2.4.4 MIC (Minimum Inhibitory Concentration) assay 
The primary bacteria panel, including Escherichia coli ATCC 25922 (GN_001) and 
Staphylococcus aureus ATCC 43300 (MRSA) (GP_020) were cultured in Muller 
Hinton broth (MHB) at 37°C overnight. A sample of each culture was then diluted 
40-fold in fresh MHB broth and incubated at 37 °C for 1.5-3 h. The compounds were 
serially diluted two-fold across the wells of non-binding surface 96-well plates (Corning; 
Cat. No 3641, NBS), with compound concentrations ranging from 0.03 μg/mL to 64 
μg/mL, plated in duplicate. The resultant mid-log phase cultures were diluted to the 
final concentration of 5×105 CFU/mL, then 50 μL was added to each well of the 
compound-containing 96-well plates, giving a final compound concentration range of 
0.015 μg/mL to 32 μg/mL. All the plates were covered and incubated at 37 °C for 24 h. 
Inhibition of bacterial growth was determined visually after 24 h, where the MIC is 








7.2.4.5 Tested Bacteria Strains 
ID Organism Strain Description Type 
GN_001:02 Escherichia coli ATCC 25922 control strain G-ve 
GN_003:02 Klebsiella pneumoniae ATCC 700603 MDR G-ve 
GN_034:02 Acinetobacter baumannii ATCC 19606 type strain G-ve 
GN_042:02 Pseudomonas aeruginosa ATCC 27853 type strain G-ve 
GN_020:02 Staphylococcus aureus ATCC 43300 MRSA G+ve 
 
7.2.5 Testing method of the DPPH testing 
DPPH assays were conducted to test the free radical scavenging ability of the 
compounds 132, 126, 121 and 153-155. The protocol developed was adapted to 96-well 
plates based on the Brand-Williams method.139 2,2-Diphenyl-1-picrylhydrazyl (DPPH, 
20 mg) was dissolved in MeOH (100 mL), stored at −20 °C, and employed as a stock 
solution. A working DPPH solution was prepared by diluting the stock solution with 
MeOH. Stock solutions of the pure compounds being tested were diluted to 
concentrations in the range 0-100 μM (0, 12.50, 18.75, 25.00, 37.50, 50.00, 75.00, and 
100.00 μM) on 96-well plates. Substrates (50 μL/well) with the above concentrations in 
triplicate were mixed with freshly prepared DPPH solution (150 μL/well). The lowest 
concentration in one of the triplicates was left blank (50 μL of MeOH without sample) 
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as a negative in order to obtain the initial DPPH absorbance at 515 nm. The absorbance 
of the reaction mixtures at 515 nm in the 96-well plates were monitored at 5, 10, 15, 30, 
45, 60 and 120 min. Absorbance changes at different concentrations of each compound 
tested were plotted as a standard curve. The inhibition percentage was calculated as 
follows: 
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Appendix 3: 1H NMR, 13C NMR spectra 
Appendix 3.1 Michellamine B analogues synthesis 
Monomeric naphthylisoquinoline 99 
 
 
Figure A3.1.1 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 99. 
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Figure 3.1.2 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 43. 
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Figure 3.1.3 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 100. 
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Figure 3.1.4 1H NMR (500 MHz, CD3OD) and 
13C NMR (126 MHz, CD3OD) spectra of 
compound 109. 
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Figure 3.1.5 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) spectra of compound 
44. 
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Figure 3.1.6 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 107. 
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Monomeric naphthylisoquinoline with ester group 96 
 
 
Figure 3.1.7 1H NMR (500 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) spectra of compound 
96. 
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Monomeric naphthylisoquinoline with ester group 97 
 
 
Figure 3.1.8 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 97. 
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Figure 3.1.9 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 98. 
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2,2'-Binaphthalene scaffold 111 
 
 
Figure 3.1.10 1H NMR (500 MHz, CDCl3) and 
13C NMR (126 MHz, CDCl3) spectra of 
compound 111. 
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Figure 3.1.11 1H NMR (500 MHz, CD3OD) and 
13C NMR (126 MHz, CD3OD) spectra of 
compound 113. 
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Dimeric naphthylisoquinoline 112 
 
 
Figure 3.1.12 1H NMR (500 MHz, CD3OD) and 
13C NMR (126 MHz, CD3OD) spectra of 
compound 112. 
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Appendix 3.2 Coelenterazine analogues synthesis 
 
Figure 3.1.13 1H NMR (500 MHz, CD3OD) spectrum of compound 121. 
 
Figure 3.1.14 1H NMR (500 MHz, CD3OD) spectrum of compound 153. 
 




Figure 3.1.15 1H NMR (300 MHz, DMSO) spectrum of compound 154. 
 
 
Figure 3.1.16 1H NMR (500 MHz, DMSO) spectrum of compound 155. 
